#+title : Robbins Basic Pathology 10th Edition 2017
* Robbins Basic Pathology 10th Edition 2017
:PROPERTIES:
:NOTER_DOCUMENT: ../../PDFs/Robbins Basic Pathology 10th Edition 2017.pdf
:NOTER_PAGE: 25
:END:
** Front Matter
:PROPERTIES:
:NOTER_PAGE: 2
:END:
*** Copyright Page
:PROPERTIES:
:NOTER_PAGE: 4
:ID:       d39bde89-8ffa-479c-aaae-424ce4dc61ec
:END:
*** Dedication
:PROPERTIES:
:NOTER_PAGE: 5
:ID:       51b1cc76-20e0-4002-abbd-8e4c6e613a4e
:END:
*** Contributors
:PROPERTIES:
:NOTER_PAGE: 6
:ID:       d81cf509-8908-4785-8db5-529aaff9a7f0
:END:
*** Clinical Consultants
:PROPERTIES:
:NOTER_PAGE: 8
:END:
*** Preface
:PROPERTIES:
:NOTER_PAGE: 9
:END:
*** Acknowledgments
:PROPERTIES:
:NOTER_PAGE: 10
:END:
*** Online Resources for Instructors and Students
:PROPERTIES:
:NOTER_PAGE: 11
:ID:       634ca15d-4ee1-4850-a980-c8a1d6cfca1e
:END:
**** Resources for Instructors
:PROPERTIES:
:NOTER_PAGE: 11
:ID:       fd9357ca-314e-4d56-bc01-c1c2021a0e0e
:END:
***** Image Collection
:PROPERTIES:
:NOTER_PAGE: 11
:END:
***** Test Bank
:PROPERTIES:
:NOTER_PAGE: 11
:END:
**** Resources for Students
:PROPERTIES:
:NOTER_PAGE: 11
:END:
***** Textbook Online
:PROPERTIES:
:NOTER_PAGE: 11
:END:
***** Targeted Therapy Boxes
:PROPERTIES:
:NOTER_PAGE: 11
:END:
***** Videos
:PROPERTIES:
:NOTER_PAGE: 11
:END:
***** Clinical Cases
:PROPERTIES:
:NOTER_PAGE: 11
:END:
***** Self-Assessment Questions
:PROPERTIES:
:NOTER_PAGE: 11
:END:
** 1 The Cell as a Unit of Health and Disease
:PROPERTIES:
:NOTER_PAGE: (12 . 0.113665)
:ID:       a4a54310-2ea0-499a-8981-9dffe5d747cd
:END:
*** Chapter Outline
:PROPERTIES:
:NOTER_PAGE: (12 . 0.293742)
:END:
*** The Genome
:PROPERTIES:
:NOTER_PAGE: (12 . 0.795658)
:END:
**** Noncoding DNA
:PROPERTIES:
:NOTER_PAGE: 12
:END:
**** Histone Organization
:PROPERTIES:
:NOTER_PAGE: (14 . 0.233716)
:ID:       37c51061-0530-46a9-9f59-9e8ad7ce6544
:END:
**** Micro-RNA and Long Noncoding RNA
:PROPERTIES:
:NOTER_PAGE: (15 . 0.067688)
:END:
***** Gene Editing
:PROPERTIES:
:NOTER_PAGE: (16 . 0.710089)
:END:
*** Cellular Housekeeping
:PROPERTIES:
:NOTER_PAGE: 17
:END:
**** Plasma Membrane: Protection and Nutrient Acquisition
:PROPERTIES:
:NOTER_PAGE: 19
:END:
***** Passive Membrane Diffusion
:PROPERTIES:
:NOTER_PAGE: 20
:END:
***** Carriers and Channels
:PROPERTIES:
:NOTER_PAGE: 20
:END:
***** Receptor-Mediated and Fluid-Phase Uptake
:PROPERTIES:
:NOTER_PAGE: 20
:END:
**** Cytoskeleton
:PROPERTIES:
:NOTER_PAGE: 22
:END:
The ability of cells to adopt a particular shape, maintainpolarity, organize the intracellular organelles, and moveabout depends on the intracellular scaffolding of pro-teins called the cytoskeleton
***** Actin microfilaments
***** Intermediate flaments
***** Microtubules
**** Cell-Cell Interactions
:PROPERTIES:
:NOTER_PAGE: 23
:ID:       5bde19b2-2d13-45fc-9dda-0e40a2f4fa69
:END:
***** Occuluding junctions(封闭连接)
- [[roam:adjacent(邻近的)]]
- [[roam:apical(顶点的,尖的)]]
- [[roam:basolateral(基底的)]]
- [[roam:epithelial(上皮的)]]
- [[roam:desmosome(桥粒)]]
***** Anchoring(抛锚) junctions(desmosomes)
- [[roam:cadherin(钙粘附蛋白)]]
***** communicating junctions(gap junctions)
- [[roam:hexamers(六聚体)]]
- [[roam:presence(存在)]]
- [[roam:absence(不存在)]]
- [[roam:disulfide(硫化物)]]
- [[roam:mutation(变异)]]
**** Biosynthetic Machinery: Endoplasmic Reticulum and Golgi Apparatus
:PROPERTIES:
:NOTER_PAGE: 23
:END:
- [[roam:exceeding(超过,超越)]]
- [[roam:cystic fibrosis(囊性纤维化)]]
- [[roam:shuttle(来往两地的航班,梭子)]]
- [[roam:cisternae(池,潴泡)]]
- [[roam:oligosaccharides(低聚糖)]]
- [[roam:mannose(甘露糖)]]
- [[roam:goblet(高脚酒杯)]]
- [[roam:sacroplasmic(肌浆网)]]
**** Waste Disposal: Lysosomes and Proteasomes(蛋白酶体)
:PROPERTIES:
:NOTER_PAGE: 24
:END:
*** Cellular Metabolism and Mitochondrial Function
:PROPERTIES:
:NOTER_PAGE: 24
:ID:       4c65f950-1031-4129-81d8-b434f2716dc3
:END:
- [[roam:proton(质子)]]
**** Energy Genearion
**** Intermediate Metabolismo
**** Cell Death
- [[roam:proverbial(谚语的)]]
*** Cellular Activation
:PROPERTIES:
:NOTER_PAGE: 27
:END:
**** Cell Signaling
:PROPERTIES:
:NOTER_PAGE: 27
:END:
**** Signal Transduction Pathways
:PROPERTIES:
:NOTER_PAGE: 27
:ID:       414928c9-b348-478a-84c2-0367b933913c
:END:
***** Receptors associated with kinase activity
- geometry(几何学,形状)
- [[roam:intrinsic(固有的内在的)]]
**** Modular Signaling Proteins, Hubs, and Nodes
:PROPERTIES:
:NOTER_PAGE: 29
:END:
**** Transcription Factors
:PROPERTIES:
:NOTER_PAGE: 30
:END:

*** Growth Factors and Receptors
:PROPERTIES:
:NOTER_PAGE: 30
:END:
*** Extracellular Matrix
**** ECM serves several key functions
:PROPERTIES:
:NOTER_PAGE: 32
:END:• Mechanical support for cell anchorage(锚固) and cell migration,and maintenance of cell polarity.
**** Components of the Extracellular Matrix
:PROPERTIES:
:NOTER_PAGE: 33
:END:
****** Collagens
******* Some collagen types (e.g., types I, II, III, and V colla-gens) form linear fibrils stabilized by interchain hydro-gen bonding
******* Nonfibrillar
****** Elastin
****** Proteoglycans and hyaluronan
****** Adhesive glycoproteins and adhesion receptors
*** Maintaining Cell Populations
:PROPERTIES:
:NOTER_PAGE: 35
:END:
**** Proliferation and the Cell Cycle
:PROPERTIES:
:NOTER_PAGE: 35
:END:
**** Stem Cells
:PROPERTIES:
:NOTER_PAGE: 36
:END:
- roam:totipoten(全能的)
- [[roam:tendency(趋势)]]
- [[roam:hematopoietic(造血的)]]
***** Regenerative Medicine
:PROPERTIES:
:NOTER_PAGE: 39
:END:
**** Concluding Remarks
:PROPERTIES:
:NOTER_PAGE: 39
:END:
*** Suggested Readings
:PROPERTIES:
:NOTER_PAGE: 40
:END:
**** Genetics and Epigenetics
:PROPERTIES:
:NOTER_PAGE: 40
:END:
**** Cellular Housekeeping
:PROPERTIES:
:NOTER_PAGE: 40
:END:
**** Cellular Metabolism and Mitochondrial Function
:PROPERTIES:
:NOTER_PAGE: 40
:END:
**** Cellular Activation
:PROPERTIES:
:NOTER_PAGE: 40
:END:
**** Maintaining Cell Populations
:PROPERTIES:
:NOTER_PAGE: 40
:END:
** 2 Cell Injury, Cell Death, and Adaptations
:PROPERTIES:
:NOTER_PAGE: 41
:END:
*** Chapter Outline
:PROPERTIES:
:NOTER_PAGE: 41
:END:
*** Introduction to Pathology
:PROPERTIES:
:NOTER_PAGE: 41
:END:
**** two important terms 
- [[file:2020123116-etiology.org][Etiology]]
- [[file:2020123116-pathogenesis.org][Pathogenesis]] provides the scienctific foundation for the practice of medicine
*** Overview of Cellular Responses to Stress and Noxious Stimuli
:PROPERTIES:
:NOTER_PAGE: 41
:END:
- [[file:2020123117-accommodate.org][accommodate]]
- [[file:2020123117-milieu.org][milieu]]
*** Causes of Cell Injury
:PROPERTIES:
:NOTER_PAGE: 42
:END:
**** Hypoxia(缺氧) and ischemia(缺血)
**** Toxins(毒素)
**** Infectious agents
- [[roam:fungi(菌类)]]
- [[roam:protozoan(原虫)]]
**** Immunologic reactions
**** Genetic abnormalities
- [[roam:aberration(差异)]]
- [[roam:sickle(镰刀)]]
**** Nutrirional imbalances
- [[roam:diabetes(糖尿病)]]
- [[roam:atherosclerosis(动脉粥样硬化)]]
- [[file:2020112213-ironic.org][ironic]]
- [[file:2021010213-impoverished.org][impoverished]]

**** Physical agents
- [[file:2020112219-trauma.org][trauma]]
**** Aging
- [[file:2021010213-senescence.org][senescence]]
- [[file:2021010213-stimuli.org][stimuli]]

  
*** Sequence of Events in Cell Injury and Cell Death
:PROPERTIES:
:NOTER_PAGE: 43
:END:
**** Reversible Cell Injury
:PROPERTIES:
:NOTER_PAGE: 43
:END:
- Reversible injury is the stage of cell injury at which the [[file:2021010213-deranged.org][deranged]] function and [[file:2021010213-morphology.org][morphology]] of the injured cells can return to normal if the damaging stimulus is removed
***** MORPHOLOGY
The two main morphologic [[file:2021010213-correlates.org][correlates]] of reversible cell injury are cellular swelling and fatty change.
- Cellular swelling (Fig. 2.4B) is commonly seen in cell injury associated with increased [[roam:permeability(渗透性)]] of the plasma membrane. It may be difficult to appreciate with the light micro-scope, but it is often apparent at the level of the whole organ. When it affects many cells in an organ, it causes [[file:2021010213-pallor.org][pallor]] (as a result of compression of capillaries), increased [[file:2021010213-turgor.org][turgor]], and an increase in organ weight. Microscopic examination may show small, clear vacuoles within the cytoplasm; these represent distended and pinched-off segments of the endoplasmic reticu- lum (ER). This pattern of [[file:2020111818-nonlethal_非致命.org][nonlethal(非致命)]] injury is sometimes called hydropic change or vacuolar degeneration.
- Fatty change is manifested by the appearance of triglyceride containing lipid vacuoles in the cytoplasm. It is principally encountered in organs that are involved in lipid metabolism, such as the liver, and hence it is discussed in Chapter 16.
  
**** Cell Death
:PROPERTIES:
:NOTER_PAGE: 44
:END:
***** When cells are injured they die by different mechanisms, depending on the nature and severity of the insult.
- Severe disturbances, such as loss of oxygen and nutrient supply and the actions of toxins, cause a rapid and uncontrollable form of death that has been called “accidental” cell death. The morphological manifestation of accidental cell death is necrosis (Greek, ~necros~ = death) (Table 2.1). Necrosis is the major pathway of cell death in many commonly encountered injuries, such as those resulting from [[file:2021011214-ischemia.org][ischemia]], exposure to toxins, various infections, and [[file:2020112219-trauma.org][trauma]]. Necrosis is traditionally considered the inevitable end result of severe damage that is beyond [[file:2021011214-salvage.org][salvage]] and is not thought to be regulated by specific signals or biochemical mechanisms; in other words, necrosis happens accidentally because the injury is too severe to be repaired and many cellular constituents simply fail or fall apart.
- In contrast, when the injury is less severe, or cells need to be [[file:2021011214-eliminated.org][eliminated]] during normal processes, they activate a [[file:2020112314-precise.org][precise]] set of molecular pathways that [[file:2021011214-culminate.org][culminate]] in death. Because this kind of cell death can be manipulated
- 
It is important to point out that cellular function may be lost long before cell death occurs, and that the morphologic changes of cell injury (or death) lag far behind loss of function and viability (Fig. 2.5). For example, myocardial cells become [[file:2021011214-noncontractile.org][noncontractile]] after 1 to 2 minutes of ischemia, but may not die until 20 to 30 minutes of ischemia have [[file:2021011214-elapsed.org][elapsed]]. Morphologic features indicative of the death of ischemic myocytes appear by electron microscopy within 2 to 3 hours after the death of the cells, but are not evident by light microscopy until 6 to 12 hours later.
**** Necrosis

#+begin_quote
Necrosis is a form of cell death in which cellular membranes fall apart, and cellular enzymes leak out and ulti mately digest the cell 
#+end_quote
-:PROPERTIES:
:NOTER_PAGE: 45
:E
Necrosis [[file:2021011214-elicits.org][elicits]] a local host reaction, called [[file:2020112215-inflammation.org][inflammation]], that is induced by substances released from dead cells and which serves to [[file:2021011215-eliminate.org][eliminate]] the [[file:2021011215-debris.org][debris]] and start the subsequent repair process (Chapter 3). The enzymes responsible for digestion of the cell are derived from lysosomes and may come from the dying cells themselves or from leukocytes recruited as part of the inflammatory reaction. Necrosis often is the culmination of reversible cell injury that cannot be corrected.
- The biochemical mechanisms of necrosis vary with different injurious stimuli. These mechanisms include:
  1. failure of energy generation in the form of ATP because of reduced oxygen supply or mitochondrial damage;
  2. damage to cellular membranes, including the plasma membrane and lysosomal membranes, which results in leakage of cellular contents including enzymes;
  3. irreversible damage to cellular lipids, proteins, and nucleic acids, which may be caused by reactive oxygen species (ROS);
  4. and others. These biochemical mechanisms are discussed later when we consider the individual causes ofcell necrosis.
***** [[file:2021010213-morphology.org][morphology]]
#+begin_quote
Necrosis is characterized by changes in the cytoplasm and nuclei  of  the  injured  cells 
#+end_quote
- ~Cytoplasmic changes~. Necrotic cells show increased [[file:2021011215-eosinophilia.org][eosinophilia]]  (i.e. they  are  stained  red  by  the  [[file:2021011215-dye.org][dye]]  [[file:2021011215-eosin.org][eosin]] —the  E  in the [[file:2021011215-hematoxylin.org][hematoxylin]] and eosin [H&E] stain), [[file:2021011215-attributable.org][attributable]] partly to increased  binding  of  eosin  to  [[file:2021011215-denatured.org][denatured]]  [[file:2021011215-cytoplasmic.org][cytoplasmic]]  proteins and partly to loss of [[file:2021011215-basophilic.org][basophilic]] [[file:2021011215-ribonucleic.org][ribonucleic]] acid (RNA) in the cytoplasm  ([[file:2021011215-basophilia.org][basophilia]]  stems  from  binding  of  the  blue  dye hematoxylin—the H in “H&E”). Compared with viable cells, the cell  may  have  a  glassy,  homogeneous  appearance,  mostly because of the loss of lighter staining glycogen [[file:2021011215-particles.org][particles]]. [[file:2021011215-myelin.org][Myelin]] figures are more [[file:2021011215-prominent.org][prominent]] in necrotic cells than in cells with reversible  injury.  When  enzymes  have  digested  cytoplasmic organelles,  the  cytoplasm  becomes  [[file:2021011215-vacuolated.org][vacuolated]]  and  appears “moth-eaten.” By electron microscopy, necrotic cells are characterized  by  discontinuities  in  plasma  and  organelle  membranes,  marked  [[file:2021011215-dilation.org][dilation]]  of  mitochondria  associated  with  the appearance  of  large  [[file:2021011215-amorphous.org][amorphous]]  intramitrochondrial  densities,  [[file:2020110314-disruption.org][disruption]] of lysosomes, and intracytoplasmic myelin figures.
- Nuclear changes. Nuclear changes [[file:2021011215-assume.org][assume]] one of three patterns,  all  resulting  from  a  breakdown  of  DNA  and  chromatin.  [[file:2021011215-pyknosis.org][Pyknosis]] is characterized by nuclear shrinkage and increased [[file:2021011215-basophilia.org][basophilia]]; the DNA condenses into a dark [[file:2021011215-shrunken.org][shrunken]] mass. The pyknotic  nucleus  can  undergo  [[file:2021011215-fragmentation.org][fragmentation]];  this  change  is called  [[file:2021011215-karyorrhexis.org][karyorrhexis]].  Ultimately,  the  nucleus  may  undergo [[file:2021011215-karyolysis.org][karyolysis]], in which the [[file:2021011215-basophilia.org][basophilia]] fades because of digestion of DNA by [[file:2021011215-deoxyribonuclease.org][deoxyribonuclease]] (DNase) activity. In 1 to 2 days,  the  nucleus  in  a  dead  cell  may  completely  disappear.
-  Fates of necrotic cells. Necrotic cells may persist for some time or may be digested by enzymes and disappear. Dead cells may  be  replaced  by  [[roam:myelin]]  figures,  which  are  either  [[file:2021011215-phagocytosed.org][phagocytosed]] by other cells or further degraded into fatty acids. These fatty acids bind calcium salts, which may result in the dead cells ultimately  becoming  calcified.
***** Morphologic Patterns of Tissue Necrosis
#+begin_quote
In severe pathologic conditions, large areas of a tissue or even entire orgrans may undergo necrosis. This may happen in association with marked ischemia, infections, and certain inflammatory reactions. There are several morphologically distinct patterns of tissue necrosis that may provide [[file:2021011216-etiologic.org][etiologic]] [[file:2021011216-clues.org][clues]]. Although the terms that describe these patterns do not reflect underlying mechanisms, such terms are commonly used and their implications are understood by [[file:2021011216-pathologists.org][pathologists]] and [[file:2021011216-clinicians.org][clinicians]].
#+end_quote
****** morphology
#+begin_quote
Most  of  the  types  of  necrosis  described  here  have  distinctive  gross  appearances;  the  exception  is  [[file:2021011216-fibrinoid.org][fibrinoid]]  necrosis,  which  is  detected  only  by  [[file:2021011216-histologic.org][histologic]]  examination.
#+end_quote

- *Coagulative* necrosis is a form of necrosis in which the underlying tissue architecture is preserved for at least several  days  after  death  of  cells  in  the  tissue  (Fig.  2.6). The  affected  tissues take on a firm texture. [[file:2021011216-presumably.org][Presumably]] the injury [[file:2021011216-denatures.org][denatures]]  *not only structural proteins but also enzymes*, thereby blocking  the  [[file:2021011216-proteolysis.org][proteolysis]]  of  the  dead  cells;  as  a  result,  eosinophilic,  [[file:2021011216-anucleate.org][anucleate]] cells may persist for days or weeks. Leukocytes are  recruited  to  the  site  of  necrosis,  and  the  dead  cells  are  ultimately  digested  by  the  action  of  [[file:2021011216-lysosomal.org][lysosomal]]  enzymes  of  the  [[file:2021011216-leukocytes.org][leukocytes]]. The cellular [[file:2021011215-debris.org][debris]] is then removed by phagocytosis  mediated primarily by [[file:2021011216-infiltrating.org][infiltrating]] [[file:2021011216-neutrophils.org][neutrophils]] and [[file:2021011216-macrophages.org][macrophages]].  Coagulative  necrosis  is  characteristic  of  [[file:2021011216-infarcts.org][infarcts]]  (areas  of  necrosis  caused  by  ischemia)  in  all  solid  organs  except  the  brain.
- [[file:2021011216-liquefactive.org][Liquefactive]] necrosis is seen in [[file:2021011216-focal.org][focal]] bacterial and, occasionally,  [[file:2021011216-fungal.org][fungal]]  infections  because  microbes  stimulate  rapid  [[file:2021011216-accumulation.org][accumulation]] of inflammatory cells, and the enzymes of [[file:2021011216-leukocytes.org][leukocytes]]  digest  (“liquefy”)  the  tissue.  For  obscure  reasons,  [[file:2021011216-hypoxic.org][hypoxic]]  death of cells within the central nervous system often [[file:2021011216-evokes.org][evokes]]  liquefactive necrosis (Fig. 2.7). Whatever the pathogenesis, the  dead cells are completely digested, transforming the tissue into  a [[file:2021011216-viscous.org][viscous]] liquid that is eventually removed by phagocytes. If the  process  is  initiated  by  acute  inflammation,  as  in  a  bacterial infection, the material is frequently [[file:2021011216-creamy.org][creamy]] yellow and is called *pus*  (Chapter  3).
- Although [[file:2021011217-gangrenous.org][gangrenous]] necrosis is not a distinctive [[file:2021011217-pattern.org][pattern]] of cell death, the term is still commonly used in clinical practice.  It usually refers to the condition of a limb (generally the lower  leg) that has lost its blood supply and has undergone coagulative  necrosis  involving  multiple  tissue  layers. When  bacterial  infection  is  [[file:2021011217-superimposed.org][superimposed]],  the  [[file:2021011217-morphologic.org][morphologic]]  appearance  changes  to  liquefactive  necrosis  because  of  the  destructive  contents of the bacteria and the attracted [[file:2021011216-leukocytes.org][leukocytes]] (resulting  in  so-called “wet  gangrene”).
- [[file:2021011217-caseous.org][Caseous]] necrosis is most often encountered in [[file:2021011217-foci.org][foci]] of tuberculous infection. Caseous means “cheeselike,” referring to the  [[file:2021011217-friable.org][friable]]  yellow-white  appearance  of  the  area  of  necrosis  on  gross examination (Fig. 2.8). On microscopic examination, the  necrotic  focus  appears  as  a  collection  of  fragmented  or  [[file:2021011217-定义.org][定义]]  cells  with  an  [[file:2021011215-amorphous.org][amorphous]]  [[file:2021011217-granular.org][granular]]  pink  appearance  in  H&E- stained tissue sections. Unlike coagulative necrosis, the tissue  architecture  is  completely  [[file:2021011217-obliterated.org][obliterated]]  and  cellular  outlines  cannot be [[file:2021011217-discerned.org][discerned]]. Caseous necrosis is often surrounded by  a collection of [[file:2021011216-macrophages.org][macrophages]] and other inflammatory cells; this  appearance is characteristic of a [[file:2021011217-nodular.org][nodular]] inflammatory [[file:2021011217-lesion.org][lesion]]  called  a  [[file:2021011217-granuloma.org][granuloma]]  (Chapter  3).
- *Fat necrosis* refers to focal areas of fat destruction, typically resulting  from  the  release  of  activated  [[file:2021011217-pancreatic.org][pancreatic]]  [[file:2021011217-lipases.org][lipases]]  into  the  substance  of  the  [[file:2021011217-pancreas.org][pancreas]]  and  the  [[file:2021011217-peritoneal.org][peritoneal]]  [[file:2021011217-cavity.org][cavity]]. This  occurs in the [[file:2021011217-calamitous.org][calamitous]] [[file:2021011217-abdominal.org][abdominal]] emergency known as acute  pancreatitis (Chapter 17). In this disorder, pancreatic enzymes  that have leaked out of [[file:2021011217-acinar.org][acinar]] cells and ducts liquefy the membranes  of  fat  cells  in  the  [[file:2021011217-peritoneum.org][peritoneum]],  and  lipases  split  the  [[file:2021011217-triglyceride.org][triglyceride]]  [[file:2021011217-esters.org][esters]]  contained  within  fat  cells. The  released  fatty  acids  combine  with  calcium  to  produce  grossly  visible  [[file:2021011217-chalky.org][chalky]]  white areas (fat [[file:2021011217-saponification.org][saponification]]), which enable the surgeon and  the  pathologist  to  identify  the  lesions  (Fig.  2.9).  On  [[file:2021011216-histologic.org][histologic]]  examination,  the  foci  of  necrosis  contain  shadowy  outlines  of  necrotic  fat  cells  surrounded  by  basophilic  calcium  deposits  and an inflammatory reaction.
- *Fibrinoid necrosis* is a special form of necrosis. It usually occurs  in  immune  reactions  in  which  complexes  of  antigens and antibodies are deposited in the walls of blood vessels, but it also may occur in severe hypertension. Deposited immune complexes  and  plasma  proteins  that  leak  into  the  wall  of damaged vessels produce a bright pink, amorphous appearance on H&E preparations called [[file:2021011216-fibrinoid.org][fibrinoid]] (fibrinlike) by pathologists (Fig. 2.10). The immunologically mediated diseases (e.g., poly- arteritis  nodosa)  in  which  this  type  of  necrosis  is  seen  are described  in  Chapter  5.
#+begin_quote
Leakage of intracellular proteins through the damaged cell membrane and ultimately into the circulation provides a means of detecting tissue-specific necrosis using blood or serum samples. Cardiac muscle, for example, contains a unique isoform of the enzyme [[file:2021011414-creatine.org][creatine]] kinase and of the contractile protein [[file:2021011414-troponin.org][troponin]], whereas hepatic bile duct epithelium contains the enzyme [[file:2021011414-alkaline.org][alkaline]] phosphatase, and hepatocytes contain [[file:2021011414-transaminases.org][transaminases]]. Irreversible injury and cell death in these tissues elevate the serum levels of these proteins, which makes them clinically useful markers of tissue damage.
#+end_quote
**** Apoptosis
:PROPERTIES:
:NOTER_PAGE: 47
:END
#+begin_quote
[[file:2021011414-apoptosis.org][Apoptosis]] is a pathway of cell death in which cells activate enzymes that [[file:2021011414-degrade.org][degrade]] the cells’ own nuclear DNA and nuclear and cytoplasmic proteins (Fig. 2.11). Fragments of the apoptotic cells then break off, giving the appearance that is responsible for the name (apoptosis, “falling off”). The plasma membrane of the apoptotic cell remains [[file:2021011414-intact.org][intact]], but the membrane is altered in such a way that the fragments, called [[file:2021011414-apoptotic.org][apoptotic]] bodies, become highly “edible,” leading to their rapid consumption by [[file:2021011414-phagocytes.org][phagocytes]]. The dead cell and its fragments are cleared with little leakage of cellular contents, so apoptotic cell death does not [[file:2021011414-elicit.org][elicit]] an inflammatory reaction. Thus, apoptosis differs in many respects from necrosis (Table 2.1).
#+end_quote
***** Causes of Apoptosis
- Physiologic apoptosis. During normal development of an organism, some cells die and are replaced by new ones. In mature organisms, highly proliferative and hormone-responsive tissues undergo cycles of proliferation and cell loss that are often determined by the levels of growth factors. In these situations, the cell death is always by apoptosis, ensuring that unwanted cells are eliminated without eliciting potentially harmful inflam- mation. In the immune system, apoptosis eliminates excess leukocytes left at the end of immune responses as well as lymphocytes that recognize self-antigens and could cause autoimmune diseases if they were not purged.
- Apoptosis in pathologic conditions. Apoptosis eliminates cells that are damaged beyond repair. This is seen when there is severe DNA damage, for example, after exposure to radiation and cytotoxic drugs. The [[file:2021011216-accumulation.org][accumulation]] of misfolded proteins also triggers apoptotic death; the underlying mechanisms of this cause of cell death and its significance in disease are discussed later, in the context of ER stress. Certain infectious agents, particularly some viruses, induce apoptotic death of infected cells.
:PROPERTIES:
:NOTER_PAGE: 47
:END:
***** Mechanisms of Apoptosis
:PROPERTIES:
:NOTER_PAGE: 48
:
#+begin_quote
Apoptosis is regulated by biochemical pathways that control the balance of death and survival-inducing signals and ultimately the activation of enzymes called [[file:2021011415-caspases.org][caspases]]. Caspases were so named because they are [[file:2021011415-cysteine.org][cysteine]] proteases that [[file:2021011415-cleave.org][cleave]] proteins after [[file:2021011415-aspartic.org][aspartic]] acid residues. Two distinct pathways [[file:2021011415-converge.org][converge]] on caspase activation: the mitochondrial pathway and the death receptor pathway (Fig. 2.12). Although these pathways can [[file:2021011415-intersect.org][intersect]], they are generally induced under different conditions, involve different molecules, and serve distinct roles in physiology and disease. The end result of apoptotic cell death is the clearance of apoptotic bodies by phagocytes.
#+end_quote

- The mitochondrial (intrinsic) pathway seems to be
responsible for apoptosis in most physiologic and pathologic situations. [[roam:Mitochondri]] contain several proteins that are capable of inducing apoptosis, including cytochrome c. When mitochondrial membranes become permeable, cytochrome c leaks out into the cytoplasm, triggering caspase activation and apoptotic death. A family of more than 20 proteins, the prototype of which is ~Bcl-2~, controls the ~permeability~ of mitochondria. In healthy cells, Bcl-2 and the related protein ~Bcl-xL~, which are produced in response to growth factors and other stimuli, maintain the integrity of mitochondrial membranes, in large part by holding two proapoptotic members of the family, Bax and Bak, in check. When cells are deprived of growth factors and survival signals, or are exposed to agents that damage DNA, or accumulate unacceptable amounts of misfolded proteins, a number of sensors are activated. These sensors are called ~BH3~ proteins because they contan the third domain seen in Bcl-family proteins. They in turn shift this delicate, life-sustaining balance in favor of pro-apoptotic Bak and Bax. As a result, Bak and Bax dimerize, insert into the mitochondrial membrane, and form channels through which cytochrome c and other mitochondrial proteins escape into the cytosol. After cytochrome c enters the cytosol, it, together with certain cofactors, activates caspase-9. The net result is the activation of a caspase [[file:2021011415-cascade.org][cascade]], ultimately leading to nuclear fragmentation and formation of apoptotic bodies.
- The death receptor ([[file:2021011415-extrinsic.org][extrinsic]]) pathway of apoptosisMany cells express surface molecules, called death receptors, that trigger [[file:2021011415-apoptosis.org][apoptosis]]. Most of these are members of the tumor necrosis factor (TNF) receptor family, which contain in their cytoplasmic regions a conserved “death domain” so named because it mediates interaction with other proteins involved in cell death. The prototypic death receptors are the type I TNF receptor and Fas (CD95). Fas [[file:2021011415-ligand.org][ligand]] (FasL) is a membrane protein expressed mainly on activated T lymphocytes. When these T cells recognize Fas-expressing targets, Fas molecules are crosslinked by FasL and bind adaptor proteins via the death domain. These then recruit and activate caspase-8, which, in turn, activates downstream caspases. The death receptor pathway is involved in the elimination of self-reactive lymphocytes and in the killing of target cells by some cytotoxic T lymphocytes (CTLs) that express FasL.In either pathway, after caspase-9 or caspase-8 is activated, it cleaves and thereby activates additional caspases that cleave numerous targets and ultimately activate enzymes that degrade the cells’ proteins and nucleus. The end result is the characteristic cellular fragmentation of apoptosis.
- [[file:2021011415-clearance.org][Clearance]] of apoptotic cells. Apoptotic cells and their fragments [[file:2021011415-entice.org][entice]] [[file:2021011414-phagocytes.org][phagocytes]] by producing a number of “eat-me” signals. For instance, in normal cells, [[file:2021011415-phosphatidylserine.org][phosphatidylserine]] is present on the inner [[file:2021011415-leaflet.org][leaflet]] of the plasma membrane, but in apoptotic cells this phospholipid “[[file:2021011415-flips.org][flips]]” to the outer leaflet, where it is recognized by tissue macrophages, leading to [[file:2021011415-phagocytosis.org][phagocytosis]] of the apoptotic cells. Cells that are dying by apoptosis also secrete soluble factors that recruit phagocytes. The plasma membrane alterations and secreted proteins facilitate prompt [[roam:clearance]] of the dead cells before the cells undergo membrane damage and release their contents (which can induce inflammation). Numerous macrophage receptors have been shown to be involved in the binding and [[file:2021011415-engulfment.org][engulfment]] of apoptotic cells. The phagocytosis of apoptotic cells is so efficient that dead cells disappear without leaving a trace, and inflammation is [[file:2020112117-virtually.org][virtually]] [[file:2021011415-absent.org][absent]].
****** [[file:2021010213-morphology.org][morphology]]
In H&E-stained tissue sections, the nuclei of apoptotic cells show  various  stages  of  chromatin  condensation  and  [[file:2021011415-aggregation.org][aggregation]]  and,  ultimately, [[file:2021011215-karyorrhexis.org][karyorrhexis]] (Fig. 2.13); at the molecular level, this is  reflected  in  the  fragmentation  of  DNA  into  nucleosome-sized  pieces. The cells rapidly shrink, form cytoplasmic buds, and frag- ment  into  apoptotic  bodies  that  are  composed  of  membrane- bound pieces of cytosol and organelles (Fig. 2.11). Because these  fragments are quickly extruded and phagocytosed without elicit- ing an inflammatory response, even substantial apoptosis may be  histologically undetectable
**** Other Pathways of Cell Death
:PROPERTIES:
:NOTER_PAGE: 50
:END:

#+begin_quote
In addition to necrosis and apoptosis, two other patterns of cell death have been described that have unusual features. Although the importance of these pathways in disease remains to be established, they are the subjects of considerable current research, and it is useful to be aware of the basic concepts.
#+end_quote

- [[file:2021011416-necroptosis.org][Necroptosis]]. This form of cell death is initiated by engagement of TNF receptors as well as other, poorly defined triggers. Unlike the extrinsic pathway of apoptosis, which also is downstream of TNF receptors, in necroptosis, kinases called receptor-interacting protein (RIP) kinases are activated, initiating a series of events that result in the dissolution of the cell, much like necrosis. The name necroptosis implies that there are features of both necrosis and apoptosis. Some infections are believed to kill cells by this pathway, and it has been [[file:2021011416-hypothesized.org][hypothesized]] to play a role in [[file:2021011416-ischemic.org][ischemic]] injury and other pathologic situations, especially those associated with inflammatory reactions in which the cytokine TNF is produced. However, when and why it occurs and how significant it is in human diseases is not well understood.
-  [[file:2021011416-pyroptosis.org][Pyroptosis]]. This form of cell death is associated with activation of a cytosolic danger-sensing protein complex called the inflammasome (Chapter 5). The net result of inflammasome activation is the activation of [[file:2021011415-caspases.org][caspases]], some of which induce the production of cytokines that induce inflammation, often manifested by fever, and others trigger apoptosis. Thus, apoptosis and inflamma- tion coexist. The name pyroptosis stems from the association of apoptosis with fever (Greek, pyro = fire). It is thought to be one mechanism by which some infectious microbes cause the death of infected cells. Its role in other pathologic situations is unknown.

*** Autophagy
:PROPERTIES:
:NOTER_PAGE: 50
:END:Autophagy (“self-eating”) refers to lysosomal digestion of the cell’s own components. It is a survival mechanism in times of nutrient [[file:2021011416-deprivation.org][deprivation]], so that the starved cell can live by eating its own contents and recycling these contents to provide nutrients and energy. In this process, intracellular organelles and portions of cytosol are first sequestered within an ER-derived autophagic vacuole, whose formation is initiated by cytosolic proteins that sense nutrient deprivation (Fig. 2.14). The [[file:2021011416-vacuole.org][vacuole]] fuses with lysosomes to form an autophagolysosome, in which lysosomal enzymes digest the cellular components. In some circumstances, autophagy may be associated with [[file:2021011416-atrophy.org][atrophy]] of tissues (discussed later) and may represent an adaptation that helps cells survive [[file:2021011416-lean.org][lean]] times. If, however, the starved cell can no longer cope by devouring its contents, autophagy may eventually lead to apoptotic cell death.
Extensive autophagy is seen in [[file:2021011416-ischemic.org][ischemic]] injury and some types of [[file:2021011416-myopathies.org][myopathies]]. Polymorphisms in a gene involved in autophagy have been associated with inflammatory bowel disease, but the mechanistic link between autophagy and intestinal inflammation is not known. The role of autophagy in cancer is discussed in Chapter 6. Thus, a once little-appreciated survival pathway in cells may prove to have wide-ranging roles in human disease.
*** Mechanisms of Cell Injury and Cell Death
:PROPERTIES:
:NOTER_PAGE: 51
:END:
#+begin_quote
Before discussing individual mechanisms of cell injury and death, some general principles should be emphasized.
- The cellular response to injurious stimuli depends on
the type of injury, its duration, and its severity. Thus, low doses of toxins or a brief period of ischemia may lead to reversible cell injury, whereas larger toxin doses or longer ischemic times may result in irreversible injury and cell death.
- The consequences of an injurious stimulus also depend on the type, status, adaptability, and genetic makeup of the injured cell. The same injury has vastly different outcomes depending on the cell type. For instance, [[file:2021011515-striated.org][striated]] [[file:2021011515-skeletal.org][skeletal]] muscle in the leg tolerates complete ischemia for 2 to 3 hours without irreversible injury, whereas cardiac muscle dies after only 20 to 30 minutes of ischemia. The nutritional (or hormonal) status also can be important; understandably, a glycogen-replete hepatocyte will survive ischemia better than one that has just burned its last glucose molecule. Genetically determined diversity in metabolic pathways can contribute to differences in responses to injurious stimuli. For instance, when exposed to the same dose of a toxin, individuals who inherit variants in genes encoding cytochrome P-450 may catabolize the toxin at different rates, leading to different outcomes. Much effort is now directed toward understanding the role of genetic polymorphisms in responses to drugs and toxins, a field of study called [[file:2021011515-pharmacogenomics.org][pharmacogenomics]]. In fact, genetic variations influence susceptibility to many complex diseases as well as responsiveness to various therapeutic agents. Using the genetic makeup of the individual patient to guide therapy is one example of “precision medicine.”
- Cell injury usually results from functional and biochemical abnormalities in one or more of a limited number of essential cellular components (Fig. 2.15). As we discuss in more detail later, different external insults and endogenous perturbations typically affect different cellular organelles and biochemical pathways. For instance, deprivation of oxygen and nutrients (as in hypoxia and ischemia) primarily impairs energy- dependent cellular functions, culminating in necrosis, whereas damage to proteins and DNA triggers apoptosis. However, it should be emphasized that the very same injurious agent may trigger multiple and overlapping biochemical pathways. Not surprisingly, therefore, it has proved difficult to prevent cell injury by targeting an individual pathway.
#+end_quote

**** Hypoxia and Ischemia
:PROPERTIES:
:NOTER_PAGE: 52
:END:
#+begin_quote
*Deficiency of oxygen leads to failure of many energy dependent metabolic pathways, and ultimately to death of cells by necrosis.* Most cellular ATP is produced from adenosine diphosphate (ADP) by oxidative phosphorylation during [[file:2021011515-reduction.org][reduction]] of oxygen in the electron transport system of mitochondria. High-energy phosphate in the form of ATP is required for membrane transport, protein synthesis, lipogenesis, and the deacylation-reacylation reactions necessary for phospholipid turnover. It is estimated that in total, the cells of a healthy human burn 50 to 75 kg of ATP every day! Not surprisingly, therefore, cells deprived of oxygen are at risk of suffering catastrophic failure of many essential functions. Oxygen deprivation is one of the most frequent causes of cell injury and necrosis in clinical medicine.
- Cells subjected to the stress of hypoxia that do not immediately die activate compensatory mechanisms that are induced by transcription factors of the hypoxia- inducible factor 1 (HIF-1) family. HIF-1 simulates the synthesis of several proteins that help the cell to survive in the face of low oxygen. Some of these proteins, such as [[file:2021011515-vascular.org][vascular]] [[file:2021011515-endothelial.org][endothelial]] growth factor (VEGF), stimulate the growth of new vessels and thus attempt to increase blood flow and the supply of oxygen. Other proteins induced by HIF-1 cause adaptive changes in cellular metabolism by stimulating the uptake of glucose and glycolysis and [[file:2021011515-dampening.org][dampening]] mitochondrial oxidative phosphorylation. [[file:2021011515-anaerobic.org][Anaerobic]] glycolysis can generate ATP in the [[file:2021011515-absence.org][absence]] of oxygen using glucose derived either from the circulation or from the [[file:2021011515-hydrolysis.org][hydrolysis]] of intracellular glycogen. Understandably, normal tissues with a greater glycolytic capacity because of the [[file:2021011515-presence.org][presence]] of glycogen (e.g., the liver and striated muscle) are more likely to survive hypoxia and decreased oxidative phosphorylation than tissues with limited glucose stores (e.g., the brain). Although it seems [[file:2021011515-counterintuitive.org][counterintuitive]], rapidly proliferating normal cells and cancer cells rely on [[file:2021011515-aerobic.org][aerobic]] glycolysis to produce much of their energy, a [[file:2020112408-phenomenon.org][phenomenon]] referred to as the Warburg effect. The reason for this is that although [[file:2021011515-glycolysis.org][glycolysis]] yields less ATP per molecule of glucose burned than oxidative phosphorylation, metabolites generated by glycolysis and the TCA cycle serve as precursors for the synthesis of cellular constituents (e.g., proteins, lipids, and nucleic acids) that are needed for cell growth and division. Alterations in cellular metabolism are frequently seen in cancer cells, so they are discussed in more detail in Chapter 6.
- Persistent or severe hypoxia and ischemia ultimately lead to failure of ATP generation and depletion of ATP in cells. Loss of this critical energy store has deleterious effects on many cellular systems (Fig. 2.16).
#+end_quote
- Reduced activity of plasma membrane ATP-dependent sodium pumps, resulting in intracellular accumulation of sodium and [[file:2021011516-efflux.org][efflux]] of [[file:2021011516-potassium.org][potassium]]. The net gain of [[file:2021011516-solute.org][solute]] is accompanied by [[file:2021011516-isoosmotic.org][isoosmotic]] gain of water, causing cell swelling and dilation of the ER.
- The [[file:2021011516-compensatory.org][compensatory]] increase in anaerobic glycolysis leads to [[file:2021011516-lactic.org][lactic]] acid accumulation, decreased intracellular pH, and decreased activity of many cellular enzymes.
- Prolonged or worsening [[file:2021011516-depletion.org][depletion]] of ATP causes structural disruption of the protein synthetic [[file:2021011116-apparatus.org][apparatus]],manifested as detachment of [[file:2021011516-ribosomes.org][ribosomes]] from the rough ER (RER) and dissociation of [[roam:polysomes]] into monosomes, with a consequent reduction in protein synthesis.
- It also has been suggested that hypoxia per se increases the accumulation of ROS. Whether this is true is a matter of debate; however, there is ample evidence that hypoxia predisposes cells to ROS-mediated damage if blood flow (and oxygen delivery) is reestablished, a phenom- enon called reperfusion injury (described later).
- Ultimately, there is irreversible damage to mitochondrial and lysosomal membranes, and the cell undergoes necro- sis. Membrane damage is a late event in cell injury caused by diverse mechanisms, and is discussed later. Although necrosis is the principal form of cell death caused by hypoxia, apoptosis by the mitochondrial pathway is also thought to contribute.
**** Ischemia-Reperfusion Injury
:PROPERTIES:
:NOTER_PAGE: 53
:END:
**** Oxidative Stress
:PROPERTIES:
:NOTER_PAGE: 53
:END:
***** Generation and Removal of Reactive Oxygen Species
:PROPERTIES:
:NOTER_PAGE: 53
:END:
***** Cell Injury Caused by Reactive Oxygen Species
:PROPERTIES:
:NOTER_PAGE: 55
:END:
**** Cell Injury Caused by Toxins
:PROPERTIES:
:NOTER_PAGE: 55
:END:
**** Endoplasmic Reticulum Stress
:PROPERTIES:
:NOTER_PAGE: 55
:END:
**** DNA Damage
:PROPERTIES:
:NOTER_PAGE: 57
:END:
**** Inflammation
:PROPERTIES:
:NOTER_PAGE: 57
:END:
**** Common Events in Cell Injury From Diverse Causes
:PROPERTIES:
:NOTER_PAGE: 57
:END:
***** Mitochondrial Dysfunction
:PROPERTIES:
:NOTER_PAGE: 57
:END:
***** Defects in Membrane Permeability
:PROPERTIES:
:NOTER_PAGE: 57
:END:
*** Cellular Adaptations to Stress
:PROPERTIES:
:NOTER_PAGE: 58
:END:
**** Hypertrophy
:PROPERTIES:
:NOTER_PAGE: 58
:END:
**** Hyperplasia
:PROPERTIES:
:NOTER_PAGE: 59
:END:
**** Atrophy
:PROPERTIES:
:NOTER_PAGE: 60
:END:
**** Metaplasia
:PROPERTIES:
:NOTER_PAGE: 60
:END:
*** Intracellular Accumulations
:PROPERTIES:
:NOTER_PAGE: 61
:END:
*** Pathologic Calcification
:PROPERTIES:
:NOTER_PAGE: 63
:END:
*** Cellular Aging
:PROPERTIES:
:NOTER_PAGE: 64
:END:
*** Suggested Readings
:PROPERTIES:
:NOTER_PAGE: 66
:END:
** 3 Inflammation and Repair
:PROPERTIES:
:NOTER_PAGE: 67
:END:
*** Chapter Outline
:PROPERTIES:
:NOTER_PAGE: 67
:END:
*** Overview of Inflammation: Definitions and General Features
:PROPERTIES:
:NOTER_PAGE: 67
:END:
*** Causes of Inflammation
:PROPERTIES:
:NOTER_PAGE: 69
:END:
*** Recognition of Microbes and Damaged Cells
:PROPERTIES:
:NOTER_PAGE: 69
:END:
*** Acute Inflammation
:PROPERTIES:
:NOTER_PAGE: 70
:END:
**** Reactions of Blood Vessels in Acute Inflammation
:PROPERTIES:
:NOTER_PAGE: 70
:END:
***** Changes in Vascular Flow and Caliber
:PROPERTIES:
:NOTER_PAGE: 70
:END:
***** Increased Vascular Permeability (Vascular Leakage)
:PROPERTIES:
:NOTER_PAGE: 71
:END:
***** Responses of Lymphatic Vessels and Lymph Nodes
:PROPERTIES:
:NOTER_PAGE: 72
:END:
**** Leukocyte Recruitment to Sites of Inflammation
:PROPERTIES:
:NOTER_PAGE: 72
:END:
***** Leukocyte Adhesion to Endothelium
:PROPERTIES:
:NOTER_PAGE: 72
:END:
***** Leukocyte Migration Through Endothelium
:PROPERTIES:
:NOTER_PAGE: 75
:END:
***** Chemotaxis of Leukocytes
:PROPERTIES:
:NOTER_PAGE: 75
:END:
**** Phagocytosis and Clearance of the Offending Agent
:PROPERTIES:
:NOTER_PAGE: 76
:END:
***** Phagocytosis
:PROPERTIES:
:NOTER_PAGE: 77
:END:
***** Intracellular Destruction of Microbes and Debris
:PROPERTIES:
:NOTER_PAGE: 78
:END:
***** Neutrophil Extracellular Traps
:PROPERTIES:
:NOTER_PAGE: 79
:END:
**** Leukocyte-Mediated Tissue Injury
:PROPERTIES:
:NOTER_PAGE: 79
:END:
**** Other Functional Responses of Activated Leukocytes
:PROPERTIES:
:NOTER_PAGE: 80
:END:
**** Termination of the Acute Inflammatory Response
:PROPERTIES:
:NOTER_PAGE: 80
:END:
*** Mediators of Inflammation
:PROPERTIES:
:NOTER_PAGE: 80
:END:
**** Vasoactive Amines: Histamine and Serotonin
:PROPERTIES:
:NOTER_PAGE: 81
:END:
**** Arachidonic Acid Metabolites
:PROPERTIES:
:NOTER_PAGE: 81
:END:
***** Prostaglandins
:PROPERTIES:
:NOTER_PAGE: 81
:END:
***** Leukotrienes
:PROPERTIES:
:NOTER_PAGE: 83
:END:
***** Lipoxins
:PROPERTIES:
:NOTER_PAGE: 83
:END:
***** Pharmacologic Inhibitors of Prostaglandins and Leukotrienes
:PROPERTIES:
:NOTER_PAGE: 83
:END:
**** Cytokines and Chemokines
:PROPERTIES:
:NOTER_PAGE: 83
:END:
***** Tumor Necrosis Factor and Interleukin-1
:PROPERTIES:
:NOTER_PAGE: 83
:END:
***** Chemokines
:PROPERTIES:
:NOTER_PAGE: 84
:END:
***** Other Cytokines in Acute Inflammation
:PROPERTIES:
:NOTER_PAGE: 85
:END:
**** Complement System
:PROPERTIES:
:NOTER_PAGE: 85
:END:
**** Other Mediators of Inflammation
:PROPERTIES:
:NOTER_PAGE: 87
:END:
***** Platelet-Activating Factor
:PROPERTIES:
:NOTER_PAGE: 87
:END:
***** Products of Coagulation
:PROPERTIES:
:NOTER_PAGE: 87
:END:
***** Kinins
:PROPERTIES:
:NOTER_PAGE: 87
:END:
***** Neuropeptides
:PROPERTIES:
:NOTER_PAGE: 87
:END:
*** Morphologic Patterns of Acute Inflammation
:PROPERTIES:
:NOTER_PAGE: 88
:END:
**** Serous Inflammation
:PROPERTIES:
:NOTER_PAGE: 88
:END:
**** Fibrinous Inflammation
:PROPERTIES:
:NOTER_PAGE: 88
:END:
**** Purulent (Suppurative) Inflammation, Abscess
:PROPERTIES:
:NOTER_PAGE: 88
:END:
**** Ulcers
:PROPERTIES:
:NOTER_PAGE: 89
:END:
*** Outcomes of Acute Inflammation
:PROPERTIES:
:NOTER_PAGE: 89
:END:
*** Chronic Inflammation
:PROPERTIES:
:NOTER_PAGE: 91
:END:
**** Causes of Chronic Inflammation
:PROPERTIES:
:NOTER_PAGE: 91
:END:
**** Morphologic Features
:PROPERTIES:
:NOTER_PAGE: 91
:END:
**** Cells and Mediators of Chronic Inflammation
:PROPERTIES:
:NOTER_PAGE: 92
:END:
***** Role of Macrophages
:PROPERTIES:
:NOTER_PAGE: 92
:END:
***** Role of Lymphocytes
:PROPERTIES:
:NOTER_PAGE: 93
:END:
***** Other Cells in Chronic Inflammation
:PROPERTIES:
:NOTER_PAGE: 94
:END:
***** Granulomatous Inflammation
:PROPERTIES:
:NOTER_PAGE: 95
:END:
*** Systemic Effects of Inflammation
:PROPERTIES:
:NOTER_PAGE: 96
:END:
*** Tissue Repair
:PROPERTIES:
:NOTER_PAGE: 97
:END:
**** Overview of Tissue Repair
:PROPERTIES:
:NOTER_PAGE: 97
:END:
**** Cell and Tissue Regeneration
:PROPERTIES:
:NOTER_PAGE: 98
:END:
***** Cell Proliferation: Signals and Control Mechanisms
:PROPERTIES:
:NOTER_PAGE: 98
:END:
***** Mechanisms of Tissue Regeneration
:PROPERTIES:
:NOTER_PAGE: 98
:END:
***** Liver Regeneration
:PROPERTIES:
:NOTER_PAGE: 99
:END:
**** Repair by Scarring
:PROPERTIES:
:NOTER_PAGE: 99
:END:
***** Steps in Scar Formation
:PROPERTIES:
:NOTER_PAGE: 99
:END:
***** Angiogenesis
:PROPERTIES:
:NOTER_PAGE: 100
:END:
***** Activation of Fibroblasts and Deposition of Connective Tissue
:PROPERTIES:
:NOTER_PAGE: 101
:END:
***** Remodeling of Connective Tissue
:PROPERTIES:
:NOTER_PAGE: 102
:END:
**** Factors That Impair Tissue Repair
:PROPERTIES:
:NOTER_PAGE: 103
:END:
**** Clinical Examples of Abnormal Wound Healing and Scarring
:PROPERTIES:
:NOTER_PAGE: 103
:END:
***** Defects in Healing: Chronic Wounds
:PROPERTIES:
:NOTER_PAGE: 103
:END:
***** Excessive Scarring
:PROPERTIES:
:NOTER_PAGE: 103
:END:
***** Fibrosis in Parenchymal Organs
:PROPERTIES:
:NOTER_PAGE: 104
:END:
*** Suggested Readings
:PROPERTIES:
:NOTER_PAGE: 105
:END:
** 4 Hemodynamic Disorders, Thromboembolism, and Shock
:PROPERTIES:
:NOTER_PAGE: 107
:END:
*** Chapter Outline
:PROPERTIES:
:NOTER_PAGE: 107
:END:
*** Hyperemia and Congestion
:PROPERTIES:
:NOTER_PAGE: 107
:END:
*** Edema
:PROPERTIES:
:NOTER_PAGE: 108
:END:
**** Increased Hydrostatic Pressure
:PROPERTIES:
:NOTER_PAGE: 109
:END:
**** Reduced Plasma Osmotic Pressure
:PROPERTIES:
:NOTER_PAGE: 109
:END:
**** Lymphatic Obstruction
:PROPERTIES:
:NOTER_PAGE: 109
:END:
**** Sodium and Water Retention
:PROPERTIES:
:NOTER_PAGE: 110
:END:
***** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 110
:END:
*** Hemorrhage
:PROPERTIES:
:NOTER_PAGE: 110
:END:
*** Hemostasis and Thrombosis
:PROPERTIES:
:NOTER_PAGE: 111
:END:
**** Normal Hemostasis
:PROPERTIES:
:NOTER_PAGE: 111
:END:
***** Platelets
:PROPERTIES:
:NOTER_PAGE: 112
:END:
***** Coagulation Cascade
:PROPERTIES:
:NOTER_PAGE: 113
:END:
****** Factors That Limit Coagulation.
:PROPERTIES:
:NOTER_PAGE: 115
:END:
***** Endothelium
:PROPERTIES:
:NOTER_PAGE: 116
:END:
**** Thrombosis
:PROPERTIES:
:NOTER_PAGE: 116
:END:
***** Endothelial Injury
:PROPERTIES:
:NOTER_PAGE: 117
:END:
***** Abnormal Blood Flow
:PROPERTIES:
:NOTER_PAGE: 118
:END:
***** Hypercoagulability
:PROPERTIES:
:NOTER_PAGE: 118
:END:
***** Fate of the Thrombus
:PROPERTIES:
:NOTER_PAGE: 120
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 121
:END:
***** Venous Thrombosis (Phlebothrombosis)
:PROPERTIES:
:NOTER_PAGE: 121
:END:
***** Arterial and Cardiac Thrombosis
:PROPERTIES:
:NOTER_PAGE: 121
:END:
**** Disseminated Intravascular Coagulation (DIC)
:PROPERTIES:
:NOTER_PAGE: 121
:END:
*** Embolism
:PROPERTIES:
:NOTER_PAGE: 122
:END:
**** Pulmonary Thromboembolism
:PROPERTIES:
:NOTER_PAGE: 122
:END:
**** Systemic Thromboembolism
:PROPERTIES:
:NOTER_PAGE: 122
:END:
**** Fat Embolism
:PROPERTIES:
:NOTER_PAGE: 122
:END:
**** Amniotic Fluid Embolism
:PROPERTIES:
:NOTER_PAGE: 123
:END:
**** Air Embolism
:PROPERTIES:
:NOTER_PAGE: 123
:END:
*** Infarction
:PROPERTIES:
:NOTER_PAGE: 124
:END:
**** Factors That Influence Infarct Development
:PROPERTIES:
:NOTER_PAGE: 125
:END:
*** Shock
:PROPERTIES:
:NOTER_PAGE: 125
:END:
**** Pathogenesis of Septic Shock
:PROPERTIES:
:NOTER_PAGE: 126
:END:
**** Stages of Shock
:PROPERTIES:
:NOTER_PAGE: 128
:END:
***** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 129
:END:
*** Suggested Readings
:PROPERTIES:
:NOTER_PAGE: 129
:END:
** 5 Diseases of the Immune System
:PROPERTIES:
:NOTER_PAGE: 130
:END:
*** Chapter Outline
:PROPERTIES:
:NOTER_PAGE: 130
:END:
*** The Normal Immune Response
:PROPERTIES:
:NOTER_PAGE: 130
:END:
**** Innate Immunity
:PROPERTIES:
:NOTER_PAGE: 131
:END:
***** Receptors of Innate Immunity
:PROPERTIES:
:NOTER_PAGE: 131
:END:
****** Toll-Like Receptors
:PROPERTIES:
:NOTER_PAGE: 132
:END:
****** NOD-Like Receptors and the Inflammasome
:PROPERTIES:
:NOTER_PAGE: 132
:END:
****** Other Receptors for Microbial Products
:PROPERTIES:
:NOTER_PAGE: 132
:END:
***** Reactions of Innate Immunity
:PROPERTIES:
:NOTER_PAGE: 132
:END:
**** Adaptive Immunity
:PROPERTIES:
:NOTER_PAGE: 133
:END:
*** Cells and Tissues of the Immune System
:PROPERTIES:
:NOTER_PAGE: 133
:END:
**** Lymphocytes
:PROPERTIES:
:NOTER_PAGE: 133
:END:
***** T Lymphocytes
:PROPERTIES:
:NOTER_PAGE: 133
:END:
***** Major Histocompatibility Complex Molecules: The Peptide Display System of Adaptive Immunity
:PROPERTIES:
:NOTER_PAGE: 135
:END:
***** B Lymphocytes
:PROPERTIES:
:NOTER_PAGE: 136
:END:
***** Natural Killer Cells and Innate Lymphoid Cells
:PROPERTIES:
:NOTER_PAGE: 137
:END:
**** Antigen-Presenting Cells
:PROPERTIES:
:NOTER_PAGE: 137
:END:
***** Dendritic Cells
:PROPERTIES:
:NOTER_PAGE: 137
:END:
***** Other Antigen-Presenting Cells
:PROPERTIES:
:NOTER_PAGE: 138
:END:
**** Lymphoid Tissues
:PROPERTIES:
:NOTER_PAGE: 138
:END:
***** Peripheral Lymphoid Organs
:PROPERTIES:
:NOTER_PAGE: 138
:END:
***** Cytokines: Messenger Molecules of the Immune System
:PROPERTIES:
:NOTER_PAGE: 139
:END:
*** Overview of Lymphocyte Activation and Adaptive Immune Responses
:PROPERTIES:
:NOTER_PAGE: 139
:END:
**** Capture and Display of Antigens
:PROPERTIES:
:NOTER_PAGE: 139
:END:
**** Cell-Mediated Immunity: Activation of T Lymphocytes and Elimination of Intracellular Microbes
:PROPERTIES:
:NOTER_PAGE: 141
:END:
**** Humoral Immunity: Activation of B Lymphocytes and Elimination of Extracellular Microbes
:PROPERTIES:
:NOTER_PAGE: 141
:END:
**** Decline of Immune Responses and Immunologic Memory
:PROPERTIES:
:NOTER_PAGE: 143
:END:
*** Hypersensitivity: Immunologically Mediated Tissue Injury
:PROPERTIES:
:NOTER_PAGE: 143
:END:
**** Causes of Hypersensitivity Reactions
:PROPERTIES:
:NOTER_PAGE: 144
:END:
**** Classification of Hypersensitivity Reactions
:PROPERTIES:
:NOTER_PAGE: 144
:END:
**** Immediate (Type I) Hypersensitivity
:PROPERTIES:
:NOTER_PAGE: 145
:END:
***** Sequence of Events in Immediate Hypersensitivity Reactions
:PROPERTIES:
:NOTER_PAGE: 145
:END:
***** Development of Allergies
:PROPERTIES:
:NOTER_PAGE: 146
:END:
***** Clinical and Pathologic Manifestations
:PROPERTIES:
:NOTER_PAGE: 147
:END:
**** Antibody-Mediated Diseases (Type II Hypersensitivity)
:PROPERTIES:
:NOTER_PAGE: 148
:END:
***** Mechanisms of Antibody-Mediated Diseases
:PROPERTIES:
:NOTER_PAGE: 148
:END:
**** Immune Complex–Mediated Diseases (Type III Hypersensitivity)
:PROPERTIES:
:NOTER_PAGE: 149
:END:
***** Systemic Immune Complex Disease
:PROPERTIES:
:NOTER_PAGE: 150
:END:
****** Formation of Immune Complexes.
:PROPERTIES:
:NOTER_PAGE: 150
:END:
****** Deposition of Immune Complexes.
:PROPERTIES:
:NOTER_PAGE: 150
:END:
****** Inflammation and Tissue Injury.
:PROPERTIES:
:NOTER_PAGE: 151
:END:
***** Local Immune Complex Disease (Arthus Reaction)
:PROPERTIES:
:NOTER_PAGE: 151
:END:
**** T Cell–Mediated Diseases (Type IV Hypersensitivity)
:PROPERTIES:
:NOTER_PAGE: 151
:END:
***** CD4+ T Cell–Mediated Inflammation
:PROPERTIES:
:NOTER_PAGE: 151
:END:
****** Clinical Examples of CD4+ T Cell–Mediated Inflammatory Reactions
:PROPERTIES:
:NOTER_PAGE: 152
:END:
***** CD8+ T Cell–Mediated Cytotoxicity
:PROPERTIES:
:NOTER_PAGE: 154
:END:
*** Autoimmune Diseases
:PROPERTIES:
:NOTER_PAGE: 154
:END:
**** Immunologic Tolerance
:PROPERTIES:
:NOTER_PAGE: 154
:END:
***** Central Tolerance
:PROPERTIES:
:NOTER_PAGE: 155
:END:
***** Peripheral Tolerance
:PROPERTIES:
:NOTER_PAGE: 155
:END:
**** Mechanisms of Autoimmunity: General Principles
:PROPERTIES:
:NOTER_PAGE: 156
:END:
***** Genetic Factors in Autoimmunity
:PROPERTIES:
:NOTER_PAGE: 156
:END:
***** Role of Infections, Tissue Injury, and Other Environmental Factors
:PROPERTIES:
:NOTER_PAGE: 157
:END:
**** Systemic Lupus Erythematosus
:PROPERTIES:
:NOTER_PAGE: 159
:END:
***** Spectrum of Autoantibodies in SLE
:PROPERTIES:
:NOTER_PAGE: 159
:END:
****** Anti-Nuclear Antibodies
:PROPERTIES:
:NOTER_PAGE: 160
:END:
****** Other Autoantibodies
:PROPERTIES:
:NOTER_PAGE: 160
:END:
****** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 161
:END:
****** Genetic Factors
:PROPERTIES:
:NOTER_PAGE: 161
:END:
****** Environmental Factors
:PROPERTIES:
:NOTER_PAGE: 161
:END:
****** Immunologic Factors
:PROPERTIES:
:NOTER_PAGE: 162
:END:
****** A Model for the Pathogenesis of SLE
:PROPERTIES:
:NOTER_PAGE: 162
:END:
****** Mechanisms of Tissue Injury
:PROPERTIES:
:NOTER_PAGE: 162
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 166
:END:
***** Chronic Discoid Lupus Erythematosus
:PROPERTIES:
:NOTER_PAGE: 166
:END:
***** Drug-Induced Lupus Erythematosus
:PROPERTIES:
:NOTER_PAGE: 166
:END:
**** Rheumatoid Arthritis
:PROPERTIES:
:NOTER_PAGE: 167
:END:
**** Sjögren Syndrome
:PROPERTIES:
:NOTER_PAGE: 167
:END:
***** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 167
:END:
***** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 167
:END:
**** Systemic Sclerosis (Scleroderma)
:PROPERTIES:
:NOTER_PAGE: 168
:END:
***** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 168
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 170
:END:
**** Inflammatory Myopathies
:PROPERTIES:
:NOTER_PAGE: 171
:END:
**** Mixed Connective Tissue Disease
:PROPERTIES:
:NOTER_PAGE: 171
:END:
**** Polyarteritis Nodosa and Other Vasculitides
:PROPERTIES:
:NOTER_PAGE: 171
:END:
**** IgG4-Related Disease
:PROPERTIES:
:NOTER_PAGE: 171
:END:
*** Rejection of Transplants
:PROPERTIES:
:NOTER_PAGE: 171
:END:
**** Recognition and Rejection of Allografts
:PROPERTIES:
:NOTER_PAGE: 171
:END:
***** Recognition of Graft Alloantigens
:PROPERTIES:
:NOTER_PAGE: 171
:END:
***** Mechanisms of Graft Rejection
:PROPERTIES:
:NOTER_PAGE: 172
:END:
***** Methods of Increasing Graft Survival
:PROPERTIES:
:NOTER_PAGE: 174
:END:
**** Transplantation of Hematopoietic Stem Cells
:PROPERTIES:
:NOTER_PAGE: 175
:END:
***** Graft-Versus-Host Disease
:PROPERTIES:
:NOTER_PAGE: 175
:END:
***** Immune Deficiencies
:PROPERTIES:
:NOTER_PAGE: 177
:END:
*** Immunodeficiency Syndromes
:PROPERTIES:
:NOTER_PAGE: 177
:END:
**** Primary (Inherited) Immunodeficiencies
:PROPERTIES:
:NOTER_PAGE: 177
:END:
***** Severe Combined Immunodeficiency
:PROPERTIES:
:NOTER_PAGE: 177
:END:
***** X-Linked Agammaglobulinemia
:PROPERTIES:
:NOTER_PAGE: 179
:END:
***** DiGeorge Syndrome (Thymic Hypoplasia)
:PROPERTIES:
:NOTER_PAGE: 179
:END:
***** Hyper-IgM Syndrome
:PROPERTIES:
:NOTER_PAGE: 179
:END:
***** Common Variable Immunodeficiency
:PROPERTIES:
:NOTER_PAGE: 180
:END:
***** Isolated IgA Deficiency
:PROPERTIES:
:NOTER_PAGE: 180
:END:
***** Other Defects in Lymphocyte Activation
:PROPERTIES:
:NOTER_PAGE: 180
:END:
***** Immunodeficiencies Associated With Systemic Diseases
:PROPERTIES:
:NOTER_PAGE: 180
:END:
**** Defects in Innate Immunity
:PROPERTIES:
:NOTER_PAGE: 181
:END:
***** Defects in Leukocyte Function
:PROPERTIES:
:NOTER_PAGE: 181
:END:
***** Deficiencies Affecting the Complement System
:PROPERTIES:
:NOTER_PAGE: 181
:END:
**** Secondary (Acquired) Immunodeficiencies
:PROPERTIES:
:NOTER_PAGE: 182
:END:
*** Acquired Immunodeficiency Syndrome
:PROPERTIES:
:NOTER_PAGE: 182
:END:
**** Epidemiology
:PROPERTIES:
:NOTER_PAGE: 182
:END:
**** Properties of HIV
:PROPERTIES:
:NOTER_PAGE: 183
:END:
***** Structure of HIV
:PROPERTIES:
:NOTER_PAGE: 183
:END:
****** Pathogenesis of HIV Infection and AIDS
:PROPERTIES:
:NOTER_PAGE: 184
:END:
***** Life Cycle of HIV
:PROPERTIES:
:NOTER_PAGE: 184
:END:
****** Infection of Cells by HIV
:PROPERTIES:
:NOTER_PAGE: 184
:END:
****** Viral Replication
:PROPERTIES:
:NOTER_PAGE: 184
:END:
***** Mechanism of T-Cell Depletion in HIV Infection
:PROPERTIES:
:NOTER_PAGE: 185
:END:
***** HIV Infection of Non–T Immune Cells
:PROPERTIES:
:NOTER_PAGE: 186
:END:
****** Macrophages.
:PROPERTIES:
:NOTER_PAGE: 186
:END:
****** Dendritic Cells.
:PROPERTIES:
:NOTER_PAGE: 186
:END:
****** B Cell Function in HIV Infection.
:PROPERTIES:
:NOTER_PAGE: 186
:END:
***** Pathogenesis of Central Nervous System Involvement
:PROPERTIES:
:NOTER_PAGE: 186
:END:
**** Natural History and Course of HIV Infection
:PROPERTIES:
:NOTER_PAGE: 187
:END:
**** Clinical Features of AIDS
:PROPERTIES:
:NOTER_PAGE: 189
:END:
***** Opportunistic Infections
:PROPERTIES:
:NOTER_PAGE: 189
:END:
***** Tumors
:PROPERTIES:
:NOTER_PAGE: 189
:END:
****** Kaposi Sarcoma.
:PROPERTIES:
:NOTER_PAGE: 189
:END:
****** Lymphomas.
:PROPERTIES:
:NOTER_PAGE: 190
:END:
****** Other Tumors.
:PROPERTIES:
:NOTER_PAGE: 190
:END:
***** Central Nervous System Disease
:PROPERTIES:
:NOTER_PAGE: 190
:END:
***** Effect of Anti-Retroviral Drug Therapy on the Course of HIV Infection
:PROPERTIES:
:NOTER_PAGE: 190
:END:
*** Amyloidosis
:PROPERTIES:
:NOTER_PAGE: 191
:END:
**** Pathogenesis of Amyloid Deposition
:PROPERTIES:
:NOTER_PAGE: 192
:END:
**** Classification of Amyloidosis and Mechanisms of Amyloid Formation
:PROPERTIES:
:NOTER_PAGE: 192
:END:
***** Primary Amyloidosis: Plasma Cell Proliferations Associated With Amyloidosis.
:PROPERTIES:
:NOTER_PAGE: 192
:END:
***** Reactive Systemic Amyloidosis.
:PROPERTIES:
:NOTER_PAGE: 193
:END:
***** Heredofamilial Amyloidosis.
:PROPERTIES:
:NOTER_PAGE: 194
:END:
***** Hemodialysis-Associated Amyloidosis.
:PROPERTIES:
:NOTER_PAGE: 194
:END:
***** Localized Amyloidosis.
:PROPERTIES:
:NOTER_PAGE: 194
:END:
***** Endocrine Amyloid.
:PROPERTIES:
:NOTER_PAGE: 194
:END:
***** Amyloid of Aging.
:PROPERTIES:
:NOTER_PAGE: 194
:END:
***** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 196
:END:
*** Suggested Readings
:PROPERTIES:
:NOTER_PAGE: 196
:END:
** 6 Neoplasia:PROPERTIES:
:NOTER_PAGE: 198
:END:
*** Chapter Outline
:PROPERTIES:
:NOTER_PAGE: 198
:END:
*** Nomenclature
:PROPERTIES:
:NOTER_PAGE: 199
:END:
**** Benign Tumors
:PROPERTIES:
:NOTER_PAGE: 199
:END:
**** Malignant Tumors
:PROPERTIES:
:NOTER_PAGE: 199
:END:
*** Characteristics of Benign and Malignant Neoplasms
:PROPERTIES:
:NOTER_PAGE: 201
:END:
**** Differentiation and Anaplasia
:PROPERTIES:
:NOTER_PAGE: 201
:END:
**** Local Invasion
:PROPERTIES:
:NOTER_PAGE: 203
:END:
**** Metastasis
:PROPERTIES:
:NOTER_PAGE: 204
:END:
*** Epidemiology
:PROPERTIES:
:NOTER_PAGE: 205
:END:
**** Cancer Incidence
:PROPERTIES:
:NOTER_PAGE: 206
:END:
**** Environmental Factors
:PROPERTIES:
:NOTER_PAGE: 206
:END:
**** Age and Cancer
:PROPERTIES:
:NOTER_PAGE: 208
:END:
**** Acquired Predisposing Conditions
:PROPERTIES:
:NOTER_PAGE: 208
:END:
**** Interactions Between Environmental and Genetic Factors
:PROPERTIES:
:NOTER_PAGE: 209
:END:
*** Cancer Genes
:PROPERTIES:
:NOTER_PAGE: 209
:END:
*** Genetic Lesions in Cancer
:PROPERTIES:
:NOTER_PAGE: 210
:END:
**** Driver and Passenger Mutations
:PROPERTIES:
:NOTER_PAGE: 210
:END:
***** Point Mutations
:PROPERTIES:
:NOTER_PAGE: 210
:END:
***** Gene Rearrangements
:PROPERTIES:
:NOTER_PAGE: 210
:END:
***** Deletions
:PROPERTIES:
:NOTER_PAGE: 211
:END:
***** Gene Amplifications
:PROPERTIES:
:NOTER_PAGE: 212
:END:
***** Aneuploidy
:PROPERTIES:
:NOTER_PAGE: 212
:END:
***** MicroRNAs and Cancer
:PROPERTIES:
:NOTER_PAGE: 212
:END:
**** Epigenetic Modifications and Cancer
:PROPERTIES:
:NOTER_PAGE: 212
:END:
*** Carcinogenesis: A Multistep Process
:PROPERTIES:
:NOTER_PAGE: 213
:END:
*** Hallmarks of Cancer
:PROPERTIES:
:NOTER_PAGE: 213
:END:
**** Self-Sufficiency in Growth Signals
:PROPERTIES:
:NOTER_PAGE: 214
:END:
***** Growth Factors
:PROPERTIES:
:NOTER_PAGE: 215
:END:
***** Growth Factor Receptors
:PROPERTIES:
:NOTER_PAGE: 215
:END:
***** Downstream Signal-Transducing Proteins
:PROPERTIES:
:NOTER_PAGE: 215
:END:
****** RAS
:PROPERTIES:
:NOTER_PAGE: 215
:END:
****** ABL
:PROPERTIES:
:NOTER_PAGE: 216
:END:
***** Nuclear Transcription Factors
:PROPERTIES:
:NOTER_PAGE: 216
:END:
***** Cyclins and Cyclin-Dependent Kinases
:PROPERTIES:
:NOTER_PAGE: 216
:END:
**** Insensitivity to Growth Inhibitory Signals: Tumor Suppressor Genes
:PROPERTIES:
:NOTER_PAGE: 217
:END:
***** RB: Governor of the Cell Cycle
:PROPERTIES:
:NOTER_PAGE: 217
:END:
***** TP53: Guardian of the Genome
:PROPERTIES:
:NOTER_PAGE: 220
:END:
***** Transforming Growth Factor-β Pathway
:PROPERTIES:
:NOTER_PAGE: 222
:END:
***** Contact Inhibition, NF2, and APC
:PROPERTIES:
:NOTER_PAGE: 222
:END:
**** Altered Cellular Metabolism
:PROPERTIES:
:NOTER_PAGE: 223
:END:
***** Autophagy
:PROPERTIES:
:NOTER_PAGE: 225
:END:
***** Oncometabolism
:PROPERTIES:
:NOTER_PAGE: 225
:END:
**** Evasion of Cell Death
:PROPERTIES:
:NOTER_PAGE: 226
:END:
**** Limitless Replicative Potential (Immortality)
:PROPERTIES:
:NOTER_PAGE: 227
:END:
**** Sustained Angiogenesis
:PROPERTIES:
:NOTER_PAGE: 228
:END:
**** Invasion and Metastasis
:PROPERTIES:
:NOTER_PAGE: 229
:END:
***** Invasion of Extracellular Matrix
:PROPERTIES:
:NOTER_PAGE: 229
:END:
***** Vascular Dissemination and Homing of Tumor Cells
:PROPERTIES:
:NOTER_PAGE: 231
:END:
***** Metastasis
:PROPERTIES:
:NOTER_PAGE: 232
:END:
**** Evasion of Immune Surveillance
:PROPERTIES:
:NOTER_PAGE: 232
:END:
***** Tumor Antigens.
:PROPERTIES:
:NOTER_PAGE: 233
:END:
***** Effective Immune Responses to Tumor Antigens.
:PROPERTIES:
:NOTER_PAGE: 233
:END:
***** Immune Evasion by Cancers.
:PROPERTIES:
:NOTER_PAGE: 233
:END:
***** Genomic Instability as an Enabler of Malignancy
:PROPERTIES:
:NOTER_PAGE: 235
:END:
***** Hereditary Nonpolyposis Colon Cancer Syndrome
:PROPERTIES:
:NOTER_PAGE: 236
:END:
***** Xeroderma Pigmentosum
:PROPERTIES:
:NOTER_PAGE: 236
:END:
***** Diseases With Defects in DNA Repair by Homologous Recombination
:PROPERTIES:
:NOTER_PAGE: 236
:END:
***** Cancers Resulting From Mutations Induced by Regulated Genomic Instability: Lymphoid Neoplasms
:PROPERTIES:
:NOTER_PAGE: 236
:END:
**** Tumor-Promoting Inflammation as an Enabler of Malignancy
:PROPERTIES:
:NOTER_PAGE: 237
:END:
*** Etiology of Cancer: Carcinogenic Agents
:PROPERTIES:
:NOTER_PAGE: 237
:END:
**** Chemical Carcinogens
:PROPERTIES:
:NOTER_PAGE: 237
:END:
***** Direct-Acting Agents
:PROPERTIES:
:NOTER_PAGE: 238
:END:
***** Indirect-Acting Agents
:PROPERTIES:
:NOTER_PAGE: 238
:END:
***** Mechanisms of Action of Chemical Carcinogens
:PROPERTIES:
:NOTER_PAGE: 239
:END:
**** Radiation Carcinogenesis
:PROPERTIES:
:NOTER_PAGE: 240
:END:
**** Viral and Microbial Oncogenesis
:PROPERTIES:
:NOTER_PAGE: 240
:END:
***** Oncogenic RNA Viruses
:PROPERTIES:
:NOTER_PAGE: 240
:END:
***** Oncogenic DNA Viruses
:PROPERTIES:
:NOTER_PAGE: 241
:END:
****** Human Papillomavirus
:PROPERTIES:
:NOTER_PAGE: 241
:END:
****** Epstein-Barr Virus
:PROPERTIES:
:NOTER_PAGE: 242
:END:
****** Hepatitis B and Hepatitis C Viruses
:PROPERTIES:
:NOTER_PAGE: 243
:END:
****** Helicobacter pylori
:PROPERTIES:
:NOTER_PAGE: 244
:END:
*** Clinical Aspects of Neoplasia
:PROPERTIES:
:NOTER_PAGE: 244
:END:
**** Effects of Tumor on Host
:PROPERTIES:
:NOTER_PAGE: 244
:END:
***** Cancer Cachexia
:PROPERTIES:
:NOTER_PAGE: 245
:END:
***** Paraneoplastic Syndromes
:PROPERTIES:
:NOTER_PAGE: 245
:END:
**** Grading and Staging of Cancer
:PROPERTIES:
:NOTER_PAGE: 245
:END:
**** Laboratory Diagnosis of Cancer
:PROPERTIES:
:NOTER_PAGE: 246
:END:
***** Morphologic Methods
:PROPERTIES:
:NOTER_PAGE: 247
:END:
***** Tumor Markers
:PROPERTIES:
:NOTER_PAGE: 247
:END:
***** Molecular Diagnosis
:PROPERTIES:
:NOTER_PAGE: 248
:END:
***** Molecular Profiling of Tumors: The Future of Cancer Diagnostics
:PROPERTIES:
:NOTER_PAGE: 248
:END:
*** Suggested Readings
:PROPERTIES:
:NOTER_PAGE: 250
:END:
** 7 Genetic and Pediatric Diseases
:PROPERTIES:
:NOTER_PAGE: 252
:END:
*** Chapter Outline
:PROPERTIES:
:NOTER_PAGE: 252
:END:
*** Genetic Diseases
:PROPERTIES:
:NOTER_PAGE: 252
:END:
**** Nature of Genetic Abnormalities Contributing to Human Disease
:PROPERTIES:
:NOTER_PAGE: 253
:END:
***** Mutations in Protein-Coding Genes
:PROPERTIES:
:NOTER_PAGE: 253
:END:
***** Alterations in Protein-Coding Genes Other Than Mutations
:PROPERTIES:
:NOTER_PAGE: 253
:END:
****** Alterations in Non-Coding RNAs
:PROPERTIES:
:NOTER_PAGE: 253
:END:
**** Mendelian Disorders: Diseases Caused by Single-Gene Defects
:PROPERTIES:
:NOTER_PAGE: 254
:END:
***** Transmission Patterns of Single-Gene Disorders
:PROPERTIES:
:NOTER_PAGE: 255
:END:
****** Disorders of Autosomal Dominant Inheritance
:PROPERTIES:
:NOTER_PAGE: 255
:END:
****** Disorders of Autosomal Recessive Inheritance
:PROPERTIES:
:NOTER_PAGE: 255
:END:
****** X-Linked Disorders
:PROPERTIES:
:NOTER_PAGE: 255
:END:
***** Diseases Caused by Mutations in Genes Encoding Structural Proteins
:PROPERTIES:
:NOTER_PAGE: 256
:END:
****** Marfan Syndrome
:PROPERTIES:
:NOTER_PAGE: 256
:END:
****** Ehlers-Danlos Syndromes
:PROPERTIES:
:NOTER_PAGE: 257
:END:
***** Diseases Caused by Mutations in Genes Encoding Receptor Proteins or Channels
:PROPERTIES:
:NOTER_PAGE: 257
:END:
****** Familial Hypercholesterolemia
:PROPERTIES:
:NOTER_PAGE: 257
:END:
******* Normal Cholesterol Metabolism.
:PROPERTIES:
:NOTER_PAGE: 257
:END:
******* Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 258
:END:
****** Cystic Fibrosis
:PROPERTIES:
:NOTER_PAGE: 259
:END:
******* Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 260
:END:
******* Clinical Course
:PROPERTIES:
:NOTER_PAGE: 262
:END:
***** Diseases Caused by Mutations in Genes Encoding Enzyme Proteins
:PROPERTIES:
:NOTER_PAGE: 263
:END:
****** Phenylketonuria (PKU)
:PROPERTIES:
:NOTER_PAGE: 263
:END:
****** Galactosemia
:PROPERTIES:
:NOTER_PAGE: 264
:END:
****** Lysosomal Storage Diseases
:PROPERTIES:
:NOTER_PAGE: 264
:END:
******* Tay-Sachs Disease (GM2 Gangliosidosis: Deficiency in Hexosaminidase β Subunit)
:PROPERTIES:
:NOTER_PAGE: 265
:END:
******* Niemann-Pick Disease Types A and B
:PROPERTIES:
:NOTER_PAGE: 266
:END:
******* Niemann-Pick Disease Type C
:PROPERTIES:
:NOTER_PAGE: 267
:END:
******* Gaucher Disease
:PROPERTIES:
:NOTER_PAGE: 267
:END:
******* Mucopolysaccharidoses
:PROPERTIES:
:NOTER_PAGE: 268
:END:
****** Glycogen Storage Diseases (Glycogenoses)
:PROPERTIES:
:NOTER_PAGE: 269
:END:
***** Diseases Caused by Mutations in Genes Encoding Proteins That Regulate Cell Growth
:PROPERTIES:
:NOTER_PAGE: 270
:END:
**** Complex Multigenic Disorders
:PROPERTIES:
:NOTER_PAGE: 270
:END:
**** Cytogenetic Disorders
:PROPERTIES:
:NOTER_PAGE: 271
:END:
***** Numeric Abnormalities
:PROPERTIES:
:NOTER_PAGE: 271
:END:
***** Structural Abnormalities
:PROPERTIES:
:NOTER_PAGE: 272
:END:
***** General Features of Chromosomal Disorders
:PROPERTIES:
:NOTER_PAGE: 273
:END:
***** Cytogenetic Disorders Involving Autosomes
:PROPERTIES:
:NOTER_PAGE: 273
:END:
****** Trisomy 21 (Down Syndrome)
:PROPERTIES:
:NOTER_PAGE: 273
:END:
****** 22q11.2 Deletion Syndrome
:PROPERTIES:
:NOTER_PAGE: 275
:END:
***** Cytogenetic Disorders Involving Sex Chromosomes
:PROPERTIES:
:NOTER_PAGE: 276
:END:
****** Klinefelter Syndrome
:PROPERTIES:
:NOTER_PAGE: 276
:END:
****** Turner Syndrome
:PROPERTIES:
:NOTER_PAGE: 276
:END:
**** Single-Gene Disorders With Atypical Patterns of Inheritance
:PROPERTIES:
:NOTER_PAGE: 278
:END:
***** Triplet Repeat Mutations
:PROPERTIES:
:NOTER_PAGE: 278
:END:
****** Fragile X Syndrome
:PROPERTIES:
:NOTER_PAGE: 278
:END:
****** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 278
:END:
****** Fragile X Tremor/Ataxia
:PROPERTIES:
:NOTER_PAGE: 279
:END:
***** Diseases Caused by Mutations in Mitochondrial Genes
:PROPERTIES:
:NOTER_PAGE: 280
:END:
***** Diseases Caused by Alterations of Imprinted Regions: Prader-Willi and Angelman Syndromes
:PROPERTIES:
:NOTER_PAGE: 280
:END:
*** Pediatric Diseases
:PROPERTIES:
:NOTER_PAGE: 282
:END:
**** Congenital Anomalies
:PROPERTIES:
:NOTER_PAGE: 282
:END:
***** Etiology
:PROPERTIES:
:NOTER_PAGE: 284
:END:
****** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 285
:END:
**** Perinatal Infections
:PROPERTIES:
:NOTER_PAGE: 286
:END:
**** Prematurity and Fetal Growth Restriction
:PROPERTIES:
:NOTER_PAGE: 286
:END:
**** Respiratory Distress Syndrome of the Newborn
:PROPERTIES:
:NOTER_PAGE: 287
:END:
***** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 287
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 287
:END:
**** Necrotizing Enterocolitis
:PROPERTIES:
:NOTER_PAGE: 288
:END:
**** Sudden Infant Death Syndrome (SIDS)
:PROPERTIES:
:NOTER_PAGE: 289
:END:
***** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 289
:END:
**** Fetal Hydrops
:PROPERTIES:
:NOTER_PAGE: 291
:END:
***** Immune Hydrops
:PROPERTIES:
:NOTER_PAGE: 292
:END:
***** Nonimmune Hydrops
:PROPERTIES:
:NOTER_PAGE: 292
:END:
****** Clinical Course
:PROPERTIES:
:NOTER_PAGE: 293
:END:
**** Tumors and Tumorlike Lesions of Infancy and Childhood
:PROPERTIES:
:NOTER_PAGE: 294
:END:
***** Benign Neoplasms
:PROPERTIES:
:NOTER_PAGE: 294
:END:
***** Malignant Neoplasms
:PROPERTIES:
:NOTER_PAGE: 295
:END:
****** Neuroblastoma
:PROPERTIES:
:NOTER_PAGE: 295
:END:
******* Clinical Course and Prognosis
:PROPERTIES:
:NOTER_PAGE: 296
:END:
****** Retinoblastoma
:PROPERTIES:
:NOTER_PAGE: 298
:END:
******* Clinical Features
:PROPERTIES:
:NOTER_PAGE: 298
:END:
****** Wilms Tumor
:PROPERTIES:
:NOTER_PAGE: 298
:END:
******* Clinical Course
:PROPERTIES:
:NOTER_PAGE: 300
:END:
**** Molecular Diagnosis of Mendelian and Complex Disorders
:PROPERTIES:
:NOTER_PAGE: 300
:END:
***** Indications for Genetic Analysis
:PROPERTIES:
:NOTER_PAGE: 301
:END:
***** Molecular Diagnosis of Copy Number Abnormalities
:PROPERTIES:
:NOTER_PAGE: 301
:END:
****** Fluorescence in Situ Hybridization
:PROPERTIES:
:NOTER_PAGE: 301
:END:
****** Array-Based Genomic Hybridization
:PROPERTIES:
:NOTER_PAGE: 302
:END:
***** Direct Detection of DNA Mutations by Polymerase Chain Reaction (PCR) Analysis
:PROPERTIES:
:NOTER_PAGE: 303
:END:
****** Next Generation Sequencing
:PROPERTIES:
:NOTER_PAGE: 304
:END:
***** Linkage Analysis and Genomewide Association Studies
:PROPERTIES:
:NOTER_PAGE: 304
:END:
****** Linkage Analysis
:PROPERTIES:
:NOTER_PAGE: 305
:END:
****** Genomewide Association Studies (GWASs)
:PROPERTIES:
:NOTER_PAGE: 305
:END:
*** Suggested Readings
:PROPERTIES:
:NOTER_PAGE: 305
:END:
** 8 Environmental and Nutritional Diseases
:PROPERTIES:
:NOTER_PAGE: 307
:END:
*** Chapter Outline
:PROPERTIES:
:NOTER_PAGE: 307
:END:
*** Health Effects of Climate Change
:PROPERTIES:
:NOTER_PAGE: 307
:END:
*** Toxicity of Chemical and Physical Agents
:PROPERTIES:
:NOTER_PAGE: 309
:END:
*** Environmental Pollution
:PROPERTIES:
:NOTER_PAGE: 310
:END:
**** Air Pollution
:PROPERTIES:
:NOTER_PAGE: 310
:END:
***** Outdoor Air Pollution
:PROPERTIES:
:NOTER_PAGE: 310
:END:
***** Indoor Air Pollution
:PROPERTIES:
:NOTER_PAGE: 311
:END:
**** Metals as Environmental Pollutants
:PROPERTIES:
:NOTER_PAGE: 312
:END:
***** Lead
:PROPERTIES:
:NOTER_PAGE: 312
:END:
***** Mercury
:PROPERTIES:
:NOTER_PAGE: 313
:END:
***** Arsenic
:PROPERTIES:
:NOTER_PAGE: 313
:END:
***** Cadmium
:PROPERTIES:
:NOTER_PAGE: 314
:END:
**** Industrial and Agricultural Exposures
:PROPERTIES:
:NOTER_PAGE: 314
:END:
*** Effects of Tobacco
:PROPERTIES:
:NOTER_PAGE: 315
:END:
*** Effects of Alcohol
:PROPERTIES:
:NOTER_PAGE: 318
:END:
*** Injury by Therapeutic Drugs and Drugs of Abuse
:PROPERTIES:
:NOTER_PAGE: 320
:END:
**** Injury by Therapeutic Drugs: Adverse Drug Reactions
:PROPERTIES:
:NOTER_PAGE: 320
:END:
***** Exogenous Estrogens and Oral Contraceptives
:PROPERTIES:
:NOTER_PAGE: 321
:END:
****** Menopausal Hormone Therapy (MHT)
:PROPERTIES:
:NOTER_PAGE: 321
:END:
****** Oral Contraceptives
:PROPERTIES:
:NOTER_PAGE: 322
:END:
***** Acetaminophen
:PROPERTIES:
:NOTER_PAGE: 322
:END:
***** Aspirin (Acetylsalicylic Acid)
:PROPERTIES:
:NOTER_PAGE: 322
:END:
**** Injury by Nontherapeutic Agents (Drug Abuse)
:PROPERTIES:
:NOTER_PAGE: 323
:END:
***** Cocaine
:PROPERTIES:
:NOTER_PAGE: 323
:END:
***** Heroin and Other Opioids
:PROPERTIES:
:NOTER_PAGE: 324
:END:
***** Marijuana
:PROPERTIES:
:NOTER_PAGE: 325
:END:
***** Other Illicit Drugs
:PROPERTIES:
:NOTER_PAGE: 325
:END:
*** Injury by Physical Agents
:PROPERTIES:
:NOTER_PAGE: 325
:END:
**** Mechanical Trauma
:PROPERTIES:
:NOTER_PAGE: 325
:END:
**** Thermal Injury
:PROPERTIES:
:NOTER_PAGE: 326
:END:
***** Thermal Burns
:PROPERTIES:
:NOTER_PAGE: 326
:END:
***** Hyperthermia
:PROPERTIES:
:NOTER_PAGE: 327
:END:
***** Hypothermia
:PROPERTIES:
:NOTER_PAGE: 327
:END:
**** Electrical Injury
:PROPERTIES:
:NOTER_PAGE: 327
:END:
**** Injury Produced by Ionizing Radiation
:PROPERTIES:
:NOTER_PAGE: 328
:END:
***** Main Determinants of the Biologic Effects of Ionizing Radiation
:PROPERTIES:
:NOTER_PAGE: 328
:END:
***** DNA Damage and Carcinogenesis
:PROPERTIES:
:NOTER_PAGE: 329
:END:
***** Fibrosis
:PROPERTIES:
:NOTER_PAGE: 329
:END:
***** Effects on Organ Systems
:PROPERTIES:
:NOTER_PAGE: 330
:END:
***** Total-Body Irradiation
:PROPERTIES:
:NOTER_PAGE: 331
:END:
*** Nutritional Diseases
:PROPERTIES:
:NOTER_PAGE: 331
:END:
**** Malnutrition
:PROPERTIES:
:NOTER_PAGE: 332
:END:
**** Severe Acute Malnutrition
:PROPERTIES:
:NOTER_PAGE: 332
:END:
***** Marasmus
:PROPERTIES:
:NOTER_PAGE: 333
:END:
***** Kwashiorkor
:PROPERTIES:
:NOTER_PAGE: 333
:END:
***** Secondary Malnutrition
:PROPERTIES:
:NOTER_PAGE: 334
:END:
**** Anorexia Nervosa and Bulimia
:PROPERTIES:
:NOTER_PAGE: 334
:END:
**** Vitamin Deficiencies
:PROPERTIES:
:NOTER_PAGE: 334
:END:
***** Vitamin A
:PROPERTIES:
:NOTER_PAGE: 335
:END:
****** Function.
:PROPERTIES:
:NOTER_PAGE: 335
:END:
****** Deficiency States.
:PROPERTIES:
:NOTER_PAGE: 336
:END:
****** Vitamin A Toxicity.
:PROPERTIES:
:NOTER_PAGE: 337
:END:
***** Vitamin D
:PROPERTIES:
:NOTER_PAGE: 337
:END:
****** Metabolism.
:PROPERTIES:
:NOTER_PAGE: 337
:END:
****** Functions.
:PROPERTIES:
:NOTER_PAGE: 337
:END:
****** Deficiency States
:PROPERTIES:
:NOTER_PAGE: 338
:END:
******* Nonskeletal Effects of Vitamin D.
:PROPERTIES:
:NOTER_PAGE: 339
:END:
******* Toxicity.
:PROPERTIES:
:NOTER_PAGE: 340
:END:
***** Vitamin C (Ascorbic Acid)
:PROPERTIES:
:NOTER_PAGE: 340
:END:
****** Function.
:PROPERTIES:
:NOTER_PAGE: 340
:END:
****** Deficiency States.
:PROPERTIES:
:NOTER_PAGE: 340
:END:
****** Toxicity.
:PROPERTIES:
:NOTER_PAGE: 340
:END:
**** Obesity
:PROPERTIES:
:NOTER_PAGE: 342
:END:
***** Leptin
:PROPERTIES:
:NOTER_PAGE: 343
:END:
***** Adiponectin
:PROPERTIES:
:NOTER_PAGE: 344
:END:
***** Adipose Tissue and Other Mediators
:PROPERTIES:
:NOTER_PAGE: 344
:END:
***** Gut Hormones
:PROPERTIES:
:NOTER_PAGE: 344
:END:
***** The Role of Gut Microbiome
:PROPERTIES:
:NOTER_PAGE: 344
:END:
***** Clinical Consequences of Obesity
:PROPERTIES:
:NOTER_PAGE: 344
:END:
****** Obesity and Cancer
:PROPERTIES:
:NOTER_PAGE: 345
:END:
**** Diet and Systemic Diseases
:PROPERTIES:
:NOTER_PAGE: 345
:END:
**** Diet and Cancer
:PROPERTIES:
:NOTER_PAGE: 346
:END:
*** Suggested Readings
:PROPERTIES:
:NOTER_PAGE: 346
:END:
** 9 General Pathology of Infectious Diseases
:PROPERTIES:
:NOTER_PAGE: 348
:END:
*** Chapter Outline
:PROPERTIES:
:NOTER_PAGE: 348
:END:
*** General Principles of Microbial Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 348
:END:
**** Categories of Infectious Agents
:PROPERTIES:
:NOTER_PAGE: 348
:END:
***** Prions
:PROPERTIES:
:NOTER_PAGE: 348
:END:
***** Viruses
:PROPERTIES:
:NOTER_PAGE: 348
:END:
***** Bacteria
:PROPERTIES:
:NOTER_PAGE: 349
:END:
***** Fungi
:PROPERTIES:
:NOTER_PAGE: 350
:END:
***** Protozoa
:PROPERTIES:
:NOTER_PAGE: 352
:END:
***** Helminths
:PROPERTIES:
:NOTER_PAGE: 352
:END:
***** Ectoparasites
:PROPERTIES:
:NOTER_PAGE: 353
:END:
*** The Microbiome
:PROPERTIES:
:NOTER_PAGE: 353
:END:
*** Techniques for Identifying Infectious Agents
:PROPERTIES:
:NOTER_PAGE: 353
:END:
*** Newly Emerging and Reemerging Infectious Diseases
:PROPERTIES:
:NOTER_PAGE: 354
:END:
*** Agents of Bioterrorism
:PROPERTIES:
:NOTER_PAGE: 355
:END:
*** Transmission and Dissemination of Microbes
:PROPERTIES:
:NOTER_PAGE: 356
:END:
**** Routes of Entry of Microbes
:PROPERTIES:
:NOTER_PAGE: 356
:END:
***** Skin
:PROPERTIES:
:NOTER_PAGE: 356
:END:
***** Gastrointestinal Tract
:PROPERTIES:
:NOTER_PAGE: 356
:END:
***** Respiratory Tract
:PROPERTIES:
:NOTER_PAGE: 357
:END:
***** Urogenital Tract
:PROPERTIES:
:NOTER_PAGE: 358
:END:
**** Spread and Dissemination of Microbes Within the Body
:PROPERTIES:
:NOTER_PAGE: 358
:END:
**** Transmission of Microbes
:PROPERTIES:
:NOTER_PAGE: 359
:END:
*** How Microorganisms Cause Disease
:PROPERTIES:
:NOTER_PAGE: 359
:END:
**** Mechanisms of Viral Injury
:PROPERTIES:
:NOTER_PAGE: 360
:END:
**** Mechanisms of Bacterial Injury
:PROPERTIES:
:NOTER_PAGE: 360
:END:
***** Bacterial Virulence
:PROPERTIES:
:NOTER_PAGE: 360
:END:
***** Bacterial Adherence to Host Cells
:PROPERTIES:
:NOTER_PAGE: 361
:END:
***** Bacterial Toxins
:PROPERTIES:
:NOTER_PAGE: 361
:END:
**** Injurious Effects of Host Immune Responses
:PROPERTIES:
:NOTER_PAGE: 362
:END:
*** Immune Evasion by Microbes
:PROPERTIES:
:NOTER_PAGE: 362
:END:
*** Spectrum of Inflammatory Responses to Infection
:PROPERTIES:
:NOTER_PAGE: 364
:END:
**** Mononuclear and Granulomatous Inflammation
:PROPERTIES:
:NOTER_PAGE: 364
:END:
**** Cytopathic-Cytoproliferative Reaction
:PROPERTIES:
:NOTER_PAGE: 364
:END:
**** Tissue Necrosis
:PROPERTIES:
:NOTER_PAGE: 365
:END:
**** Chronic Inflammation and Scarring
:PROPERTIES:
:NOTER_PAGE: 365
:END:
**** Infections in Individuals With Immunodeficiencies
:PROPERTIES:
:NOTER_PAGE: 365
:END:
*** Suggested Readings
:PROPERTIES:
:NOTER_PAGE: 366
:END:
** 10 Blood Vessels
:PROPERTIES:
:NOTER_PAGE: 368
:END:
*** Chapter Outline
:PROPERTIES:
:NOTER_PAGE: 368
:END:
*** Structure and Function of Blood Vessels
:PROPERTIES:
:NOTER_PAGE: 368
:END:
**** Vascular Organization
:PROPERTIES:
:NOTER_PAGE: 369
:END:
**** Endothelial Cells
:PROPERTIES:
:NOTER_PAGE: 370
:END:
**** Vascular Smooth Muscle Cells
:PROPERTIES:
:NOTER_PAGE: 371
:END:
*** Congenital Anomalies
:PROPERTIES:
:NOTER_PAGE: 371
:END:
*** Blood Pressure Regulation
:PROPERTIES:
:NOTER_PAGE: 371
:END:
*** Hypertensive Vascular Disease
:PROPERTIES:
:NOTER_PAGE: 373
:END:
**** Epidemiology of Hypertension
:PROPERTIES:
:NOTER_PAGE: 373
:END:
***** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 374
:END:
**** Mechanisms of Essential Hypertension
:PROPERTIES:
:NOTER_PAGE: 374
:END:
*** Vascular Wall Response to Injury
:PROPERTIES:
:NOTER_PAGE: 375
:END:
**** Intimal Thickening: A Stereotypical Response to Vascular Injury
:PROPERTIES:
:NOTER_PAGE: 375
:END:
*** Arteriosclerosis
:PROPERTIES:
:NOTER_PAGE: 376
:END:
*** Atherosclerosis
:PROPERTIES:
:NOTER_PAGE: 376
:END:
**** Epidemiology of Atherosclerosis
:PROPERTIES:
:NOTER_PAGE: 377
:END:
***** Constitutional Risk Factors
:PROPERTIES:
:NOTER_PAGE: 377
:END:
***** Modifiable Major Risk Factors
:PROPERTIES:
:NOTER_PAGE: 378
:END:
***** Additional Risk Factors
:PROPERTIES:
:NOTER_PAGE: 378
:END:
****** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 379
:END:
****** Endothelial Injury
:PROPERTIES:
:NOTER_PAGE: 379
:END:
****** Hemodynamic Disturbances
:PROPERTIES:
:NOTER_PAGE: 380
:END:
****** Lipids
:PROPERTIES:
:NOTER_PAGE: 380
:END:
****** Inflammation
:PROPERTIES:
:NOTER_PAGE: 381
:END:
****** SMC Proliferation and Matrix Synthesis
:PROPERTIES:
:NOTER_PAGE: 381
:END:
**** Clinicopathologic Consequences of Atherosclerosis
:PROPERTIES:
:NOTER_PAGE: 383
:END:
***** Atherosclerotic Stenosis
:PROPERTIES:
:NOTER_PAGE: 383
:END:
***** Acute Plaque Change
:PROPERTIES:
:NOTER_PAGE: 384
:END:
*** Aneurysms and Dissections
:PROPERTIES:
:NOTER_PAGE: 385
:END:
**** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 385
:END:
**** Abdominal Aortic Aneurysm
:PROPERTIES:
:NOTER_PAGE: 386
:END:
***** Clinical Consequences
:PROPERTIES:
:NOTER_PAGE: 387
:END:
**** Thoracic Aortic Aneurysm
:PROPERTIES:
:NOTER_PAGE: 387
:END:
**** Aortic Dissection
:PROPERTIES:
:NOTER_PAGE: 387
:END:
***** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 388
:END:
***** Clinical Consequences
:PROPERTIES:
:NOTER_PAGE: 388
:END:
*** Vasculitis
:PROPERTIES:
:NOTER_PAGE: 389
:END:
**** Noninfectious Vasculitis
:PROPERTIES:
:NOTER_PAGE: 389
:END:
***** Immune Complex–Associated Vasculitis
:PROPERTIES:
:NOTER_PAGE: 389
:END:
***** Anti-Neutrophil Cytoplasmic Antibodies
:PROPERTIES:
:NOTER_PAGE: 391
:END:
***** Anti-Endothelial Cell Antibodies and Autoreactive T Cells
:PROPERTIES:
:NOTER_PAGE: 391
:END:
***** Giant Cell (Temporal) Arteritis
:PROPERTIES:
:NOTER_PAGE: 391
:END:
****** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 391
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 392
:END:
***** Takayasu Arteritis
:PROPERTIES:
:NOTER_PAGE: 392
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 393
:END:
***** Polyarteritis Nodosa
:PROPERTIES:
:NOTER_PAGE: 393
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 394
:END:
***** Kawasaki Disease
:PROPERTIES:
:NOTER_PAGE: 394
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 394
:END:
***** Microscopic Polyangiitis
:PROPERTIES:
:NOTER_PAGE: 394
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 394
:END:
***** Granulomatosis With Polyangiitis
:PROPERTIES:
:NOTER_PAGE: 395
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 395
:END:
***** Churg-Strauss Syndrome
:PROPERTIES:
:NOTER_PAGE: 396
:END:
***** Thromboangiitis Obliterans (Buerger Disease)
:PROPERTIES:
:NOTER_PAGE: 396
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 396
:END:
***** Vasculitis Associated With Other Noninfectious Disorders
:PROPERTIES:
:NOTER_PAGE: 396
:END:
**** Infectious Vasculitis
:PROPERTIES:
:NOTER_PAGE: 396
:END:
*** Disorders of Blood Vessel Hyperreactivity
:PROPERTIES:
:NOTER_PAGE: 397
:END:
**** Raynaud Phenomenon
:PROPERTIES:
:NOTER_PAGE: 397
:END:
**** Myocardial Vessel Vasospasm
:PROPERTIES:
:NOTER_PAGE: 397
:END:
*** Veins and Lymphatics
:PROPERTIES:
:NOTER_PAGE: 397
:END:
**** Varicose Veins of the Extremities
:PROPERTIES:
:NOTER_PAGE: 397
:END:
***** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 397
:END:
**** Varicosities of Other Sites
:PROPERTIES:
:NOTER_PAGE: 397
:END:
**** Thrombophlebitis and Phlebothrombosis
:PROPERTIES:
:NOTER_PAGE: 398
:END:
**** Superior and Inferior Vena Cava Syndromes
:PROPERTIES:
:NOTER_PAGE: 398
:END:
**** Lymphangitis and Lymphedema
:PROPERTIES:
:NOTER_PAGE: 398
:END:
*** Tumors
:PROPERTIES:
:NOTER_PAGE: 398
:END:
**** Benign Tumors and Tumor-Like Conditions
:PROPERTIES:
:NOTER_PAGE: 399
:END:
***** Vascular Ectasias
:PROPERTIES:
:NOTER_PAGE: 399
:END:
***** Hemangiomas
:PROPERTIES:
:NOTER_PAGE: 399
:END:
***** Lymphangiomas
:PROPERTIES:
:NOTER_PAGE: 400
:END:
***** Glomus Tumors (Glomangiomas)
:PROPERTIES:
:NOTER_PAGE: 401
:END:
***** Bacillary Angiomatosis
:PROPERTIES:
:NOTER_PAGE: 401
:END:
**** Intermediate-Grade (Borderline) Tumors
:PROPERTIES:
:NOTER_PAGE: 401
:END:
***** Kaposi Sarcoma
:PROPERTIES:
:NOTER_PAGE: 401
:END:
****** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 402
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 402
:END:
***** Hemangioendotheliomas
:PROPERTIES:
:NOTER_PAGE: 402
:END:
**** Malignant Tumors
:PROPERTIES:
:NOTER_PAGE: 403
:END:
***** Angiosarcomas
:PROPERTIES:
:NOTER_PAGE: 403
:END:
*** Pathology of Vascular Intervention
:PROPERTIES:
:NOTER_PAGE: 404
:END:
**** Endovascular Stenting
:PROPERTIES:
:NOTER_PAGE: 404
:END:
**** Vascular Replacement
:PROPERTIES:
:NOTER_PAGE: 404
:END:
*** Suggested Readings
:PROPERTIES:
:NOTER_PAGE: 405
:END:
** 11 Heart
:PROPERTIES:
:NOTER_PAGE: 406
:END:
*** Chapter Outline
:PROPERTIES:
:NOTER_PAGE: 406
:END:
*** Overview of Heart Disease
:PROPERTIES:
:NOTER_PAGE: 406
:END:
*** Heart Failure
:PROPERTIES:
:NOTER_PAGE: 407
:END:
**** Left-Sided Heart Failure
:PROPERTIES:
:NOTER_PAGE: 408
:END:
***** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 409
:END:
**** Right-Sided Heart Failure
:PROPERTIES:
:NOTER_PAGE: 409
:END:
***** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 410
:END:
*** Congenital Heart Disease
:PROPERTIES:
:NOTER_PAGE: 410
:END:
**** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 410
:END:
**** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 411
:END:
**** Malformations Associated With Left-to-Right Shunts
:PROPERTIES:
:NOTER_PAGE: 411
:END:
***** Atrial Septal Defects and Patent Foramen Ovale
:PROPERTIES:
:NOTER_PAGE: 412
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 412
:END:
***** Ventricular Septal Defects
:PROPERTIES:
:NOTER_PAGE: 412
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 413
:END:
***** Patent Ductus Arteriosus
:PROPERTIES:
:NOTER_PAGE: 413
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 413
:END:
**** Malformations Associated With Right-to-Left Shunts
:PROPERTIES:
:NOTER_PAGE: 413
:END:
***** Tetralogy of Fallot
:PROPERTIES:
:NOTER_PAGE: 413
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 414
:END:
***** Transposition of the Great Arteries
:PROPERTIES:
:NOTER_PAGE: 414
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 414
:END:
**** Malformations Associated With Obstructive Lesions
:PROPERTIES:
:NOTER_PAGE: 414
:END:
***** Aortic Coarctation
:PROPERTIES:
:NOTER_PAGE: 414
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 415
:END:
*** Ischemic Heart Disease
:PROPERTIES:
:NOTER_PAGE: 415
:END:
**** Epidemiology
:PROPERTIES:
:NOTER_PAGE: 416
:END:
**** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 416
:END:
**** Acute Plaque Change
:PROPERTIES:
:NOTER_PAGE: 417
:END:
**** Angina Pectoris
:PROPERTIES:
:NOTER_PAGE: 418
:END:
**** Myocardial Infarction
:PROPERTIES:
:NOTER_PAGE: 418
:END:
***** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 418
:END:
***** Coronary Artery Occlusion
:PROPERTIES:
:NOTER_PAGE: 418
:END:
***** Myocardial Response to Ischemia
:PROPERTIES:
:NOTER_PAGE: 418
:END:
***** Patterns of Infarction
:PROPERTIES:
:NOTER_PAGE: 419
:END:
***** Infarct Modification by Reperfusion
:PROPERTIES:
:NOTER_PAGE: 422
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 423
:END:
***** Consequences and Complications of Myocardial Infarction
:PROPERTIES:
:NOTER_PAGE: 424
:END:
**** Chronic Ischemic Heart Disease
:PROPERTIES:
:NOTER_PAGE: 426
:END:
**** Cardiac Stem Cells
:PROPERTIES:
:NOTER_PAGE: 426
:END:
*** Arrhythmias
:PROPERTIES:
:NOTER_PAGE: 426
:END:
**** Sudden Cardiac Death
:PROPERTIES:
:NOTER_PAGE: 427
:END:
*** Hypertensive Heart Disease
:PROPERTIES:
:NOTER_PAGE: 427
:END:
**** Systemic (Left-Sided) Hypertensive Heart Disease
:PROPERTIES:
:NOTER_PAGE: 428
:END:
***** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 429
:END:
**** Pulmonary Hypertensive Heart Disease— Cor Pulmonale
:PROPERTIES:
:NOTER_PAGE: 429
:END:
*** Valvular Heart Disease
:PROPERTIES:
:NOTER_PAGE: 429
:END:
**** Degenerative Valve Disease
:PROPERTIES:
:NOTER_PAGE: 430
:END:
***** Calcific Aortic Stenosis
:PROPERTIES:
:NOTER_PAGE: 430
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 431
:END:
***** Myxomatous Mitral Valve
:PROPERTIES:
:NOTER_PAGE: 431
:END:
****** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 431
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 432
:END:
**** Rheumatic Valvular Disease
:PROPERTIES:
:NOTER_PAGE: 432
:END:
***** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 432
:END:
***** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 432
:END:
**** Infective Endocarditis
:PROPERTIES:
:NOTER_PAGE: 434
:END:
***** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 434
:END:
***** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 434
:END:
**** Noninfected Vegetations
:PROPERTIES:
:NOTER_PAGE: 435
:END:
***** Nonbacterial Thrombotic Endocarditis
:PROPERTIES:
:NOTER_PAGE: 435
:END:
***** Endocarditis in Systemic Lupus Erythematosus: Libman-Sacks Endocarditis
:PROPERTIES:
:NOTER_PAGE: 436
:END:
*** Cardiomyopathies and Myocarditis
:PROPERTIES:
:NOTER_PAGE: 436
:END:
**** Dilated Cardiomyopathy
:PROPERTIES:
:NOTER_PAGE: 436
:END:
***** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 437
:END:
***** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 438
:END:
**** Arrhythmogenic Right Ventricular Cardiomyopathy
:PROPERTIES:
:NOTER_PAGE: 439
:END:
**** Hypertrophic Cardiomyopathy
:PROPERTIES:
:NOTER_PAGE: 439
:END:
***** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 439
:END:
***** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 440
:END:
**** Restrictive Cardiomyopathy
:PROPERTIES:
:NOTER_PAGE: 440
:END:
**** Myocarditis
:PROPERTIES:
:NOTER_PAGE: 441
:END:
***** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 441
:END:
***** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 442
:END:
**** Other Causes of Myocardial Disease
:PROPERTIES:
:NOTER_PAGE: 442
:END:
***** Cardiotoxic Drugs
:PROPERTIES:
:NOTER_PAGE: 442
:END:
***** Catecholamines
:PROPERTIES:
:NOTER_PAGE: 442
:END:
*** Pericardial Disease
:PROPERTIES:
:NOTER_PAGE: 443
:END:
**** Pericardial Effusion and Hemopericardium
:PROPERTIES:
:NOTER_PAGE: 443
:END:
**** Pericarditis
:PROPERTIES:
:NOTER_PAGE: 443
:END:
***** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 444
:END:
*** Cardiac Tumors
:PROPERTIES:
:NOTER_PAGE: 444
:END:
**** Primary Neoplasms
:PROPERTIES:
:NOTER_PAGE: 444
:END:
***** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 445
:END:
**** Cardiac Effects of Noncardiac Neoplasms
:PROPERTIES:
:NOTER_PAGE: 445
:END:
***** Carcinoid Heart Disease
:PROPERTIES:
:NOTER_PAGE: 445
:END:
***** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 446
:END:
*** Cardiac Transplantation
:PROPERTIES:
:NOTER_PAGE: 446
:END:
*** Suggested Readings
:PROPERTIES:
:NOTER_PAGE: 446
:END:
** 12 Hematopoietic and Lymphoid Systems
:PROPERTIES:
:NOTER_PAGE: 448
:END:
*** Chapter Outline
:PROPERTIES:
:NOTER_PAGE: 448
:END:
*** Red Cell Disorders
:PROPERTIES:
:NOTER_PAGE: 449
:END:
**** Anemia of Blood Loss: Hemorrhage
:PROPERTIES:
:NOTER_PAGE: 450
:END:
**** Hemolytic Anemia
:PROPERTIES:
:NOTER_PAGE: 450
:END:
***** Hereditary Spherocytosis
:PROPERTIES:
:NOTER_PAGE: 451
:END:
****** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 451
:END:
******* Clinical Features.
:PROPERTIES:
:NOTER_PAGE: 452
:END:
***** Sickle Cell Anemia
:PROPERTIES:
:NOTER_PAGE: 452
:END:
****** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 452
:END:
******* Clinical Features.
:PROPERTIES:
:NOTER_PAGE: 453
:END:
***** Thalassemia
:PROPERTIES:
:NOTER_PAGE: 454
:END:
****** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 454
:END:
****** β-Thalassemia
:PROPERTIES:
:NOTER_PAGE: 455
:END:
****** α-Thalassemia
:PROPERTIES:
:NOTER_PAGE: 455
:END:
******* Clinical Features.
:PROPERTIES:
:NOTER_PAGE: 456
:END:
***** Glucose-6-Phosphate Dehydrogenase Deficiency
:PROPERTIES:
:NOTER_PAGE: 457
:END:
****** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 457
:END:
******* Clinical Features.
:PROPERTIES:
:NOTER_PAGE: 457
:END:
***** Paroxysmal Nocturnal Hemoglobinuria
:PROPERTIES:
:NOTER_PAGE: 457
:END:
***** Immunohemolytic Anemia
:PROPERTIES:
:NOTER_PAGE: 458
:END:
****** Warm Antibody Immunohemolytic Anemia
:PROPERTIES:
:NOTER_PAGE: 458
:END:
****** Cold Antibody Immunohemolytic Anemia
:PROPERTIES:
:NOTER_PAGE: 458
:END:
***** Hemolytic Anemia Resulting From Mechanical Trauma to Red Cells
:PROPERTIES:
:NOTER_PAGE: 458
:END:
***** Malaria
:PROPERTIES:
:NOTER_PAGE: 459
:END:
****** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 459
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 460
:END:
**** Anemia of Diminished Erythropoiesis
:PROPERTIES:
:NOTER_PAGE: 460
:END:
***** Iron Deficiency Anemia
:PROPERTIES:
:NOTER_PAGE: 460
:END:
****** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 462
:END:
******* Clinical Features.
:PROPERTIES:
:NOTER_PAGE: 462
:END:
***** Anemia of Chronic Inflammation
:PROPERTIES:
:NOTER_PAGE: 462
:END:
****** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 463
:END:
******* Clinical Features.
:PROPERTIES:
:NOTER_PAGE: 463
:END:
***** Megaloblastic Anemias
:PROPERTIES:
:NOTER_PAGE: 463
:END:
****** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 463
:END:
****** Folate (Folic Acid) Deficiency Anemia
:PROPERTIES:
:NOTER_PAGE: 463
:END:
******* Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 464
:END:
******** Clinical Features.
:PROPERTIES:
:NOTER_PAGE: 464
:END:
****** Vitamin B12 (Cobalamin) Deficiency Anemia
:PROPERTIES:
:NOTER_PAGE: 464
:END:
******* Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 464
:END:
******** Clinical Features.
:PROPERTIES:
:NOTER_PAGE: 464
:END:
***** Aplastic Anemia
:PROPERTIES:
:NOTER_PAGE: 465
:END:
****** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 465
:END:
******* Clinical Features.
:PROPERTIES:
:NOTER_PAGE: 465
:END:
***** Myelophthisic Anemia
:PROPERTIES:
:NOTER_PAGE: 465
:END:
**** Polycythemia
:PROPERTIES:
:NOTER_PAGE: 466
:END:
*** White Cell Disorders
:PROPERTIES:
:NOTER_PAGE: 466
:END:
**** Nonneoplastic Disorders of White Cells
:PROPERTIES:
:NOTER_PAGE: 466
:END:
***** Leukopenia
:PROPERTIES:
:NOTER_PAGE: 466
:END:
****** Neutropenia/Agranulocytosis
:PROPERTIES:
:NOTER_PAGE: 466
:END:
******* Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 466
:END:
******** Clinical Features.
:PROPERTIES:
:NOTER_PAGE: 467
:END:
***** Reactive Leukocytosis
:PROPERTIES:
:NOTER_PAGE: 467
:END:
****** Infectious Mononucleosis
:PROPERTIES:
:NOTER_PAGE: 467
:END:
******* Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 467
:END:
******** Clinical Features.
:PROPERTIES:
:NOTER_PAGE: 468
:END:
***** Reactive Lymphadenitis
:PROPERTIES:
:NOTER_PAGE: 468
:END:
****** Acute Nonspecific Lymphadenitis
:PROPERTIES:
:NOTER_PAGE: 468
:END:
****** Chronic Nonspecific Lymphadenitis
:PROPERTIES:
:NOTER_PAGE: 469
:END:
****** Cat-Scratch Disease
:PROPERTIES:
:NOTER_PAGE: 469
:END:
****** Hemophagocytic Lymphohistiocytosis (HLH)
:PROPERTIES:
:NOTER_PAGE: 469
:END:
**** Neoplastic Proliferations of White Cells
:PROPERTIES:
:NOTER_PAGE: 470
:END:
***** Lymphoid Neoplasms
:PROPERTIES:
:NOTER_PAGE: 470
:END:
****** Precursor B and T Cell Neoplasms
:PROPERTIES:
:NOTER_PAGE: 472
:END:
******* Acute Lymphoblastic Leukemia/Lymphoma
:PROPERTIES:
:NOTER_PAGE: 472
:END:
******* Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 472
:END:
******** Genetics.
:PROPERTIES:
:NOTER_PAGE: 473
:END:
******** Immunophenotype.
:PROPERTIES:
:NOTER_PAGE: 473
:END:
******** Clinical Features.
:PROPERTIES:
:NOTER_PAGE: 473
:END:
******* Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
:PROPERTIES:
:NOTER_PAGE: 474
:END:
******* Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 474
:END:
******** Immunophenotype and Genetics.
:PROPERTIES:
:NOTER_PAGE: 474
:END:
******** Clinical Features.
:PROPERTIES:
:NOTER_PAGE: 475
:END:
******* Follicular Lymphoma
:PROPERTIES:
:NOTER_PAGE: 475
:END:
******* Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 475
:END:
******** Immunophenotype.
:PROPERTIES:
:NOTER_PAGE: 475
:END:
******** Clinical Features.
:PROPERTIES:
:NOTER_PAGE: 475
:END:
******* Mantle Cell Lymphoma
:PROPERTIES:
:NOTER_PAGE: 476
:END:
******* Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 476
:END:
******** Immunophenotype.
:PROPERTIES:
:NOTER_PAGE: 476
:END:
******** Clinical Features.
:PROPERTIES:
:NOTER_PAGE: 476
:END:
******* Extranodal Marginal Zone Lymphoma
:PROPERTIES:
:NOTER_PAGE: 476
:END:
******* Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 476
:END:
******** Immunophenotype.
:PROPERTIES:
:NOTER_PAGE: 477
:END:
******** Clinical Features.
:PROPERTIES:
:NOTER_PAGE: 477
:END:
******* Diffuse Large B Cell Lymphoma
:PROPERTIES:
:NOTER_PAGE: 477
:END:
******* Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 477
:END:
******** Immunophenotype.
:PROPERTIES:
:NOTER_PAGE: 477
:END:
******** Special Subtypes.
:PROPERTIES:
:NOTER_PAGE: 477
:END:
******** Clinical Features.
:PROPERTIES:
:NOTER_PAGE: 477
:END:
******* Burkitt Lymphoma
:PROPERTIES:
:NOTER_PAGE: 478
:END:
******* Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 478
:END:
******** Immunophenotype.
:PROPERTIES:
:NOTER_PAGE: 478
:END:
******** Clinical Features.
:PROPERTIES:
:NOTER_PAGE: 478
:END:
******* Plasma Cell Neoplasms and Related Entities
:PROPERTIES:
:NOTER_PAGE: 478
:END:
******* Multiple Myeloma
:PROPERTIES:
:NOTER_PAGE: 479
:END:
******* Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 479
:END:
******** Clinical Features.
:PROPERTIES:
:NOTER_PAGE: 479
:END:
******* Lymphoplasmacytic Lymphoma
:PROPERTIES:
:NOTER_PAGE: 480
:END:
******* Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 480
:END:
******** Immunophenotype.
:PROPERTIES:
:NOTER_PAGE: 481
:END:
******** Clinical Features.
:PROPERTIES:
:NOTER_PAGE: 481
:END:
******* Hodgkin Lymphoma
:PROPERTIES:
:NOTER_PAGE: 481
:END:
******** Classification.
:PROPERTIES:
:NOTER_PAGE: 481
:END:
******* Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 483
:END:
******** Clinical Features.
:PROPERTIES:
:NOTER_PAGE: 483
:END:
******* Miscellaneous Lymphoid Neoplasms
:PROPERTIES:
:NOTER_PAGE: 484
:END:
******** Hairy Cell Leukemia.
:PROPERTIES:
:NOTER_PAGE: 484
:END:
******** Mycosis Fungoides and Sézary Syndrome.
:PROPERTIES:
:NOTER_PAGE: 484
:END:
******** Adult T Cell Leukemia/Lymphoma.
:PROPERTIES:
:NOTER_PAGE: 484
:END:
******** Peripheral T Cell Lymphoma.
:PROPERTIES:
:NOTER_PAGE: 484
:END:
***** Myeloid Neoplasms
:PROPERTIES:
:NOTER_PAGE: 485
:END:
****** Acute Myeloid Leukemia
:PROPERTIES:
:NOTER_PAGE: 486
:END:
******* Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 486
:END:
******** Classification.
:PROPERTIES:
:NOTER_PAGE: 486
:END:
******** Immunophenotype.
:PROPERTIES:
:NOTER_PAGE: 486
:END:
******** Clinical Features.
:PROPERTIES:
:NOTER_PAGE: 487
:END:
****** Myelodysplastic Syndromes
:PROPERTIES:
:NOTER_PAGE: 487
:END:
******* Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 488
:END:
******** Clinical Features.
:PROPERTIES:
:NOTER_PAGE: 488
:END:
****** Myeloproliferative Neoplasms
:PROPERTIES:
:NOTER_PAGE: 488
:END:
****** Chronic Myeloid Leukemia
:PROPERTIES:
:NOTER_PAGE: 488
:END:
******* Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 488
:END:
******* Clinical Features
:PROPERTIES:
:NOTER_PAGE: 489
:END:
****** Polycythemia Vera
:PROPERTIES:
:NOTER_PAGE: 489
:END:
******* Clinical Features
:PROPERTIES:
:NOTER_PAGE: 490
:END:
****** Primary Myelofibrosis
:PROPERTIES:
:NOTER_PAGE: 490
:END:
******* Clinical Features
:PROPERTIES:
:NOTER_PAGE: 491
:END:
***** Histiocytic Neoplasms
:PROPERTIES:
:NOTER_PAGE: 491
:END:
****** Langerhans Cell Histiocytoses
:PROPERTIES:
:NOTER_PAGE: 491
:END:
*** Bleeding Disorders
:PROPERTIES:
:NOTER_PAGE: 492
:END:
**** Disseminated Intravascular Coagulation (DIC)
:PROPERTIES:
:NOTER_PAGE: 493
:END:
***** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 493
:END:
***** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 494
:END:
**** Thrombocytopenia
:PROPERTIES:
:NOTER_PAGE: 495
:END:
***** Immune Thrombocytopenic Purpura
:PROPERTIES:
:NOTER_PAGE: 495
:END:
***** Heparin-Induced Thrombocytopenia
:PROPERTIES:
:NOTER_PAGE: 495
:END:
***** Thrombotic Microangiopathies: Thrombotic Thrombocytopenic Purpura and Hemolytic Uremic Syndrome
:PROPERTIES:
:NOTER_PAGE: 496
:END:
**** Coagulation Disorders
:PROPERTIES:
:NOTER_PAGE: 496
:END:
***** Deficiencies of Factor VIII–von Willebrand Factor Complex
:PROPERTIES:
:NOTER_PAGE: 496
:END:
****** von Willebrand Disease
:PROPERTIES:
:NOTER_PAGE: 497
:END:
****** Hemophilia A—Factor VIII Deficiency
:PROPERTIES:
:NOTER_PAGE: 497
:END:
****** Hemophilia B—Factor IX Deficiency
:PROPERTIES:
:NOTER_PAGE: 497
:END:
*** Complications of Transfusion
:PROPERTIES:
:NOTER_PAGE: 498
:END:
**** Allergic Reactions
:PROPERTIES:
:NOTER_PAGE: 498
:END:
**** Hemolytic Reactions
:PROPERTIES:
:NOTER_PAGE: 498
:END:
**** Transfusion-Related Acute Lung Injury
:PROPERTIES:
:NOTER_PAGE: 499
:END:
**** Infectious Complications
:PROPERTIES:
:NOTER_PAGE: 499
:END:
*** Disorders of the Spleen and Thymus
:PROPERTIES:
:NOTER_PAGE: 499
:END:
**** Splenomegaly
:PROPERTIES:
:NOTER_PAGE: 499
:END:
**** Disorders of the Thymus
:PROPERTIES:
:NOTER_PAGE: 500
:END:
***** Thymic Hyperplasia
:PROPERTIES:
:NOTER_PAGE: 500
:END:
***** Thymoma
:PROPERTIES:
:NOTER_PAGE: 500
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 500
:END:
*** Suggested Readings
:PROPERTIES:
:NOTER_PAGE: 500
:END:
**** Red Cell Disorders
:PROPERTIES:
:NOTER_PAGE: 500
:END:
**** White Cell Disorders
:PROPERTIES:
:NOTER_PAGE: 500
:END:
**** Bleeding Disorders
:PROPERTIES:
:NOTER_PAGE: 501
:END:
**** Disorders That Affect the Spleen and Thymus
:PROPERTIES:
:NOTER_PAGE: 501
:END:
** 13 Lung
:PROPERTIES:
:NOTER_PAGE: 502
:END:
*** Chapter Outline
:PROPERTIES:
:NOTER_PAGE: 502
:END:
*** Atelectasis (Collapse)
:PROPERTIES:
:NOTER_PAGE: 502
:END:
*** Acute Respiratory Distress Syndrome
:PROPERTIES:
:NOTER_PAGE: 503
:END:
**** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 503
:END:
**** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 504
:END:
*** Obstructive Versus Restrictive Pulmonary Diseases
:PROPERTIES:
:NOTER_PAGE: 505
:END:
*** Obstructive Lung (Airway) Diseases
:PROPERTIES:
:NOTER_PAGE: 505
:END:
**** Emphysema
:PROPERTIES:
:NOTER_PAGE: 505
:END:
***** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 507
:END:
***** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 508
:END:
***** Conditions Related to Emphysema
:PROPERTIES:
:NOTER_PAGE: 508
:END:
**** Chronic Bronchitis
:PROPERTIES:
:NOTER_PAGE: 509
:END:
***** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 509
:END:
***** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 509
:END:
**** Asthma
:PROPERTIES:
:NOTER_PAGE: 510
:END:
***** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 510
:END:
***** Atopic Asthma
:PROPERTIES:
:NOTER_PAGE: 510
:END:
***** Non-Atopic Asthma
:PROPERTIES:
:NOTER_PAGE: 510
:END:
***** Drug-Induced Asthma
:PROPERTIES:
:NOTER_PAGE: 510
:END:
***** Occupational Asthma
:PROPERTIES:
:NOTER_PAGE: 510
:END:
***** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 512
:END:
**** Bronchiectasis
:PROPERTIES:
:NOTER_PAGE: 512
:END:
***** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 513
:END:
***** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 513
:END:
*** Chronic Interstitial (Restrictive, Infiltrative) Lung Diseases
:PROPERTIES:
:NOTER_PAGE: 513
:END:
**** Fibrosing Diseases
:PROPERTIES:
:NOTER_PAGE: 514
:END:
***** Idiopathic Pulmonary Fibrosis
:PROPERTIES:
:NOTER_PAGE: 514
:END:
****** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 514
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 515
:END:
***** Other Fibrosing Diseases
:PROPERTIES:
:NOTER_PAGE: 515
:END:
***** Pneumoconioses
:PROPERTIES:
:NOTER_PAGE: 515
:END:
****** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 516
:END:
***** Coal Worker’s Pneumoconiosis
:PROPERTIES:
:NOTER_PAGE: 516
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 516
:END:
***** Silicosis
:PROPERTIES:
:NOTER_PAGE: 517
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 518
:END:
***** Asbestosis and Asbestos-Related Diseases
:PROPERTIES:
:NOTER_PAGE: 518
:END:
****** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 518
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 518
:END:
***** Drug- and Radiation-Induced Pulmonary Disease
:PROPERTIES:
:NOTER_PAGE: 519
:END:
**** Granulomatous Diseases
:PROPERTIES:
:NOTER_PAGE: 519
:END:
***** Sarcoidosis
:PROPERTIES:
:NOTER_PAGE: 519
:END:
****** Epidemiology
:PROPERTIES:
:NOTER_PAGE: 519
:END:
****** Etiology and Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 519
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 521
:END:
***** Hypersensitivity Pneumonitis
:PROPERTIES:
:NOTER_PAGE: 521
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 522
:END:
**** Pulmonary Eosinophilia
:PROPERTIES:
:NOTER_PAGE: 522
:END:
**** Smoking-Related Interstitial Diseases
:PROPERTIES:
:NOTER_PAGE: 522
:END:
*** Pulmonary Diseases of Vascular Origin
:PROPERTIES:
:NOTER_PAGE: 522
:END:
**** Pulmonary Embolism, Hemorrhage, and Infarction
:PROPERTIES:
:NOTER_PAGE: 522
:END:
***** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 523
:END:
**** Pulmonary Hypertension
:PROPERTIES:
:NOTER_PAGE: 524
:END:
***** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 524
:END:
***** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 525
:END:
**** Diffuse Alveolar Hemorrhage Syndromes
:PROPERTIES:
:NOTER_PAGE: 526
:END:
***** Goodpasture Syndrome
:PROPERTIES:
:NOTER_PAGE: 526
:END:
***** Granulomatosis and Polyangiitis
:PROPERTIES:
:NOTER_PAGE: 526
:END:
*** Pulmonary Infections
:PROPERTIES:
:NOTER_PAGE: 526
:END:
**** Community-Acquired Bacterial Pneumonias
:PROPERTIES:
:NOTER_PAGE: 527
:END:
***** Streptococcus pneumoniae
:PROPERTIES:
:NOTER_PAGE: 527
:END:
***** Haemophilus influenzae
:PROPERTIES:
:NOTER_PAGE: 528
:END:
***** Moraxella catarrhalis
:PROPERTIES:
:NOTER_PAGE: 528
:END:
***** Staphylococcus aureus
:PROPERTIES:
:NOTER_PAGE: 528
:END:
***** Klebsiella pneumoniae
:PROPERTIES:
:NOTER_PAGE: 528
:END:
***** Pseudomonas aeruginosa
:PROPERTIES:
:NOTER_PAGE: 528
:END:
***** Legionella pneumophila
:PROPERTIES:
:NOTER_PAGE: 528
:END:
***** Mycoplasma pneumoniae
:PROPERTIES:
:NOTER_PAGE: 529
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 530
:END:
**** Community-Acquired Viral Pneumonias
:PROPERTIES:
:NOTER_PAGE: 530
:END:
***** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 531
:END:
***** Influenza Infections
:PROPERTIES:
:NOTER_PAGE: 531
:END:
**** Hospital-Acquired Pneumonias
:PROPERTIES:
:NOTER_PAGE: 531
:END:
**** Aspiration Pneumonia
:PROPERTIES:
:NOTER_PAGE: 532
:END:
**** Lung Abscess
:PROPERTIES:
:NOTER_PAGE: 532
:END:
***** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 532
:END:
**** Chronic Pneumonias
:PROPERTIES:
:NOTER_PAGE: 532
:END:
**** Tuberculosis
:PROPERTIES:
:NOTER_PAGE: 533
:END:
***** Epidemiology
:PROPERTIES:
:NOTER_PAGE: 533
:END:
****** Etiology and Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 533
:END:
****** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 533
:END:
***** Primary Tuberculosis
:PROPERTIES:
:NOTER_PAGE: 535
:END:
***** Secondary Tuberculosis (Reactivation Tuberculosis)
:PROPERTIES:
:NOTER_PAGE: 535
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 537
:END:
***** Nontuberculous Mycobacterial Disease
:PROPERTIES:
:NOTER_PAGE: 539
:END:
**** Histoplasmosis, Coccidioidomycosis, and Blastomycosis
:PROPERTIES:
:NOTER_PAGE: 539
:END:
***** Epidemiology
:PROPERTIES:
:NOTER_PAGE: 539
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 539
:END:
**** Pneumonia in the Immunocompromised Host
:PROPERTIES:
:NOTER_PAGE: 540
:END:
***** Cytomegalovirus Infection
:PROPERTIES:
:NOTER_PAGE: 540
:END:
***** Cytomegalovirus Mononucleosis
:PROPERTIES:
:NOTER_PAGE: 541
:END:
***** Cytomegalovirus Infection in Immunosuppressed Individuals
:PROPERTIES:
:NOTER_PAGE: 541
:END:
***** Pneumocystis
:PROPERTIES:
:NOTER_PAGE: 541
:END:
**** Opportunistic Fungal Infections
:PROPERTIES:
:NOTER_PAGE: 542
:END:
***** Candidiasis
:PROPERTIES:
:NOTER_PAGE: 542
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 542
:END:
***** Cryptococcosis
:PROPERTIES:
:NOTER_PAGE: 543
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 543
:END:
***** The Opportunistic Molds
:PROPERTIES:
:NOTER_PAGE: 544
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 544
:END:
**** Pulmonary Disease in Human Immunodeficiency Virus Infection
:PROPERTIES:
:NOTER_PAGE: 544
:END:
*** Lung Tumors
:PROPERTIES:
:NOTER_PAGE: 544
:END:
**** Carcinomas
:PROPERTIES:
:NOTER_PAGE: 544
:END:
***** Etiology and Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 545
:END:
***** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 547
:END:
**** Carcinoid Tumors
:PROPERTIES:
:NOTER_PAGE: 550
:END:
*** Pleural Lesions
:PROPERTIES:
:NOTER_PAGE: 551
:END:
**** Pleural Effusion and Pleuritis
:PROPERTIES:
:NOTER_PAGE: 551
:END:
**** Pneumothorax, Hemothorax, and Chylothorax
:PROPERTIES:
:NOTER_PAGE: 551
:END:
**** Malignant Mesothelioma
:PROPERTIES:
:NOTER_PAGE: 551
:END:
*** Lesions of the Upper Respiratory Tract
:PROPERTIES:
:NOTER_PAGE: 552
:END:
**** Acute Infections
:PROPERTIES:
:NOTER_PAGE: 552
:END:
**** Nasopharyngeal Carcinoma
:PROPERTIES:
:NOTER_PAGE: 553
:END:
**** Laryngeal Tumors
:PROPERTIES:
:NOTER_PAGE: 553
:END:
***** Nonmalignant Lesions
:PROPERTIES:
:NOTER_PAGE: 553
:END:
***** Carcinoma of the Larynx
:PROPERTIES:
:NOTER_PAGE: 553
:END:
*** Suggested Readings
:PROPERTIES:
:NOTER_PAGE: 554
:END:
** 14 Kidney and Its Collecting System
:PROPERTIES:
:NOTER_PAGE: 556
:END:
*** Chapter Outline
:PROPERTIES:
:NOTER_PAGE: 556
:END:
*** Clinical Manifestations of Renal Diseases
:PROPERTIES:
:NOTER_PAGE: 556
:END:
*** Glomerular Diseases
:PROPERTIES:
:NOTER_PAGE: 557
:END:
**** Mechanisms of Glomerular Injury and Disease
:PROPERTIES:
:NOTER_PAGE: 559
:END:
***** Glomerulonephritis Caused by Circulating Immune Complexes
:PROPERTIES:
:NOTER_PAGE: 559
:END:
***** Glomerulonephritis Caused by Immune Complexes Formed in Situ
:PROPERTIES:
:NOTER_PAGE: 560
:END:
***** Anti-Glomerular Basement Membrane Antibody–Mediated Glomerulonephritis
:PROPERTIES:
:NOTER_PAGE: 561
:END:
***** Glomerular Diseases Caused by Complement Activation
:PROPERTIES:
:NOTER_PAGE: 561
:END:
***** Mediators of Immune Injury
:PROPERTIES:
:NOTER_PAGE: 561
:END:
***** Non-immune Mechanisms of Glomerular Injury
:PROPERTIES:
:NOTER_PAGE: 561
:END:
****** Podocyte Injury
:PROPERTIES:
:NOTER_PAGE: 561
:END:
****** Nephron Loss
:PROPERTIES:
:NOTER_PAGE: 562
:END:
***** Minimal-Change Disease
:PROPERTIES:
:NOTER_PAGE: 562
:END:
****** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 562
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 562
:END:
***** Focal Segmental Glomerulosclerosis
:PROPERTIES:
:NOTER_PAGE: 563
:END:
****** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 563
:END:
****** Clinical Course
:PROPERTIES:
:NOTER_PAGE: 564
:END:
***** Membranous Nephropathy
:PROPERTIES:
:NOTER_PAGE: 564
:END:
****** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 565
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 565
:END:
***** Membranoproliferative Glomerulonephritis
:PROPERTIES:
:NOTER_PAGE: 566
:END:
****** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 566
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 566
:END:
***** C3 Glomerulopathy
:PROPERTIES:
:NOTER_PAGE: 567
:END:
****** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 567
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 567
:END:
***** Acute Postinfectious (Poststreptococcal) Glomerulonephritis
:PROPERTIES:
:NOTER_PAGE: 567
:END:
****** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 567
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 567
:END:
***** IgA Nephropathy
:PROPERTIES:
:NOTER_PAGE: 568
:END:
****** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 568
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 569
:END:
***** Hereditary Nephritis
:PROPERTIES:
:NOTER_PAGE: 569
:END:
****** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 569
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 569
:END:
***** Rapidly Progressive Glomerulonephritis
:PROPERTIES:
:NOTER_PAGE: 569
:END:
****** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 569
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 570
:END:
*** Diseases Affecting Tubules and Interstitium
:PROPERTIES:
:NOTER_PAGE: 571
:END:
**** Tubulointerstitial Nephritis
:PROPERTIES:
:NOTER_PAGE: 571
:END:
***** Acute Pyelonephritis
:PROPERTIES:
:NOTER_PAGE: 571
:END:
****** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 571
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 573
:END:
***** Chronic Pyelonephritis and Reflux Nephropathy
:PROPERTIES:
:NOTER_PAGE: 573
:END:
****** Chronic Obstructive Pyelonephritis
:PROPERTIES:
:NOTER_PAGE: 573
:END:
****** Chronic Reflux–Associated Pyelonephritis (Reflux Nephropathy)
:PROPERTIES:
:NOTER_PAGE: 573
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 573
:END:
***** Drug-Induced Tubulointerstitial Nephritis
:PROPERTIES:
:NOTER_PAGE: 574
:END:
****** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 574
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 574
:END:
**** Acute Tubular Injury/Necrosis
:PROPERTIES:
:NOTER_PAGE: 574
:END:
***** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 575
:END:
***** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 576
:END:
*** Diseases Involving Blood Vessels
:PROPERTIES:
:NOTER_PAGE: 576
:END:
**** Nephrosclerosis
:PROPERTIES:
:NOTER_PAGE: 576
:END:
***** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 576
:END:
***** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 577
:END:
**** Malignant Hypertension
:PROPERTIES:
:NOTER_PAGE: 577
:END:
***** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 577
:END:
***** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 577
:END:
**** Thrombotic Microangiopathies
:PROPERTIES:
:NOTER_PAGE: 578
:END:
***** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 578
:END:
***** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 579
:END:
*** Chronic Kidney Disease
:PROPERTIES:
:NOTER_PAGE: 579
:END:
**** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 580
:END:
**** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 580
:END:
*** Cystic Diseases of the Kidney
:PROPERTIES:
:NOTER_PAGE: 580
:END:
**** Simple Cysts
:PROPERTIES:
:NOTER_PAGE: 580
:END:
**** Autosomal Dominant (Adult) Polycystic Kidney Disease
:PROPERTIES:
:NOTER_PAGE: 581
:END:
***** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 581
:END:
***** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 581
:END:
**** Autosomal Recessive (Childhood) Polycystic Kidney Disease
:PROPERTIES:
:NOTER_PAGE: 582
:END:
***** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 582
:END:
**** Medullary Diseases With Cysts
:PROPERTIES:
:NOTER_PAGE: 582
:END:
***** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 583
:END:
*** Urinary Outflow Obstruction
:PROPERTIES:
:NOTER_PAGE: 583
:END:
**** Renal Stones (Urolithiasis)
:PROPERTIES:
:NOTER_PAGE: 583
:END:
***** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 583
:END:
***** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 584
:END:
**** Hydronephrosis
:PROPERTIES:
:NOTER_PAGE: 584
:END:
***** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 584
:END:
***** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 584
:END:
*** Congenital and Developmental Anomalies
:PROPERTIES:
:NOTER_PAGE: 585
:END:
*** Neoplasms
:PROPERTIES:
:NOTER_PAGE: 585
:END:
**** Neoplasms of the Kidney
:PROPERTIES:
:NOTER_PAGE: 585
:END:
***** Oncocytoma
:PROPERTIES:
:NOTER_PAGE: 585
:END:
***** Renal Cell Carcinoma
:PROPERTIES:
:NOTER_PAGE: 585
:END:
****** Clear Cell Carcinomas
:PROPERTIES:
:NOTER_PAGE: 586
:END:
****** Papillary Renal Cell Carcinomas
:PROPERTIES:
:NOTER_PAGE: 586
:END:
****** Chromophobe Renal Carcinomas
:PROPERTIES:
:NOTER_PAGE: 586
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 587
:END:
***** Wilms Tumor
:PROPERTIES:
:NOTER_PAGE: 587
:END:
*** Suggested Readings
:PROPERTIES:
:NOTER_PAGE: 587
:END:
** 15 Oral Cavities and Gastrointestinal Tract
:PROPERTIES:
:NOTER_PAGE: 589
:END:
*** Chapter Outline
:PROPERTIES:
:NOTER_PAGE: 589
:END:
*** Oral Cavity
:PROPERTIES:
:NOTER_PAGE: 589
:END:
**** Diseases of Teeth and Supporting Structures
:PROPERTIES:
:NOTER_PAGE: 590
:END:
***** Caries
:PROPERTIES:
:NOTER_PAGE: 590
:END:
***** Gingivitis
:PROPERTIES:
:NOTER_PAGE: 590
:END:
***** Periodontitis
:PROPERTIES:
:NOTER_PAGE: 590
:END:
**** Oral Inflammatory Lesions
:PROPERTIES:
:NOTER_PAGE: 590
:END:
***** Aphthous Ulcers (Canker Sores)
:PROPERTIES:
:NOTER_PAGE: 590
:END:
***** Herpes Simplex Virus Infections
:PROPERTIES:
:NOTER_PAGE: 590
:END:
***** Oral Candidiasis (Thrush)
:PROPERTIES:
:NOTER_PAGE: 591
:END:
**** Proliferative and Neoplastic Lesions of the Oral Cavity
:PROPERTIES:
:NOTER_PAGE: 591
:END:
***** Fibrous Proliferative Lesions
:PROPERTIES:
:NOTER_PAGE: 591
:END:
***** Leukoplakia and Erythroplakia
:PROPERTIES:
:NOTER_PAGE: 591
:END:
***** Squamous Cell Carcinoma
:PROPERTIES:
:NOTER_PAGE: 592
:END:
****** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 592
:END:
**** Diseases of Salivary Glands
:PROPERTIES:
:NOTER_PAGE: 593
:END:
***** Xerostomia
:PROPERTIES:
:NOTER_PAGE: 593
:END:
***** Sialadenitis
:PROPERTIES:
:NOTER_PAGE: 594
:END:
***** Neoplasms
:PROPERTIES:
:NOTER_PAGE: 594
:END:
****** Pleomorphic Adenoma
:PROPERTIES:
:NOTER_PAGE: 595
:END:
****** Mucoepidermoid Carcinoma
:PROPERTIES:
:NOTER_PAGE: 595
:END:
**** Odontogenic Cysts and Tumors
:PROPERTIES:
:NOTER_PAGE: 596
:END:
*** Esophagus
:PROPERTIES:
:NOTER_PAGE: 596
:END:
**** Obstructive and Vascular Diseases
:PROPERTIES:
:NOTER_PAGE: 596
:END:
***** Mechanical Obstruction
:PROPERTIES:
:NOTER_PAGE: 596
:END:
***** Functional Obstruction
:PROPERTIES:
:NOTER_PAGE: 597
:END:
***** Ectopia
:PROPERTIES:
:NOTER_PAGE: 597
:END:
***** Esophageal Varices
:PROPERTIES:
:NOTER_PAGE: 597
:END:
****** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 597
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 597
:END:
**** Esophagitis
:PROPERTIES:
:NOTER_PAGE: 597
:END:
***** Esophageal Lacerations, Mucosal Injury, and Infections
:PROPERTIES:
:NOTER_PAGE: 597
:END:
****** Chemical and Infectious Esophagitis
:PROPERTIES:
:NOTER_PAGE: 597
:END:
***** Reflux Esophagitis
:PROPERTIES:
:NOTER_PAGE: 599
:END:
****** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 600
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 600
:END:
***** Eosinophilic Esophagitis
:PROPERTIES:
:NOTER_PAGE: 600
:END:
***** Barrett Esophagus
:PROPERTIES:
:NOTER_PAGE: 601
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 601
:END:
**** Esophageal Tumors
:PROPERTIES:
:NOTER_PAGE: 602
:END:
***** Adenocarcinoma
:PROPERTIES:
:NOTER_PAGE: 602
:END:
****** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 602
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 602
:END:
***** Squamous Cell Carcinoma
:PROPERTIES:
:NOTER_PAGE: 602
:END:
****** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 602
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 603
:END:
*** Stomach
:PROPERTIES:
:NOTER_PAGE: 604
:END:
**** Gastropathy and Acute Gastritis
:PROPERTIES:
:NOTER_PAGE: 604
:END:
***** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 604
:END:
***** Stress-Related Mucosal Disease
:PROPERTIES:
:NOTER_PAGE: 605
:END:
****** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 605
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 605
:END:
**** Chronic Gastritis
:PROPERTIES:
:NOTER_PAGE: 605
:END:
***** Helicobacter pylori Gastritis
:PROPERTIES:
:NOTER_PAGE: 606
:END:
****** Epidemiology
:PROPERTIES:
:NOTER_PAGE: 606
:END:
****** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 606
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 606
:END:
***** Autoimmune Gastritis
:PROPERTIES:
:NOTER_PAGE: 606
:END:
****** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 607
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 607
:END:
**** Complications of Chronic Gastritis
:PROPERTIES:
:NOTER_PAGE: 607
:END:
***** Peptic Ulcer Disease
:PROPERTIES:
:NOTER_PAGE: 607
:END:
****** Epidemiology
:PROPERTIES:
:NOTER_PAGE: 608
:END:
****** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 608
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 608
:END:
***** Mucosal Atrophy and Intestinal Metaplasia
:PROPERTIES:
:NOTER_PAGE: 609
:END:
***** Dysplasia
:PROPERTIES:
:NOTER_PAGE: 609
:END:
**** GASTRIC POLYPS AND TUMORS
:PROPERTIES:
:NOTER_PAGE: 609
:END:
***** Gastric Polyps
:PROPERTIES:
:NOTER_PAGE: 609
:END:
****** Inflammatory and Hyperplastic Polyps
:PROPERTIES:
:NOTER_PAGE: 609
:END:
****** Fundic Gland Polyps
:PROPERTIES:
:NOTER_PAGE: 609
:END:
****** Gastric Adenoma
:PROPERTIES:
:NOTER_PAGE: 609
:END:
***** Gastric Adenocarcinoma
:PROPERTIES:
:NOTER_PAGE: 610
:END:
****** Epidemiology
:PROPERTIES:
:NOTER_PAGE: 610
:END:
****** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 610
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 611
:END:
***** Lymphoma
:PROPERTIES:
:NOTER_PAGE: 611
:END:
***** Neuroendocrine (Carcinoid) Tumor
:PROPERTIES:
:NOTER_PAGE: 611
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 612
:END:
***** Gastrointestinal Stromal Tumor
:PROPERTIES:
:NOTER_PAGE: 612
:END:
****** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 612
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 613
:END:
*** Small and Large Intestines
:PROPERTIES:
:NOTER_PAGE: 613
:END:
**** Intestinal Obstruction
:PROPERTIES:
:NOTER_PAGE: 613
:END:
***** Intussusception
:PROPERTIES:
:NOTER_PAGE: 614
:END:
***** Hirschsprung Disease
:PROPERTIES:
:NOTER_PAGE: 614
:END:
****** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 614
:END:
***** Abdominal Hernia
:PROPERTIES:
:NOTER_PAGE: 615
:END:
**** Vascular Disorders of Bowel
:PROPERTIES:
:NOTER_PAGE: 615
:END:
***** Ischemic Bowel Disease
:PROPERTIES:
:NOTER_PAGE: 615
:END:
****** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 615
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 616
:END:
***** Hemorrhoids
:PROPERTIES:
:NOTER_PAGE: 616
:END:
**** Diarrheal Disease
:PROPERTIES:
:NOTER_PAGE: 617
:END:
***** Malabsorptive Diarrhea
:PROPERTIES:
:NOTER_PAGE: 617
:END:
****** Cystic Fibrosis
:PROPERTIES:
:NOTER_PAGE: 618
:END:
****** Celiac Disease
:PROPERTIES:
:NOTER_PAGE: 618
:END:
******* Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 618
:END:
******* Clinical Features
:PROPERTIES:
:NOTER_PAGE: 619
:END:
****** Environmental Enteric Dysfunction
:PROPERTIES:
:NOTER_PAGE: 619
:END:
****** Lactase (Disaccharidase) Deficiency
:PROPERTIES:
:NOTER_PAGE: 620
:END:
****** Abetalipoproteinemia
:PROPERTIES:
:NOTER_PAGE: 620
:END:
****** Microscopic Colitis
:PROPERTIES:
:NOTER_PAGE: 620
:END:
****** Graft-Versus-Host Disease
:PROPERTIES:
:NOTER_PAGE: 620
:END:
***** Infectious Enterocolitis
:PROPERTIES:
:NOTER_PAGE: 620
:END:
****** Cholera
:PROPERTIES:
:NOTER_PAGE: 620
:END:
******* Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 622
:END:
******* Clinical Features
:PROPERTIES:
:NOTER_PAGE: 622
:END:
****** Campylobacter Enterocolitis
:PROPERTIES:
:NOTER_PAGE: 622
:END:
******* Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 622
:END:
******* Clinical Features
:PROPERTIES:
:NOTER_PAGE: 622
:END:
****** Shigellosis
:PROPERTIES:
:NOTER_PAGE: 623
:END:
******* Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 623
:END:
******* Clinical Features
:PROPERTIES:
:NOTER_PAGE: 623
:END:
****** Escherichia coli
:PROPERTIES:
:NOTER_PAGE: 623
:END:
****** Salmonellosis
:PROPERTIES:
:NOTER_PAGE: 623
:END:
******* Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 624
:END:
****** Typhoid Fever
:PROPERTIES:
:NOTER_PAGE: 624
:END:
****** Pseudomembranous Colitis
:PROPERTIES:
:NOTER_PAGE: 624
:END:
******* Clinical Features
:PROPERTIES:
:NOTER_PAGE: 624
:END:
****** Mycobacterial Infection
:PROPERTIES:
:NOTER_PAGE: 625
:END:
****** Norovirus
:PROPERTIES:
:NOTER_PAGE: 625
:END:
****** Rotavirus
:PROPERTIES:
:NOTER_PAGE: 625
:END:
****** Parasitic Disease
:PROPERTIES:
:NOTER_PAGE: 625
:END:
**** Inflammatory Intestinal Disease
:PROPERTIES:
:NOTER_PAGE: 626
:END:
***** Sigmoid Diverticulitis
:PROPERTIES:
:NOTER_PAGE: 626
:END:
****** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 626
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 627
:END:
***** Inflammatory Bowel Disease
:PROPERTIES:
:NOTER_PAGE: 627
:END:
****** Epidemiology
:PROPERTIES:
:NOTER_PAGE: 627
:END:
****** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 628
:END:
****** Crohn Disease
:PROPERTIES:
:NOTER_PAGE: 629
:END:
******* Clinical Features
:PROPERTIES:
:NOTER_PAGE: 630
:END:
****** Ulcerative Colitis
:PROPERTIES:
:NOTER_PAGE: 630
:END:
******* Clinical Features
:PROPERTIES:
:NOTER_PAGE: 631
:END:
****** Colitis-Associated Neoplasia
:PROPERTIES:
:NOTER_PAGE: 631
:END:
**** Colonic Polyps and Neoplastic Disease
:PROPERTIES:
:NOTER_PAGE: 632
:END:
***** Inflammatory Polyps
:PROPERTIES:
:NOTER_PAGE: 632
:END:
***** Hamartomatous Polyps
:PROPERTIES:
:NOTER_PAGE: 632
:END:
****** Juvenile Polyps
:PROPERTIES:
:NOTER_PAGE: 632
:END:
****** Peutz-Jeghers Syndrome
:PROPERTIES:
:NOTER_PAGE: 632
:END:
***** Hyperplastic Polyps
:PROPERTIES:
:NOTER_PAGE: 633
:END:
***** Adenomas
:PROPERTIES:
:NOTER_PAGE: 633
:END:
***** Familial Syndromes
:PROPERTIES:
:NOTER_PAGE: 635
:END:
****** Familial Adenomatous Polyps
:PROPERTIES:
:NOTER_PAGE: 635
:END:
****** Hereditary Nonpolyposis Colorectal Cancer
:PROPERTIES:
:NOTER_PAGE: 636
:END:
***** Adenocarcinoma
:PROPERTIES:
:NOTER_PAGE: 636
:END:
****** Epidemiology
:PROPERTIES:
:NOTER_PAGE: 636
:END:
****** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 637
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 638
:END:
*** Appendix
:PROPERTIES:
:NOTER_PAGE: 640
:END:
**** Acute Appendicitis
:PROPERTIES:
:NOTER_PAGE: 640
:END:
***** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 640
:END:
***** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 641
:END:
**** Tumors of the Appendix
:PROPERTIES:
:NOTER_PAGE: 641
:END:
*** Suggested Readings
:PROPERTIES:
:NOTER_PAGE: 641
:END:
**** Oral Cavity
:PROPERTIES:
:NOTER_PAGE: 641
:END:
**** Esophagus
:PROPERTIES:
:NOTER_PAGE: 641
:END:
**** Stomach
:PROPERTIES:
:NOTER_PAGE: 641
:END:
**** Intestinal Obstruction
:PROPERTIES:
:NOTER_PAGE: 641
:END:
**** Diarrhea
:PROPERTIES:
:NOTER_PAGE: 641
:END:
**** Sigmoid Diverticulitis
:PROPERTIES:
:NOTER_PAGE: 642
:END:
**** Inflammatory Bowel Disease
:PROPERTIES:
:NOTER_PAGE: 642
:END:
**** Colonic Polyps and Neoplastic Disease
:PROPERTIES:
:NOTER_PAGE: 642
:END:
**** Appendix
:PROPERTIES:
:NOTER_PAGE: 642
:END:
** 16 Liver and Gallbladder
:PROPERTIES:
:NOTER_PAGE: 643
:END:
*** Chapter Outline
:PROPERTIES:
:NOTER_PAGE: 643
:END:
*** The Liver and Bile Ducts
:PROPERTIES:
:NOTER_PAGE: 643
:END:
**** General Features of Liver Disease
:PROPERTIES:
:NOTER_PAGE: 644
:END:
***** Mechanisms of Injury and Repair
:PROPERTIES:
:NOTER_PAGE: 644
:END:
***** Liver Failure
:PROPERTIES:
:NOTER_PAGE: 645
:END:
****** Acute Liver Failure
:PROPERTIES:
:NOTER_PAGE: 645
:END:
******* Clinical Features
:PROPERTIES:
:NOTER_PAGE: 645
:END:
****** Chronic Liver Failure and Cirrhosis
:PROPERTIES:
:NOTER_PAGE: 646
:END:
******* Clinical Features
:PROPERTIES:
:NOTER_PAGE: 647
:END:
****** Acute-on-Chronic Liver Failure
:PROPERTIES:
:NOTER_PAGE: 648
:END:
**** Infectious Disorders
:PROPERTIES:
:NOTER_PAGE: 648
:END:
***** Viral Hepatitis
:PROPERTIES:
:NOTER_PAGE: 648
:END:
****** Hepatitis A Virus (HAV)
:PROPERTIES:
:NOTER_PAGE: 648
:END:
****** Hepatitis B Virus (HBV)
:PROPERTIES:
:NOTER_PAGE: 649
:END:
****** Hepatitis C Virus (HCV)
:PROPERTIES:
:NOTER_PAGE: 651
:END:
****** Hepatitis D Virus (HDV)
:PROPERTIES:
:NOTER_PAGE: 653
:END:
****** Hepatitis E Virus (HEV)
:PROPERTIES:
:NOTER_PAGE: 653
:END:
****** Clinicopathologic Syndromes of Viral Hepatitis
:PROPERTIES:
:NOTER_PAGE: 654
:END:
******* Acute Asymptomatic Infection With Recovery.
:PROPERTIES:
:NOTER_PAGE: 654
:END:
******* Acute Symptomatic Infection With Recovery.
:PROPERTIES:
:NOTER_PAGE: 654
:END:
******* Fulminant Hepatic Failure.
:PROPERTIES:
:NOTER_PAGE: 654
:END:
******* Chronic Hepatitis.
:PROPERTIES:
:NOTER_PAGE: 654
:END:
******* The Carrier State.
:PROPERTIES:
:NOTER_PAGE: 654
:END:
******* HIV and Chronic Viral Hepatitis.
:PROPERTIES:
:NOTER_PAGE: 654
:END:
***** Bacterial, Parasitic, and Helminthic Infections
:PROPERTIES:
:NOTER_PAGE: 656
:END:
**** Autoimmune Hepatitis
:PROPERTIES:
:NOTER_PAGE: 657
:END:
***** Clinicopathologic Features
:PROPERTIES:
:NOTER_PAGE: 657
:END:
**** Drug- and Toxin-Induced Liver Injury
:PROPERTIES:
:NOTER_PAGE: 657
:END:
**** Alcoholic and Nonalcoholic Fatty Liver Disease
:PROPERTIES:
:NOTER_PAGE: 658
:END:
***** Alcoholic Liver Disease
:PROPERTIES:
:NOTER_PAGE: 659
:END:
****** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 659
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 660
:END:
***** Nonalcoholic Fatty Liver Disease
:PROPERTIES:
:NOTER_PAGE: 661
:END:
****** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 661
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 661
:END:
**** Inherited Metabolic Liver Diseases
:PROPERTIES:
:NOTER_PAGE: 662
:END:
***** Hemochromatosis
:PROPERTIES:
:NOTER_PAGE: 662
:END:
****** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 662
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 663
:END:
***** Wilson Disease
:PROPERTIES:
:NOTER_PAGE: 663
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 664
:END:
***** α1-Anti-Trypsin Deficiency
:PROPERTIES:
:NOTER_PAGE: 664
:END:
****** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 664
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 665
:END:
**** Cholestatic Syndromes
:PROPERTIES:
:NOTER_PAGE: 665
:END:
***** Bilirubin and Bile Formation
:PROPERTIES:
:NOTER_PAGE: 665
:END:
***** Pathophysiology of Jaundice
:PROPERTIES:
:NOTER_PAGE: 666
:END:
***** Defects in Hepatocellular Bilirubin Metabolism
:PROPERTIES:
:NOTER_PAGE: 667
:END:
****** Neonatal Jaundice
:PROPERTIES:
:NOTER_PAGE: 667
:END:
****** Hereditary Hyperbilirubinemias
:PROPERTIES:
:NOTER_PAGE: 667
:END:
***** Cholestasis
:PROPERTIES:
:NOTER_PAGE: 667
:END:
****** Bile Duct Obstruction and Ascending Cholangitis
:PROPERTIES:
:NOTER_PAGE: 667
:END:
***** Neonatal Cholestasis
:PROPERTIES:
:NOTER_PAGE: 668
:END:
***** Biliary Atresia
:PROPERTIES:
:NOTER_PAGE: 669
:END:
****** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 669
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 669
:END:
***** Autoimmune Cholangiopathies
:PROPERTIES:
:NOTER_PAGE: 669
:END:
****** Primary Biliary Cholangitis
:PROPERTIES:
:NOTER_PAGE: 669
:END:
******* Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 669
:END:
******* Clinical Features
:PROPERTIES:
:NOTER_PAGE: 670
:END:
****** Primary Sclerosing Cholangitis
:PROPERTIES:
:NOTER_PAGE: 670
:END:
******* Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 671
:END:
******* Clinical Features
:PROPERTIES:
:NOTER_PAGE: 671
:END:
**** Circulatory Disorders
:PROPERTIES:
:NOTER_PAGE: 672
:END:
***** Impaired Blood Flow Into the Liver
:PROPERTIES:
:NOTER_PAGE: 672
:END:
****** Hepatic Artery Compromise
:PROPERTIES:
:NOTER_PAGE: 672
:END:
****** Portal Vein Obstruction and Thrombosis
:PROPERTIES:
:NOTER_PAGE: 672
:END:
***** Impaired Blood Flow Through the Liver
:PROPERTIES:
:NOTER_PAGE: 673
:END:
***** Hepatic Venous Outflow Obstruction
:PROPERTIES:
:NOTER_PAGE: 673
:END:
****** Hepatic Vein Thrombosis
:PROPERTIES:
:NOTER_PAGE: 673
:END:
***** Passive Congestion and Centrilobular Necrosis
:PROPERTIES:
:NOTER_PAGE: 673
:END:
**** Nodules and Tumors
:PROPERTIES:
:NOTER_PAGE: 674
:END:
***** Focal Nodular Hyperplasia
:PROPERTIES:
:NOTER_PAGE: 674
:END:
***** Benign Neoplasms
:PROPERTIES:
:NOTER_PAGE: 675
:END:
****** Hepatocellular Adenomas
:PROPERTIES:
:NOTER_PAGE: 675
:END:
***** Malignant Neoplasms
:PROPERTIES:
:NOTER_PAGE: 675
:END:
****** Hepatocellular Carcinoma (HCC)
:PROPERTIES:
:NOTER_PAGE: 675
:END:
******* Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 675
:END:
******* Clinical Features
:PROPERTIES:
:NOTER_PAGE: 676
:END:
****** Cholangiocarcinoma
:PROPERTIES:
:NOTER_PAGE: 677
:END:
*** Gallbladder
:PROPERTIES:
:NOTER_PAGE: 678
:END:
**** Gallstone Disease
:PROPERTIES:
:NOTER_PAGE: 678
:END:
***** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 678
:END:
***** Prevalence and Risk Factors
:PROPERTIES:
:NOTER_PAGE: 678
:END:
***** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 679
:END:
**** Cholecystitis
:PROPERTIES:
:NOTER_PAGE: 680
:END:
***** Acute Calculous Cholecystitis
:PROPERTIES:
:NOTER_PAGE: 680
:END:
***** Acute Acalculous Cholecystitis
:PROPERTIES:
:NOTER_PAGE: 680
:END:
***** Chronic Cholecystitis
:PROPERTIES:
:NOTER_PAGE: 680
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 680
:END:
**** Carcinoma of the Gallbladder
:PROPERTIES:
:NOTER_PAGE: 681
:END:
***** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 681
:END:
*** Suggested Readings
:PROPERTIES:
:NOTER_PAGE: 682
:END:
**** Mechanisms of Liver Injury and Repair
:PROPERTIES:
:NOTER_PAGE: 682
:END:
**** Acute, Chronic, and Acute-on-Chronic Liver Failure
:PROPERTIES:
:NOTER_PAGE: 682
:END:
**** Viral Hepatitis
:PROPERTIES:
:NOTER_PAGE: 682
:END:
**** Autoimmune Liver Diseases
:PROPERTIES:
:NOTER_PAGE: 682
:END:
**** Drug- and Toxin-Induced Liver Injury
:PROPERTIES:
:NOTER_PAGE: 682
:END:
**** Metabolic Liver Diseases
:PROPERTIES:
:NOTER_PAGE: 682
:END:
**** Cholestatic Syndromes
:PROPERTIES:
:NOTER_PAGE: 683
:END:
**** Benign and Malignant Liver Tumors
:PROPERTIES:
:NOTER_PAGE: 683
:END:
** 17 Pancreas
:PROPERTIES:
:NOTER_PAGE: 684
:END:
*** Chapter Outline
:PROPERTIES:
:NOTER_PAGE: 684
:END:
*** Congenital Anomalies
:PROPERTIES:
:NOTER_PAGE: 685
:END:
**** Agenesis
:PROPERTIES:
:NOTER_PAGE: 685
:END:
**** Pancreas Divisum
:PROPERTIES:
:NOTER_PAGE: 685
:END:
**** Annular Pancreas
:PROPERTIES:
:NOTER_PAGE: 685
:END:
**** Ectopic Pancreas
:PROPERTIES:
:NOTER_PAGE: 685
:END:
**** Congenital Cysts
:PROPERTIES:
:NOTER_PAGE: 685
:END:
*** Pancreatitis
:PROPERTIES:
:NOTER_PAGE: 685
:END:
**** Acute Pancreatitis
:PROPERTIES:
:NOTER_PAGE: 685
:END:
***** Etiology
:PROPERTIES:
:NOTER_PAGE: 685
:END:
****** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 686
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 687
:END:
***** Pancreatic Pseudocysts
:PROPERTIES:
:NOTER_PAGE: 688
:END:
**** Chronic Pancreatitis
:PROPERTIES:
:NOTER_PAGE: 688
:END:
***** Etiology
:PROPERTIES:
:NOTER_PAGE: 688
:END:
****** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 689
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 689
:END:
*** Pancreatic Neoplasms
:PROPERTIES:
:NOTER_PAGE: 690
:END:
**** Cystic Neoplasms
:PROPERTIES:
:NOTER_PAGE: 690
:END:
***** Intraductal Papillary Mucinous Neoplasms
:PROPERTIES:
:NOTER_PAGE: 691
:END:
**** Pancreatic Carcinoma
:PROPERTIES:
:NOTER_PAGE: 691
:END:
***** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 692
:END:
***** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 693
:END:
*** Suggested Readings
:PROPERTIES:
:NOTER_PAGE: 694
:END:
** 18 Male Genital System and Lower Urinary Tract
:PROPERTIES:
:NOTER_PAGE: 695
:END:
*** Chapter Outline
:PROPERTIES:
:NOTER_PAGE: 695
:END:
*** Penis
:PROPERTIES:
:NOTER_PAGE: 695
:END:
**** Malformations
:PROPERTIES:
:NOTER_PAGE: 695
:END:
**** Inflammatory Lesions
:PROPERTIES:
:NOTER_PAGE: 695
:END:
**** Neoplasms
:PROPERTIES:
:NOTER_PAGE: 695
:END:
*** Scrotum, Testis, and Epididymis
:PROPERTIES:
:NOTER_PAGE: 696
:END:
**** Cryptorchidism and Testicular Atrophy
:PROPERTIES:
:NOTER_PAGE: 696
:END:
**** Inflammatory Lesions
:PROPERTIES:
:NOTER_PAGE: 697
:END:
**** Vascular Disturbances
:PROPERTIES:
:NOTER_PAGE: 697
:END:
**** Testicular Neoplasms
:PROPERTIES:
:NOTER_PAGE: 697
:END:
***** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 700
:END:
*** Prostate
:PROPERTIES:
:NOTER_PAGE: 701
:END:
**** Prostatitis
:PROPERTIES:
:NOTER_PAGE: 701
:END:
***** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 702
:END:
**** Benign Prostatic Hyperplasia
:PROPERTIES:
:NOTER_PAGE: 702
:END:
***** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 702
:END:
**** Carcinoma of the Prostate
:PROPERTIES:
:NOTER_PAGE: 703
:END:
***** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 703
:END:
***** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 704
:END:
*** Ureter, Bladder, and Urethra
:PROPERTIES:
:NOTER_PAGE: 705
:END:
**** Ureter
:PROPERTIES:
:NOTER_PAGE: 706
:END:
**** Urinary Bladder
:PROPERTIES:
:NOTER_PAGE: 706
:END:
***** Nonneoplastic Conditions
:PROPERTIES:
:NOTER_PAGE: 706
:END:
***** Neoplasms
:PROPERTIES:
:NOTER_PAGE: 706
:END:
****** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 706
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 708
:END:
*** Sexually Transmitted Diseases
:PROPERTIES:
:NOTER_PAGE: 708
:END:
**** Syphilis
:PROPERTIES:
:NOTER_PAGE: 709
:END:
***** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 711
:END:
**** Gonorrhea
:PROPERTIES:
:NOTER_PAGE: 712
:END:
***** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 713
:END:
**** Nongonococcal Urethritis and Cervicitis
:PROPERTIES:
:NOTER_PAGE: 713
:END:
**** Lymphogranuloma Venereum
:PROPERTIES:
:NOTER_PAGE: 714
:END:
***** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 714
:END:
**** Chancroid (Soft Chancre)
:PROPERTIES:
:NOTER_PAGE: 714
:END:
***** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 714
:END:
**** Granuloma Inguinale
:PROPERTIES:
:NOTER_PAGE: 715
:END:
**** Trichomoniasis
:PROPERTIES:
:NOTER_PAGE: 715
:END:
**** Genital Herpes Simplex
:PROPERTIES:
:NOTER_PAGE: 715
:END:
***** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 715
:END:
**** Human Papillomavirus Infection
:PROPERTIES:
:NOTER_PAGE: 716
:END:
*** Suggested Readings
:PROPERTIES:
:NOTER_PAGE: 716
:END:
** 19 Female Genital System and Breast
:PROPERTIES:
:NOTER_PAGE: 717
:END:
*** Chapter Outline
:PROPERTIES:
:NOTER_PAGE: 717
:END:
*** Vulva
:PROPERTIES:
:NOTER_PAGE: 717
:END:
**** Vulvitis
:PROPERTIES:
:NOTER_PAGE: 717
:END:
***** Nonneoplastic Epithelial Disorders
:PROPERTIES:
:NOTER_PAGE: 718
:END:
****** Lichen Sclerosus
:PROPERTIES:
:NOTER_PAGE: 718
:END:
****** Lichen Simplex Chronicus
:PROPERTIES:
:NOTER_PAGE: 718
:END:
**** Tumors
:PROPERTIES:
:NOTER_PAGE: 718
:END:
***** Condylomas
:PROPERTIES:
:NOTER_PAGE: 718
:END:
***** Carcinoma of the Vulva
:PROPERTIES:
:NOTER_PAGE: 719
:END:
***** Extramammary Paget Disease
:PROPERTIES:
:NOTER_PAGE: 719
:END:
*** Vagina
:PROPERTIES:
:NOTER_PAGE: 720
:END:
**** Vaginitis
:PROPERTIES:
:NOTER_PAGE: 720
:END:
**** Malignant Neoplasms
:PROPERTIES:
:NOTER_PAGE: 720
:END:
***** Squamous Cell Carcinoma
:PROPERTIES:
:NOTER_PAGE: 720
:END:
***** Clear Cell Adenocarcinoma
:PROPERTIES:
:NOTER_PAGE: 720
:END:
***** Sarcoma Botryoides
:PROPERTIES:
:NOTER_PAGE: 721
:END:
*** Cervix
:PROPERTIES:
:NOTER_PAGE: 721
:END:
**** Cervicitis
:PROPERTIES:
:NOTER_PAGE: 721
:END:
**** Neoplasia of the Cervix
:PROPERTIES:
:NOTER_PAGE: 721
:END:
***** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 721
:END:
***** Squamous Intraepithelial Lesion (SIL, Cervical Intraepithelial Lesion)
:PROPERTIES:
:NOTER_PAGE: 722
:END:
***** Invasive Carcinoma of the Cervix
:PROPERTIES:
:NOTER_PAGE: 724
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 724
:END:
***** Endocervical Polyp
:PROPERTIES:
:NOTER_PAGE: 724
:END:
*** Uterus
:PROPERTIES:
:NOTER_PAGE: 725
:END:
**** Endometritis
:PROPERTIES:
:NOTER_PAGE: 725
:END:
**** Adenomyosis
:PROPERTIES:
:NOTER_PAGE: 725
:END:
**** Endometriosis
:PROPERTIES:
:NOTER_PAGE: 725
:END:
***** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 726
:END:
**** Abnormal Uterine Bleeding
:PROPERTIES:
:NOTER_PAGE: 726
:END:
**** Proliferative Lesions of the Endometrium and Myometrium
:PROPERTIES:
:NOTER_PAGE: 727
:END:
***** Endometrial Hyperplasia
:PROPERTIES:
:NOTER_PAGE: 727
:END:
***** Endometrial Carcinoma
:PROPERTIES:
:NOTER_PAGE: 728
:END:
****** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 728
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 728
:END:
***** Endometrial Polyps
:PROPERTIES:
:NOTER_PAGE: 728
:END:
***** Leiomyoma
:PROPERTIES:
:NOTER_PAGE: 729
:END:
***** Leiomyosarcoma
:PROPERTIES:
:NOTER_PAGE: 730
:END:
*** Fallopian Tubes
:PROPERTIES:
:NOTER_PAGE: 730
:END:
*** Ovaries
:PROPERTIES:
:NOTER_PAGE: 731
:END:
**** Follicle and Luteal Cysts
:PROPERTIES:
:NOTER_PAGE: 731
:END:
**** Polycystic Ovarian Syndrome
:PROPERTIES:
:NOTER_PAGE: 731
:END:
**** Tumors of the Ovary
:PROPERTIES:
:NOTER_PAGE: 731
:END:
***** Surface Epithelial Tumors
:PROPERTIES:
:NOTER_PAGE: 731
:END:
***** Serous Tumors
:PROPERTIES:
:NOTER_PAGE: 732
:END:
***** Mucinous Tumors
:PROPERTIES:
:NOTER_PAGE: 733
:END:
***** Endometrioid Tumors
:PROPERTIES:
:NOTER_PAGE: 733
:END:
***** Brenner Tumor
:PROPERTIES:
:NOTER_PAGE: 733
:END:
***** Other Ovarian Tumors
:PROPERTIES:
:NOTER_PAGE: 734
:END:
****** Teratomas
:PROPERTIES:
:NOTER_PAGE: 734
:END:
******* Benign (Mature) Cystic Teratomas
:PROPERTIES:
:NOTER_PAGE: 734
:END:
******* Immature Malignant Teratomas
:PROPERTIES:
:NOTER_PAGE: 734
:END:
******* Specialized Teratomas
:PROPERTIES:
:NOTER_PAGE: 734
:END:
******* Clinical Features
:PROPERTIES:
:NOTER_PAGE: 735
:END:
*** Diseases of Pregnancy
:PROPERTIES:
:NOTER_PAGE: 736
:END:
**** Placental Inflammations and Infections
:PROPERTIES:
:NOTER_PAGE: 736
:END:
**** Ectopic Pregnancy
:PROPERTIES:
:NOTER_PAGE: 736
:END:
**** Gestational Trophoblastic Disease
:PROPERTIES:
:NOTER_PAGE: 737
:END:
***** Hydatidiform Mole: Complete and Partial
:PROPERTIES:
:NOTER_PAGE: 737
:END:
***** Invasive Mole
:PROPERTIES:
:NOTER_PAGE: 737
:END:
***** Gestational Choriocarcinoma
:PROPERTIES:
:NOTER_PAGE: 738
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 738
:END:
***** Placental Site Trophoblastic Tumor
:PROPERTIES:
:NOTER_PAGE: 739
:END:
***** Preeclampsia/Eclampsia (Toxemia of Pregnancy)
:PROPERTIES:
:NOTER_PAGE: 739
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 739
:END:
*** Breast
:PROPERTIES:
:NOTER_PAGE: 740
:END:
**** Clinical Presentations of Breast Disease
:PROPERTIES:
:NOTER_PAGE: 740
:END:
**** Inflammatory Processes
:PROPERTIES:
:NOTER_PAGE: 741
:END:
**** Stromal NEOPLASMS
:PROPERTIES:
:NOTER_PAGE: 742
:END:
**** Benign Epithelial Lesions
:PROPERTIES:
:NOTER_PAGE: 742
:END:
**** Carcinoma
:PROPERTIES:
:NOTER_PAGE: 743
:END:
***** Epidemiology and Risk Factors
:PROPERTIES:
:NOTER_PAGE: 745
:END:
****** Age and Gender.
:PROPERTIES:
:NOTER_PAGE: 745
:END:
****** Family History of Breast Cancer.
:PROPERTIES:
:NOTER_PAGE: 745
:END:
****** Geographic Factors.
:PROPERTIES:
:NOTER_PAGE: 745
:END:
****** Race/Ethnicity.
:PROPERTIES:
:NOTER_PAGE: 745
:END:
****** Reproductive History.
:PROPERTIES:
:NOTER_PAGE: 745
:END:
****** Ionizing Radiation.
:PROPERTIES:
:NOTER_PAGE: 745
:END:
****** Other Risk Factors.
:PROPERTIES:
:NOTER_PAGE: 745
:END:
****** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 745
:END:
******* Genetic.
:PROPERTIES:
:NOTER_PAGE: 745
:END:
******* Hormonal Influences.
:PROPERTIES:
:NOTER_PAGE: 746
:END:
******* Environmental Factors.
:PROPERTIES:
:NOTER_PAGE: 746
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 748
:END:
*** Suggested Readings
:PROPERTIES:
:NOTER_PAGE: 751
:END:
** 20 Endocrine System
:PROPERTIES:
:NOTER_PAGE: 752
:END:
*** Chapter Outline
:PROPERTIES:
:NOTER_PAGE: 752
:END:
*** Pituitary
:PROPERTIES:
:NOTER_PAGE: 753
:END:
**** Anterior Pituitary Tumors
:PROPERTIES:
:NOTER_PAGE: 753
:END:
***** Pituitary Adenomas: General Features
:PROPERTIES:
:NOTER_PAGE: 753
:END:
****** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 754
:END:
***** Functioning Adenomas and Hyperpituatarism
:PROPERTIES:
:NOTER_PAGE: 756
:END:
****** Lactotroph Adenomas
:PROPERTIES:
:NOTER_PAGE: 756
:END:
****** Somatotroph Adenomas
:PROPERTIES:
:NOTER_PAGE: 756
:END:
****** Corticotroph Adenomas
:PROPERTIES:
:NOTER_PAGE: 757
:END:
***** Other Anterior Pituitary Neoplasms
:PROPERTIES:
:NOTER_PAGE: 757
:END:
**** Hypopituitarism
:PROPERTIES:
:NOTER_PAGE: 757
:END:
**** Posterior Pituitary Syndromes
:PROPERTIES:
:NOTER_PAGE: 758
:END:
*** Thyroid
:PROPERTIES:
:NOTER_PAGE: 758
:END:
**** Hyperthyroidism
:PROPERTIES:
:NOTER_PAGE: 759
:END:
**** Hypothyroidism
:PROPERTIES:
:NOTER_PAGE: 760
:END:
**** Autoimmune Thyroid Disease
:PROPERTIES:
:NOTER_PAGE: 761
:END:
***** Chronic Lymphocytic (Hashimoto) Thyroiditis
:PROPERTIES:
:NOTER_PAGE: 761
:END:
****** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 761
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 762
:END:
***** Subacute Granulomatous (de Quervain) Thyroiditis
:PROPERTIES:
:NOTER_PAGE: 762
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 763
:END:
***** Subacute Lymphocytic Thyroiditis
:PROPERTIES:
:NOTER_PAGE: 763
:END:
***** Other Forms of Thyroiditis
:PROPERTIES:
:NOTER_PAGE: 763
:END:
***** Graves Disease
:PROPERTIES:
:NOTER_PAGE: 763
:END:
****** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 763
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 764
:END:
**** Diffuse and Multinodular Goiter
:PROPERTIES:
:NOTER_PAGE: 765
:END:
***** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 765
:END:
***** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 766
:END:
**** Thyroid Neoplasms
:PROPERTIES:
:NOTER_PAGE: 766
:END:
***** Adenomas
:PROPERTIES:
:NOTER_PAGE: 766
:END:
****** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 766
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 767
:END:
***** Carcinomas
:PROPERTIES:
:NOTER_PAGE: 767
:END:
****** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 767
:END:
******* Environmental Factors.
:PROPERTIES:
:NOTER_PAGE: 768
:END:
****** Papillary Carcinoma
:PROPERTIES:
:NOTER_PAGE: 768
:END:
******* Clinical Features
:PROPERTIES:
:NOTER_PAGE: 769
:END:
****** Follicular Carcinoma
:PROPERTIES:
:NOTER_PAGE: 769
:END:
******* Clinical Features
:PROPERTIES:
:NOTER_PAGE: 770
:END:
****** Anaplastic Carcinoma
:PROPERTIES:
:NOTER_PAGE: 770
:END:
******* Clinical Features
:PROPERTIES:
:NOTER_PAGE: 771
:END:
****** Medullary Carcinoma
:PROPERTIES:
:NOTER_PAGE: 771
:END:
******* Clinical Features
:PROPERTIES:
:NOTER_PAGE: 771
:END:
*** Parathyroid Glands
:PROPERTIES:
:NOTER_PAGE: 772
:END:
**** Hyperparathyroidism
:PROPERTIES:
:NOTER_PAGE: 772
:END:
***** Primary Hyperparathyroidism
:PROPERTIES:
:NOTER_PAGE: 772
:END:
****** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 772
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 773
:END:
***** Secondary Hyperparathyroidism
:PROPERTIES:
:NOTER_PAGE: 774
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 774
:END:
**** Hypoparathyroidism
:PROPERTIES:
:NOTER_PAGE: 774
:END:
*** Endocrine Pancreas
:PROPERTIES:
:NOTER_PAGE: 775
:END:
**** Diabetes Mellitus
:PROPERTIES:
:NOTER_PAGE: 775
:END:
***** Diagnosis
:PROPERTIES:
:NOTER_PAGE: 775
:END:
***** Classification
:PROPERTIES:
:NOTER_PAGE: 775
:END:
***** Normal Insulin Physiology and Glucose Homeostasis
:PROPERTIES:
:NOTER_PAGE: 776
:END:
***** Pathogenesis of Type 1 Diabetes
:PROPERTIES:
:NOTER_PAGE: 777
:END:
***** Pathogenesis of Type 2 Diabetes
:PROPERTIES:
:NOTER_PAGE: 778
:END:
****** Insulin Resistance
:PROPERTIES:
:NOTER_PAGE: 778
:END:
****** Obesity and Insulin Resistance
:PROPERTIES:
:NOTER_PAGE: 778
:END:
****** Beta Cell Dysfunction
:PROPERTIES:
:NOTER_PAGE: 779
:END:
***** Monogenic Forms of Diabetes
:PROPERTIES:
:NOTER_PAGE: 779
:END:
***** Other Subtypes of Diabetes
:PROPERTIES:
:NOTER_PAGE: 779
:END:
***** Acute Metabolic Complications of Diabetes
:PROPERTIES:
:NOTER_PAGE: 780
:END:
****** Initial Presentation
:PROPERTIES:
:NOTER_PAGE: 780
:END:
****** Diabetic Ketoacidosis and Hyperosmolar Non-ketotic Coma
:PROPERTIES:
:NOTER_PAGE: 781
:END:
***** Chronic Complications of Diabetes
:PROPERTIES:
:NOTER_PAGE: 781
:END:
****** Pathogenesis of Chronic Complications of Diabetes
:PROPERTIES:
:NOTER_PAGE: 781
:END:
****** Clinical Features of Chronic Diabetes
:PROPERTIES:
:NOTER_PAGE: 785
:END:
**** Pancreatic Neuroendocrine Tumors
:PROPERTIES:
:NOTER_PAGE: 787
:END:
***** Insulinomas
:PROPERTIES:
:NOTER_PAGE: 787
:END:
***** Gastrinomas
:PROPERTIES:
:NOTER_PAGE: 787
:END:
*** Adrenal Cortex
:PROPERTIES:
:NOTER_PAGE: 787
:END:
**** Adrenocortical Hyperfunction: Hyperadrenalism
:PROPERTIES:
:NOTER_PAGE: 788
:END:
***** Hypercortisolism: Cushing Syndrome
:PROPERTIES:
:NOTER_PAGE: 788
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 790
:END:
***** Hyperaldosteronism
:PROPERTIES:
:NOTER_PAGE: 791
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 792
:END:
***** Adrenogenital Syndromes
:PROPERTIES:
:NOTER_PAGE: 792
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 792
:END:
**** Adrenal Insufficiency
:PROPERTIES:
:NOTER_PAGE: 793
:END:
***** Acute Adrenocortical Insufficiency
:PROPERTIES:
:NOTER_PAGE: 793
:END:
***** Chronic Adrenocortical Insufficiency: Addison Disease
:PROPERTIES:
:NOTER_PAGE: 793
:END:
***** Secondary Adrenocortical Insufficiency
:PROPERTIES:
:NOTER_PAGE: 794
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 794
:END:
**** Adrenocortical Neoplasms
:PROPERTIES:
:NOTER_PAGE: 795
:END:
*** Adrenal Medulla
:PROPERTIES:
:NOTER_PAGE: 796
:END:
**** Tumors of the Adrenal Medulla
:PROPERTIES:
:NOTER_PAGE: 796
:END:
***** Pheochromocytoma
:PROPERTIES:
:NOTER_PAGE: 796
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 797
:END:
***** Neuroblastoma and Other Neuronal Neoplasms
:PROPERTIES:
:NOTER_PAGE: 797
:END:
*** Multiple Endocrine Neoplasia (MEN) Syndromes
:PROPERTIES:
:NOTER_PAGE: 798
:END:
**** Multiple Endocrine Neoplasia Type 1
:PROPERTIES:
:NOTER_PAGE: 798
:END:
**** Multiple Endocrine Neoplasia Type 2
:PROPERTIES:
:NOTER_PAGE: 798
:END:
***** Multiple Endocrine Neoplasia Type 2A
:PROPERTIES:
:NOTER_PAGE: 798
:END:
***** Multiple Endocrine Neoplasia Type 2B
:PROPERTIES:
:NOTER_PAGE: 798
:END:
*** Suggested Readings
:PROPERTIES:
:NOTER_PAGE: 798
:END:
** 21 Bones, Joints, and Soft Tissue Tumors
:PROPERTIES:
:NOTER_PAGE: 800
:END:
*** Chapter Outline
:PROPERTIES:
:NOTER_PAGE: 800
:END:
*** Bone
:PROPERTIES:
:NOTER_PAGE: 800
:END:
**** Basic Structure and Function of Bone
:PROPERTIES:
:NOTER_PAGE: 800
:END:
***** Matrix
:PROPERTIES:
:NOTER_PAGE: 800
:END:
***** Cells
:PROPERTIES:
:NOTER_PAGE: 800
:END:
***** Development
:PROPERTIES:
:NOTER_PAGE: 801
:END:
***** Homeostasis and Remodeling
:PROPERTIES:
:NOTER_PAGE: 802
:END:
**** Congenital Disorders of Bone and Cartilage
:PROPERTIES:
:NOTER_PAGE: 802
:END:
***** Achondroplasia
:PROPERTIES:
:NOTER_PAGE: 803
:END:
***** Thanatophoric Dysplasia
:PROPERTIES:
:NOTER_PAGE: 803
:END:
***** Type I Collagen Diseases (Osteogenesis Imperfecta)
:PROPERTIES:
:NOTER_PAGE: 803
:END:
***** Osteopetrosis
:PROPERTIES:
:NOTER_PAGE: 803
:END:
**** Metabolic Disorders of Bone
:PROPERTIES:
:NOTER_PAGE: 804
:END:
***** Osteopenia and Osteoporosis
:PROPERTIES:
:NOTER_PAGE: 804
:END:
****** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 804
:END:
****** Clinical Course
:PROPERTIES:
:NOTER_PAGE: 805
:END:
***** Rickets and Osteomalacia
:PROPERTIES:
:NOTER_PAGE: 805
:END:
***** Hyperparathyroidism
:PROPERTIES:
:NOTER_PAGE: 805
:END:
****** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 805
:END:
****** Clinical Course
:PROPERTIES:
:NOTER_PAGE: 806
:END:
**** Paget Disease of Bone (Osteitis Deformans)
:PROPERTIES:
:NOTER_PAGE: 806
:END:
***** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 807
:END:
***** Clinical Course
:PROPERTIES:
:NOTER_PAGE: 807
:END:
**** Fractures
:PROPERTIES:
:NOTER_PAGE: 808
:END:
***** Healing of Fractures
:PROPERTIES:
:NOTER_PAGE: 808
:END:
**** Osteonecrosis (Avascular Necrosis)
:PROPERTIES:
:NOTER_PAGE: 809
:END:
***** Clinical Course
:PROPERTIES:
:NOTER_PAGE: 809
:END:
**** Osteomyelitis
:PROPERTIES:
:NOTER_PAGE: 809
:END:
***** Pyogenic Osteomyelitis
:PROPERTIES:
:NOTER_PAGE: 809
:END:
****** Clinical Course
:PROPERTIES:
:NOTER_PAGE: 810
:END:
***** Mycobacterial Osteomyelitis
:PROPERTIES:
:NOTER_PAGE: 810
:END:
**** Bone Tumors and Tumorlike Lesions
:PROPERTIES:
:NOTER_PAGE: 811
:END:
***** Bone-Forming Tumors
:PROPERTIES:
:NOTER_PAGE: 811
:END:
****** Osteoid Osteoma and Osteoblastoma
:PROPERTIES:
:NOTER_PAGE: 811
:END:
****** Osteosarcoma
:PROPERTIES:
:NOTER_PAGE: 812
:END:
******* Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 812
:END:
******* Clinical Course
:PROPERTIES:
:NOTER_PAGE: 813
:END:
***** Cartilage-Forming Tumors
:PROPERTIES:
:NOTER_PAGE: 813
:END:
****** Osteochondroma
:PROPERTIES:
:NOTER_PAGE: 813
:END:
******* Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 813
:END:
******* Clinical Course
:PROPERTIES:
:NOTER_PAGE: 814
:END:
****** Chondroma
:PROPERTIES:
:NOTER_PAGE: 814
:END:
******* Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 815
:END:
******* Clinical Course
:PROPERTIES:
:NOTER_PAGE: 815
:END:
****** Chondrosarcoma
:PROPERTIES:
:NOTER_PAGE: 815
:END:
******* Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 815
:END:
******* Clinical Course
:PROPERTIES:
:NOTER_PAGE: 815
:END:
***** Tumors of Unknown Origin
:PROPERTIES:
:NOTER_PAGE: 815
:END:
****** Ewing Sarcoma
:PROPERTIES:
:NOTER_PAGE: 815
:END:
******* Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 816
:END:
******* Clinical Course
:PROPERTIES:
:NOTER_PAGE: 816
:END:
****** Giant Cell Tumor
:PROPERTIES:
:NOTER_PAGE: 816
:END:
******* Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 817
:END:
******* Clinical Course
:PROPERTIES:
:NOTER_PAGE: 817
:END:
****** Aneurysmal Bone Cyst
:PROPERTIES:
:NOTER_PAGE: 817
:END:
******* Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 817
:END:
******* Clinical Course
:PROPERTIES:
:NOTER_PAGE: 817
:END:
***** Lesions Simulating Primary Neoplasms
:PROPERTIES:
:NOTER_PAGE: 817
:END:
****** Nonossifying Fibroma
:PROPERTIES:
:NOTER_PAGE: 817
:END:
****** Fibrous Dysplasia
:PROPERTIES:
:NOTER_PAGE: 818
:END:
******* Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 819
:END:
******* Clinical Course
:PROPERTIES:
:NOTER_PAGE: 819
:END:
***** Metastatic Tumors
:PROPERTIES:
:NOTER_PAGE: 819
:END:
*** Joints
:PROPERTIES:
:NOTER_PAGE: 820
:END:
**** Arthritis
:PROPERTIES:
:NOTER_PAGE: 820
:END:
***** Osteoarthritis
:PROPERTIES:
:NOTER_PAGE: 820
:END:
****** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 820
:END:
****** Clinical Course
:PROPERTIES:
:NOTER_PAGE: 821
:END:
***** Rheumatoid Arthritis
:PROPERTIES:
:NOTER_PAGE: 821
:END:
****** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 821
:END:
****** Clinical Course
:PROPERTIES:
:NOTER_PAGE: 824
:END:
***** Juvenile Idiopathic Arthritis
:PROPERTIES:
:NOTER_PAGE: 824
:END:
***** Seronegative Spondyloarthropathies
:PROPERTIES:
:NOTER_PAGE: 825
:END:
***** Infectious Arthritis
:PROPERTIES:
:NOTER_PAGE: 825
:END:
****** Suppurative Arthritis
:PROPERTIES:
:NOTER_PAGE: 825
:END:
***** Lyme Arthritis
:PROPERTIES:
:NOTER_PAGE: 825
:END:
***** Crystal-Induced Arthritis
:PROPERTIES:
:NOTER_PAGE: 826
:END:
****** Gout
:PROPERTIES:
:NOTER_PAGE: 826
:END:
******* Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 826
:END:
******* Clinical Course
:PROPERTIES:
:NOTER_PAGE: 827
:END:
****** Calcium Pyrophosphate Crystal Deposition Disease (Pseudogout)
:PROPERTIES:
:NOTER_PAGE: 828
:END:
******* Clinical Course
:PROPERTIES:
:NOTER_PAGE: 828
:END:
**** Joint Tumors and Tumorlike Conditions
:PROPERTIES:
:NOTER_PAGE: 829
:END:
***** Ganglion and Synovial Cysts
:PROPERTIES:
:NOTER_PAGE: 829
:END:
***** Tenosynovial Giant Cell Tumor
:PROPERTIES:
:NOTER_PAGE: 829
:END:
****** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 829
:END:
****** Clinical Course
:PROPERTIES:
:NOTER_PAGE: 830
:END:
*** Soft Tissue Tumors
:PROPERTIES:
:NOTER_PAGE: 830
:END:
**** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 830
:END:
**** Tumors of Adipose Tissue
:PROPERTIES:
:NOTER_PAGE: 831
:END:
***** Lipoma
:PROPERTIES:
:NOTER_PAGE: 831
:END:
***** Liposarcoma
:PROPERTIES:
:NOTER_PAGE: 831
:END:
****** Clinical Course
:PROPERTIES:
:NOTER_PAGE: 831
:END:
**** Fibrous Tumors
:PROPERTIES:
:NOTER_PAGE: 831
:END:
***** Nodular Fasciitis
:PROPERTIES:
:NOTER_PAGE: 831
:END:
***** Fibromatoses
:PROPERTIES:
:NOTER_PAGE: 831
:END:
****** Superficial Fibromatosis
:PROPERTIES:
:NOTER_PAGE: 831
:END:
****** Deep Fibromatosis
:PROPERTIES:
:NOTER_PAGE: 832
:END:
**** Skeletal Muscle Tumors
:PROPERTIES:
:NOTER_PAGE: 833
:END:
***** Rhabdomyosarcoma
:PROPERTIES:
:NOTER_PAGE: 833
:END:
**** Smooth Muscle Tumors
:PROPERTIES:
:NOTER_PAGE: 833
:END:
***** Leiomyoma
:PROPERTIES:
:NOTER_PAGE: 833
:END:
***** Leiomyosarcoma
:PROPERTIES:
:NOTER_PAGE: 834
:END:
****** Clinical Course
:PROPERTIES:
:NOTER_PAGE: 834
:END:
**** Tumors of Uncertain Origin
:PROPERTIES:
:NOTER_PAGE: 834
:END:
***** Synovial Sarcoma
:PROPERTIES:
:NOTER_PAGE: 834
:END:
***** Undifferentiated Pleomorphic Sarcoma
:PROPERTIES:
:NOTER_PAGE: 834
:END:
**** Acknowledgment
:PROPERTIES:
:NOTER_PAGE: 835
:END:
*** Suggested Readings
:PROPERTIES:
:NOTER_PAGE: 835
:END:
**** Basic Structure and Biology of Bone
:PROPERTIES:
:NOTER_PAGE: 835
:END:
**** Skeletal Dysplasias
:PROPERTIES:
:NOTER_PAGE: 835
:END:
**** Osteoporosis
:PROPERTIES:
:NOTER_PAGE: 835
:END:
**** Hyperparathyroidism
:PROPERTIES:
:NOTER_PAGE: 835
:END:
**** Paget Disease
:PROPERTIES:
:NOTER_PAGE: 835
:END:
**** Osteonecrosis
:PROPERTIES:
:NOTER_PAGE: 835
:END:
**** Osteosarcoma
:PROPERTIES:
:NOTER_PAGE: 835
:END:
**** Chondrogenic Tumors
:PROPERTIES:
:NOTER_PAGE: 836
:END:
**** Ewing Sarcoma
:PROPERTIES:
:NOTER_PAGE: 836
:END:
**** Giant Cell Tumor of Bone
:PROPERTIES:
:NOTER_PAGE: 836
:END:
**** Aneurysmal Bone Cyst
:PROPERTIES:
:NOTER_PAGE: 836
:END:
**** Fibrous Dysplasia
:PROPERTIES:
:NOTER_PAGE: 836
:END:
**** Osteoarthritis
:PROPERTIES:
:NOTER_PAGE: 836
:END:
**** Rheumatoid Arthritis
:PROPERTIES:
:NOTER_PAGE: 836
:END:
**** Lyme Disease
:PROPERTIES:
:NOTER_PAGE: 836
:END:
**** Gout and Pseudogout
:PROPERTIES:
:NOTER_PAGE: 836
:END:
**** Tenosynovial Giant Cell Tumor
:PROPERTIES:
:NOTER_PAGE: 836
:END:
**** Soft Tissue Sarcomas
:PROPERTIES:
:NOTER_PAGE: 836
:END:
** 22 Peripheral Nerves and Muscles
:PROPERTIES:
:NOTER_PAGE: 837
:END:
*** Chapter Outline
:PROPERTIES:
:NOTER_PAGE: 837
:END:
*** Disorders of Peripheral Nerves
:PROPERTIES:
:NOTER_PAGE: 837
:END:
**** Patterns of Peripheral Nerve Injury
:PROPERTIES:
:NOTER_PAGE: 837
:END:
**** Disorders Associated With Peripheral Nerve Injury
:PROPERTIES:
:NOTER_PAGE: 839
:END:
***** Guillain-Barré Syndrome
:PROPERTIES:
:NOTER_PAGE: 840
:END:
***** Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
:PROPERTIES:
:NOTER_PAGE: 840
:END:
***** Diabetic Peripheral Neuropathy
:PROPERTIES:
:NOTER_PAGE: 840
:END:
***** Toxic, Vasculitic, and Inherited Forms of Peripheral Neuropathy
:PROPERTIES:
:NOTER_PAGE: 840
:END:
*** Disorders of Neuromuscular Junction
:PROPERTIES:
:NOTER_PAGE: 841
:END:
**** Myasthenia Gravis
:PROPERTIES:
:NOTER_PAGE: 841
:END:
**** Lambert-Eaton Syndrome
:PROPERTIES:
:NOTER_PAGE: 841
:END:
**** Miscellaneous Neuromuscular Junction Disorders
:PROPERTIES:
:NOTER_PAGE: 841
:END:
*** Disorders of Skeletal Muscle
:PROPERTIES:
:NOTER_PAGE: 842
:END:
**** Patterns of Skeletal Muscle Injury and Atrophy
:PROPERTIES:
:NOTER_PAGE: 842
:END:
**** Inherited Disorders of Skeletal Muscle
:PROPERTIES:
:NOTER_PAGE: 843
:END:
***** Dystrophinopathies: Duchenne and Becker Muscular Dystrophy
:PROPERTIES:
:NOTER_PAGE: 844
:END:
****** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 845
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 845
:END:
***** Other X-Linked and Autosomal Muscular Dystrophies
:PROPERTIES:
:NOTER_PAGE: 845
:END:
***** Channelopathies, Metabolic Myopathies, and Mitochondrial Myopathies
:PROPERTIES:
:NOTER_PAGE: 846
:END:
**** Acquired Disorders of Skeletal Muscle
:PROPERTIES:
:NOTER_PAGE: 846
:END:
***** Inflammatory Myopathies
:PROPERTIES:
:NOTER_PAGE: 846
:END:
***** Toxic Myopathies
:PROPERTIES:
:NOTER_PAGE: 847
:END:
***** Tumors of Skeletal Muscles
:PROPERTIES:
:NOTER_PAGE: 847
:END:
*** Peripheral Nerve Sheath Tumors
:PROPERTIES:
:NOTER_PAGE: 848
:END:
**** Schwannomas and Neurofibromatosis Type 2
:PROPERTIES:
:NOTER_PAGE: 848
:END:
**** Neurofibromas
:PROPERTIES:
:NOTER_PAGE: 848
:END:
**** Neurofibromatosis Type 1
:PROPERTIES:
:NOTER_PAGE: 848
:END:
**** Malignant Peripheral Nerve Sheath Tumors
:PROPERTIES:
:NOTER_PAGE: 848
:END:
**** Traumatic Neuroma
:PROPERTIES:
:NOTER_PAGE: 849
:END:
*** Suggested Readings
:PROPERTIES:
:NOTER_PAGE: 850
:END:
** 23 Central Nervous System
:PROPERTIES:
:NOTER_PAGE: 851
:END:
*** Chapter Outline
:PROPERTIES:
:NOTER_PAGE: 851
:END:
*** Edema, Herniation, and Hydrocephalus
:PROPERTIES:
:NOTER_PAGE: 852
:END:
**** Cerebral Edema
:PROPERTIES:
:NOTER_PAGE: 852
:END:
**** Hydrocephalus
:PROPERTIES:
:NOTER_PAGE: 853
:END:
**** Herniation
:PROPERTIES:
:NOTER_PAGE: 853
:END:
*** Cerebrovascular Diseases
:PROPERTIES:
:NOTER_PAGE: 854
:END:
**** Hypoxia, Ischemia, and Infarction
:PROPERTIES:
:NOTER_PAGE: 854
:END:
***** Global Cerebral Ischemia
:PROPERTIES:
:NOTER_PAGE: 854
:END:
***** Focal Cerebral Ischemia
:PROPERTIES:
:NOTER_PAGE: 855
:END:
**** Intracranial Hemorrhage
:PROPERTIES:
:NOTER_PAGE: 856
:END:
***** Primary Brain Parenchymal Hemorrhage
:PROPERTIES:
:NOTER_PAGE: 856
:END:
***** Cerebral Amyloid Angiopathy
:PROPERTIES:
:NOTER_PAGE: 857
:END:
***** Subarachnoid Hemorrhage and Saccular Aneurysms
:PROPERTIES:
:NOTER_PAGE: 857
:END:
***** Vascular Malformations
:PROPERTIES:
:NOTER_PAGE: 857
:END:
**** Other Vascular Diseases
:PROPERTIES:
:NOTER_PAGE: 858
:END:
***** Hypertensive Cerebrovascular Disease
:PROPERTIES:
:NOTER_PAGE: 858
:END:
***** Vasculitis
:PROPERTIES:
:NOTER_PAGE: 859
:END:
*** Central Nervous System Trauma
:PROPERTIES:
:NOTER_PAGE: 859
:END:
**** Traumatic Parenchymal Injuries
:PROPERTIES:
:NOTER_PAGE: 859
:END:
**** Traumatic Vascular Injury
:PROPERTIES:
:NOTER_PAGE: 860
:END:
***** Epidural Hematoma
:PROPERTIES:
:NOTER_PAGE: 860
:END:
***** Subdural Hematoma
:PROPERTIES:
:NOTER_PAGE: 860
:END:
*** Congenital Malformations and Perinatal Brain Injury
:PROPERTIES:
:NOTER_PAGE: 862
:END:
**** Malformations
:PROPERTIES:
:NOTER_PAGE: 862
:END:
***** Neural Tube Defects
:PROPERTIES:
:NOTER_PAGE: 862
:END:
***** Forebrain Malformations
:PROPERTIES:
:NOTER_PAGE: 863
:END:
***** Posterior Fossa Anomalies
:PROPERTIES:
:NOTER_PAGE: 863
:END:
**** Perinatal Brain Injury
:PROPERTIES:
:NOTER_PAGE: 863
:END:
*** Infections of the Nervous System
:PROPERTIES:
:NOTER_PAGE: 864
:END:
**** Epidural and Subdural Infections
:PROPERTIES:
:NOTER_PAGE: 864
:END:
**** Meningitis
:PROPERTIES:
:NOTER_PAGE: 864
:END:
***** Acute Pyogenic Meningitis (Bacterial Meningitis)
:PROPERTIES:
:NOTER_PAGE: 865
:END:
***** Aseptic Meningitis (Viral Meningitis)
:PROPERTIES:
:NOTER_PAGE: 865
:END:
***** Chronic Meningitis
:PROPERTIES:
:NOTER_PAGE: 865
:END:
****** Tuberculous Meningitis
:PROPERTIES:
:NOTER_PAGE: 865
:END:
****** Spirochetal Infections
:PROPERTIES:
:NOTER_PAGE: 866
:END:
****** Fungal Meningitis
:PROPERTIES:
:NOTER_PAGE: 866
:END:
**** Parenchymal Infections
:PROPERTIES:
:NOTER_PAGE: 866
:END:
***** Brain Abscesses
:PROPERTIES:
:NOTER_PAGE: 867
:END:
***** Viral Encephalitis
:PROPERTIES:
:NOTER_PAGE: 867
:END:
****** Arboviruses
:PROPERTIES:
:NOTER_PAGE: 867
:END:
****** Herpesviruses
:PROPERTIES:
:NOTER_PAGE: 868
:END:
****** Cytomegalovirus
:PROPERTIES:
:NOTER_PAGE: 869
:END:
****** Poliovirus
:PROPERTIES:
:NOTER_PAGE: 869
:END:
****** Rabies Virus
:PROPERTIES:
:NOTER_PAGE: 869
:END:
****** Human Immunodeficiency Virus
:PROPERTIES:
:NOTER_PAGE: 869
:END:
****** Polyomavirus and Progressive Multifocal Leukoencephalopathy
:PROPERTIES:
:NOTER_PAGE: 869
:END:
***** Fungal Encephalitis
:PROPERTIES:
:NOTER_PAGE: 870
:END:
***** Other Meningoencephalitides
:PROPERTIES:
:NOTER_PAGE: 870
:END:
****** Cerebral Toxoplasmosis
:PROPERTIES:
:NOTER_PAGE: 870
:END:
****** Cysticercosis
:PROPERTIES:
:NOTER_PAGE: 870
:END:
****** Amebiasis
:PROPERTIES:
:NOTER_PAGE: 870
:END:
**** Prion Diseases
:PROPERTIES:
:NOTER_PAGE: 871
:END:
***** Creutzfeldt-Jakob Disease (CJD)
:PROPERTIES:
:NOTER_PAGE: 871
:END:
***** Variant Creutzfeldt-Jakob Disease
:PROPERTIES:
:NOTER_PAGE: 872
:END:
*** Diseases of Myelin
:PROPERTIES:
:NOTER_PAGE: 872
:END:
**** Multiple Sclerosis (MS)
:PROPERTIES:
:NOTER_PAGE: 873
:END:
***** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 873
:END:
***** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 873
:END:
**** Other Acquired Demyelinating Diseases
:PROPERTIES:
:NOTER_PAGE: 873
:END:
**** Leukodystrophies
:PROPERTIES:
:NOTER_PAGE: 874
:END:
*** Genetic Metabolic Diseases
:PROPERTIES:
:NOTER_PAGE: 875
:END:
*** Acquired Metabolic and Toxic Disturbances
:PROPERTIES:
:NOTER_PAGE: 875
:END:
**** Nutritional Diseases
:PROPERTIES:
:NOTER_PAGE: 875
:END:
***** Thiamine Deficiency
:PROPERTIES:
:NOTER_PAGE: 875
:END:
***** Vitamin B12 Deficiency
:PROPERTIES:
:NOTER_PAGE: 875
:END:
**** Metabolic Disorders
:PROPERTIES:
:NOTER_PAGE: 875
:END:
***** Hypoglycemia
:PROPERTIES:
:NOTER_PAGE: 875
:END:
***** Hyperglycemia
:PROPERTIES:
:NOTER_PAGE: 875
:END:
***** Hepatic Encephalopathy
:PROPERTIES:
:NOTER_PAGE: 875
:END:
**** Toxic Disorders
:PROPERTIES:
:NOTER_PAGE: 876
:END:
*** Neurodegenerative Diseases
:PROPERTIES:
:NOTER_PAGE: 876
:END:
**** Alzheimer Disease
:PROPERTIES:
:NOTER_PAGE: 876
:END:
***** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 877
:END:
**** Frontotemporal Lobar Degeneration
:PROPERTIES:
:NOTER_PAGE: 879
:END:
**** Parkinson Disease
:PROPERTIES:
:NOTER_PAGE: 879
:END:
***** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 879
:END:
***** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 881
:END:
**** Huntington Disease
:PROPERTIES:
:NOTER_PAGE: 881
:END:
***** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 881
:END:
**** Spinocerebellar Ataxias
:PROPERTIES:
:NOTER_PAGE: 881
:END:
**** Amyotrophic Lateral Sclerosis
:PROPERTIES:
:NOTER_PAGE: 882
:END:
***** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 882
:END:
*** Tumors
:PROPERTIES:
:NOTER_PAGE: 883
:END:
**** Gliomas
:PROPERTIES:
:NOTER_PAGE: 883
:END:
***** Diffuse Astrocytoma
:PROPERTIES:
:NOTER_PAGE: 883
:END:
***** Oligodendroglioma
:PROPERTIES:
:NOTER_PAGE: 883
:END:
****** Genetics and Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 884
:END:
***** Midline Glioma
:PROPERTIES:
:NOTER_PAGE: 884
:END:
***** Pilocytic Astrocytoma
:PROPERTIES:
:NOTER_PAGE: 885
:END:
***** Ependymoma
:PROPERTIES:
:NOTER_PAGE: 885
:END:
**** Neuronal Tumors
:PROPERTIES:
:NOTER_PAGE: 885
:END:
**** Embryonal (Primitive) Neoplasms
:PROPERTIES:
:NOTER_PAGE: 886
:END:
***** Medulloblastoma
:PROPERTIES:
:NOTER_PAGE: 886
:END:
****** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 886
:END:
**** Other Parenchymal Tumors
:PROPERTIES:
:NOTER_PAGE: 886
:END:
***** Primary Central Nervous System Lymphoma
:PROPERTIES:
:NOTER_PAGE: 886
:END:
***** Germ Cell Tumors
:PROPERTIES:
:NOTER_PAGE: 887
:END:
**** Meningiomas
:PROPERTIES:
:NOTER_PAGE: 887
:END:
**** Metastatic Tumors
:PROPERTIES:
:NOTER_PAGE: 887
:END:
**** Familial Tumor Syndromes
:PROPERTIES:
:NOTER_PAGE: 888
:END:
***** Tuberous Sclerosis
:PROPERTIES:
:NOTER_PAGE: 888
:END:
***** von Hippel–Lindau Disease
:PROPERTIES:
:NOTER_PAGE: 889
:END:
*** Suggested Readings
:PROPERTIES:
:NOTER_PAGE: 889
:END:
**** Central Nervous System Trauma
:PROPERTIES:
:NOTER_PAGE: 889
:END:
**** Congenital Malformations and Perinatal Brain Injury
:PROPERTIES:
:NOTER_PAGE: 889
:END:
**** Infections of the Nervous System
:PROPERTIES:
:NOTER_PAGE: 889
:END:
**** Demyelinating Diseases
:PROPERTIES:
:NOTER_PAGE: 889
:END:
**** Neurodegenerative Diseases
:PROPERTIES:
:NOTER_PAGE: 889
:END:
**** Brain Tumors
:PROPERTIES:
:NOTER_PAGE: 890
:END:
** 24 Skin
:PROPERTIES:
:NOTER_PAGE: 891
:END:
*** Chapter Outline
:PROPERTIES:
:NOTER_PAGE: 891
:END:
*** Acute Inflammatory Dermatoses
:PROPERTIES:
:NOTER_PAGE: 891
:END:
**** Urticaria
:PROPERTIES:
:NOTER_PAGE: 891
:END:
***** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 891
:END:
***** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 892
:END:
**** Acute Eczematous Dermatitis
:PROPERTIES:
:NOTER_PAGE: 892
:END:
***** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 893
:END:
**** Erythema Multiforme
:PROPERTIES:
:NOTER_PAGE: 893
:END:
***** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 894
:END:
*** Chronic Inflammatory Dermatoses
:PROPERTIES:
:NOTER_PAGE: 894
:END:
**** Psoriasis
:PROPERTIES:
:NOTER_PAGE: 894
:END:
***** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 894
:END:
***** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 894
:END:
**** Lichen Planus
:PROPERTIES:
:NOTER_PAGE: 895
:END:
***** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 896
:END:
**** Lichen Simplex Chronicus
:PROPERTIES:
:NOTER_PAGE: 896
:END:
***** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 896
:END:
*** Infectious Dermatoses
:PROPERTIES:
:NOTER_PAGE: 896
:END:
**** Bacterial Infections
:PROPERTIES:
:NOTER_PAGE: 896
:END:
***** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 896
:END:
**** Fungal Infections
:PROPERTIES:
:NOTER_PAGE: 896
:END:
***** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 897
:END:
**** Verrucae (Warts)
:PROPERTIES:
:NOTER_PAGE: 897
:END:
***** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 897
:END:
*** Blistering (Bullous) Disorders
:PROPERTIES:
:NOTER_PAGE: 897
:END:
**** Pemphigus (Vulgaris and Foliaceus)
:PROPERTIES:
:NOTER_PAGE: 897
:END:
***** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 898
:END:
***** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 898
:END:
**** Bullous Pemphigoid
:PROPERTIES:
:NOTER_PAGE: 898
:END:
***** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 898
:END:
***** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 899
:END:
**** Dermatitis Herpetiformis
:PROPERTIES:
:NOTER_PAGE: 900
:END:
***** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 900
:END:
*** Tumors of the Skin
:PROPERTIES:
:NOTER_PAGE: 901
:END:
**** Benign and Premalignant Epithelial Lesions
:PROPERTIES:
:NOTER_PAGE: 901
:END:
***** Seborrheic Keratosis
:PROPERTIES:
:NOTER_PAGE: 901
:END:
***** Actinic Keratosis
:PROPERTIES:
:NOTER_PAGE: 902
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 902
:END:
**** Malignant Epidermal Tumors
:PROPERTIES:
:NOTER_PAGE: 902
:END:
***** Squamous Cell Carcinoma
:PROPERTIES:
:NOTER_PAGE: 902
:END:
****** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 902
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 903
:END:
***** Basal Cell Carcinoma
:PROPERTIES:
:NOTER_PAGE: 904
:END:
****** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 904
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 904
:END:
**** Melanocytic Proliferations
:PROPERTIES:
:NOTER_PAGE: 905
:END:
***** Melanocytic Nevi
:PROPERTIES:
:NOTER_PAGE: 905
:END:
****** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 905
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 905
:END:
***** Dysplastic Nevus
:PROPERTIES:
:NOTER_PAGE: 905
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 906
:END:
***** Melanoma
:PROPERTIES:
:NOTER_PAGE: 907
:END:
****** Pathogenesis
:PROPERTIES:
:NOTER_PAGE: 907
:END:
****** Clinical Features
:PROPERTIES:
:NOTER_PAGE: 908
:END:
*** Suggested Readings
:PROPERTIES:
:NOTER_PAGE: 910
:END:
